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ABSTRACT 
Breast cancer is the most common cancer in the UK and in women globally. Imaging methods 
like mammography, ultrasound (US) and magnetic resonance imaging (MRI) play an important 
role in the diagnosis and management of breast cancer; they are generally utilised to provide 
anatomical or structural description of tumours in the clinical setting. It is widely accepted that 
the tumour microenvironment influences the phenotype, progression and treatment of breast 
cancer. This gave the impetus to move beyond tumour visualization in images to radiomics in 
order to provide additional disease characterisation and early biomarkers of tumour response. 
Due to their ability to assess physiological processes in vivo, positron emission tomography 
(PET) and MRI can provide non-invasive characterisation of the tumour microenvironment, 
including perfusion, vascular permeability, cellularity and hypoxia, which is associated with 
poor clinical outcome and metastasis. Clinical imaging studies in breast tumours have hitherto 
assessed tumour physiological parameters separately, with only few directly comparing data 
from these modalities. To this end, hybrid PET-MRI represents an attractive option as it can 
allow examination of functional processes and features of tumours simultaneously, while also 
conferring methodological advantages to the way imaging information is combined. 
The main aim of this thesis is to provide a better understanding of breast cancer 
pathophysiology using simultaneous PET and multi-parametric MRI. In particular, this work 
aims to explore relationships between imaging biomarkers of tumour vascularity measured by 
dynamic contrast-enhanced (DCE) MRI, cellularity using diffusion-weighted imaging (DWI) 
and hypoxia using 18F-fluoromisonidazole (18F-FMISO) PET. Correlations between functional 
PET-MRI parameters and immunohistochemical (IHC) biomarkers of hypoxia and vascularity 
as well as MRI morphological tumour descriptors are also presented. The thesis concludes with 
an investigation of the utility of MRI markers of perfusion and surrogate markers of hypoxia 
to quantitatively monitor and predict pathological response in patients undergoing neo-
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COMMONLY USED ABBREVIATIONS 
 
 
PET-MR: Positron Emission Tomography- Magnetic Resonance Imaging 
AJCC: American Joint Committee on Cancer  
TNM: Tumour-Node-Metastasis 
HER2: Human epidermal growth factor 2 receptor  
WHO: World Health Organisation 
TDLU: Terminal duct lobular unit  
NST: No special type 
IHC: Immunohistochemistry  
ER: Oestrogen receptor 
PR: Progesterone receptor 
Ki-67: Protein presented in proliferating cells. Hence, it is used as tumour proliferation 
marker. 
TNBC: Triple negative breast cancer 
ECM: Extracellular matrix 
IFP: Interstitial fluid pressure 
TCA: Tricarboxylic acid cycle 
ETC: Electron transport chain 
ATP: Adenosine triphosphate 
AMPK: 5' AMP-activated protein kinase 
HIF: Hypoxia inducible factor 
HREs: Hypoxia-response elements  
PHD: Prolyl hydroxylase-domain protein  
pVHL: Von Hippel-Lindau protein  
GLUT: Glucose transporter 
LDHA: Lactate dehydrogenase A 
PDK1: Pyruvate dehydrogenase kinase 1  
MXI1: MAX interactor 1  
VEGF: Vascular Endothelial Growth Factor  
EPCs: Endothelial progenitor cells  
ECs: Endothelial cells 





HbO2: Oxy haemoglobin  
CXCL 12: C-X-C motif chemokine 12  
EMT: Epithelial mesenchymal transition  
ERS: Endoplasmic reticulum stress  
pHe: Extracellular pH  
pHi: Intracellular pH 
CEM: Contrast-enhanced mammography 
CEDM: Contrast-enhanced digital mammography 
CET: Contrast-enhanced tomosynthesis 
CT: Tomography 
DCE-MRI: Dynamic Contrast enhanced magnetic resonance imaging 
TME: Tumour microenvironment 
Mp-MRI: Multiparametric magnetic resonance imaging 
ROI: Region of interest 
Gd: Gadolinium  
EES: Extravascular-extracellular space 
AIF: Arterial Input Function 
NAC: Neoadjuvant chemotherapy 
iAUC: Initial area under the curve 
TTP: Time to peak 
BI-RADS: Breast Imaging Reporting and Data System 
ACR: American College of Radiology 
DCIS: Ductal carcinoma in-situ 
DWI: Diffusion weighted imaging 
DW-MRI: Diffusion weighted magnetic resonance imaging 
ADC: Apparent Diffusion Coefficient 
DWIBS: Body background signal suppression 
Dt: Tissue diffusion coefficient 
Dp: Pseudo-diffusion coefficient   
F: Microvascular volume fraction 
DKI: Diffusion weighted Kurtosis 
IVIM: Intravoxel Incoherent motion  





FA: Fractional Anisotropy 
BOLD-MRI: Blood oxygen level-dependent magnetic resonance imaging 
Oxy-hb: Oxygenated haemoglobin 
Deoxy-hb: Deoxygenated haemoglobin 
OE-MRI: Oxygen-enhanced magnetic resonance imaging 
DR1: Change of R1 
NSCLC: Non-small cell lung cancer 
MRS: Magnetic Resonance Spectroscopy 
1H-MRS: Proton Magnetic Resonance Spectroscopy 
tCho: Total choline peak 
SNR: Signal to noise ratio 
TE: Echo time 
LDH-A: Lactic dehydrogenase A 
HP 13C-MRI: Hyperpolarized carbon-13 Magnetic Resonance Imaging 
PET: Positron Emission Tomography 
T1/2: Half-life 
18F-FDG: 18Fluoro-2-deoxy-glucose 
GLUT: Glucose transporter 
SUV: Standardized uptake value 
15O-H2O: 15O-labelled water 




PET-MRI: Positron emission tomography – Magnetic Resonance Imaging 
ERα: Oestrogen receptor-α 
HIF-1α: Hypoxia-inducible factor 1α 
CAIX: Carbonic anhydrase nine 
TOF-OSEM: Time-of-flight ordered-subsets expectation-maximisation 
MIP: Maximum-intensity projection 
SE: Standard errors 
MBq: Megabecquerel 





IDC: Invasive ductal carcinoma 
ILC: Invasive lobular carcinoma 
IMC: Invasive mucinous carcinoma 
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Chapter 1. The clinical problem: Breast cancer 
 
 
Breast cancer is the most common cancer in women worldwide and the second most common 
cancer overall1. It is a leading cause of cancer death in less developed countries and the second 
leading cause of cancer death in British women, exceeded only by lung cancer2. The chance 
that a woman will die from breast cancer is about 1 in 37 (about 2.7%)3. Over 50,000 women 
are diagnosed with breast cancer each year in the UK and one in eight women will develop 
breast cancer at some point in their lifetime4. 
 
Breast tumours are very heterogeneous cancers exhibiting diverse metabolic and functional 
phenotypic characteristics that determine the risk of cancer progression and therapeutic 
resistance5. As with all solid tumours, malignant breast tumour cells can vary both 
genotypically and phenotypically within a primary tumour (intra-tumoural heterogeneity), 
between the primary tumour and its metastases or between tumours of the same 
histopathological sub-type (inter-tumoural heterogeneity)6,7. This heterogeneity confers 
different biological properties to breast tumours (vascularity, metabolism, proliferation rate, 
etc.)7 amplifying the complexity of breast disease. Despite technological advances like whole- 
genome sequencing and functional viability screens, the impact of this heterogeneity and the 
microenvironment of breast cancer on tumour evolution remains poorly understood5,8 and the 





1.1.1 Breast cancer anatomic staging 
 
 
The American Joint Committee on Cancer (AJCC) has published eight editions of the tumour- 
node-metastasis (TNM) system for cancer anatomic staging. The last edition, published in 
2017, included many new changes for breast cancer9. A major change was the incorporation of 
breast cancer biomarkers (tumour grade, hormone receptor status, HER2 expression and 
multigene panels) into the anatomic TNM staging10. 
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This 8th edition of the AJCC staging system of breast cancer is available online11 and 
magnificent reviews of this new staging system of breast cancer have been published by Jieun 
and Min Jung Kim in 201910 and by A. Giuliano et al9 in 2017. 
 
 
1.1.2 Breast cancer histological types 
 
 
In August 2019 the World Health Organization (WHO) published a new classification of breast 
tumours in the second volume of the fifth edition of the WHO books on the classification of 
human tumours12. Breast carcinomas are divided into non-invasive or in-situ carcinoma and 
invasive carcinoma, when tumour cells have disseminated beyond the breast epithelium to the 
stroma13. Morphologically, breast carcinomas are originated from the epithelium of the ducts 
or the lobules that supply milk to the ducts and, according to where the tumour arises, breast 
carcinomas (in-situ and/or invasive breast carcinoma) are called ductal or lobular13,14. Both 
types, ductal and lobular, arise from the terminal duct lobular unit (TDLU)13, see figure 1.1. 
However, it was suggested that cytoarchitectural features should be considered to classify the 
tumour as either ductal or lobular15. 
 
According to the latest version of the WHO classification, invasive breast carcinomas should be 
categorized into the following subtypes: Invasive breast carcinoma of no special type (NST); 
including carcinomas with medullary features which for clinical purposes are now considered 
one end of the spectrum of the tumour infiltrating lymphocytes- rich invasive breast cancer-NST 
(TIL-rich IBC-NSTs) rather than a distinct morphological subtype. It is recommended to use the 
term “IBC-NST with medullary pattern”. In addition, oncocytic, lipid-rich, glycogen-rich clear 
cell, sebaceous carcinomas, which are rarely encountered, are also now recognized as special 
patterns of NST along with carcinoma with osteoclast-like stromal giant cells, pleomorphic 
carcinoma, choriocarcinomatous and melanotic patterns. The second WHO category of invasive 
breast carcinomas is invasive breast carcinomas of special type such as microinvasive carcinoma, 
invasive lobular carcinoma, tubular carcinoma, cribriform carcinoma, mucinous carcinoma, 
invasive micropapillary carcinoma, carcinoma with apocrine differentiation and metaplastic 
carcinoma16. Special type means that when the pathologist observes the cells under a microscope, 
they will show certain f.eatures. The WHO classification of tumour editorial board also stated that 
if the invasive breast carcinoma has mixed components, both subtypes present need to be reported 










1.1.3 Breast cancer molecular sub-types 
 
 
Current molecular subtype classification of breast cancer is based on expression of a small 
number of genes which is quantified using DNA microarray technique17,18. This classification 
which is also based on immunohistochemistry (IHC) markers of breast cancer such as estrogen 
receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 receptor (HER2) 
and Ki-6719, was suggested by the St. Gallen International Expert Consensus in 2011 and 
approved again in 201320. According to the St. Gallen International Expert Consensus 
recommendations breast cancers can fall into 5 categories: luminal A, luminal-B/HER2 
negative, luminal-B/HER2 positive, HER2 type and triple negative. 
Luminal A breast cancers are hormone receptor positive (oestrogen and/or progesterone 
receptor positive) and HER2 negative. They produce low levels of Ki-67 (lower than 14%) - a 
protein which is associated to tumour cell proliferation and growth18 - and have the best 
prognosis among breast cancer molecular sub-types. 
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Luminal -B/HER2 negative breast cancers are also hormone receptor positive (estrogen and/or 
progesterone receptor positive) and HER2 negative. They usually show higher levels of Ki-67 
than luminal A breast cancers (equal or higher than 14%). 
Luminal -B/HER2 positive breast cancers are hormone receptor positive (estrogen and/or 
progesterone receptor positive) and HER2 positive. Their expression of Ki-67 varies. 
Luminal types of breast cancer express high amounts of luminal cytokeratins and genetic 
markers of luminal epithelial cells of the normal breast tissue21. 
Her2-enriched breast cancers are hormone receptor negative (do not have neither estrogen nor 
progesterone receptors) and HER2 positive. They can be treated with chemotherapeutic drugs 
which target the HER2 protein. Their expression of Ki-67 also varies. 
Triple negative (TNBC) or basal-like breast tumours22 are hormone-receptor negative and 
HER2 negative. This type of breast cancer is related to mutations of the BRCA1 gene23. These 
breast cancers tend to be more aggressive than luminal type breast cancers and they do not 





1.1.4 Breast cancer grading 
 
It has been widely accepted that the morphological appearances of tumour cells can be 
correlated with the degree of tumour malignancy25,26. The grade of a breast cancer identifies 
how different tumour cells are from normal epithelial breast cells, therefore, it depicts the 
aggressive potential of the tumour and it can be considered a prognostic factor27. 
 
Many scoring systems are available for determining the grade of breast cancers27. The 
Department of Breast Pathology of Addenbrookes’ University hospital in Cambridge, UK, 
utilizes the Elston-Ellis modification of Scarff-Bloom-Richardson grading system which is 
used in this thesis. This grading method applies only to invasive breast carcinomas, in-situ 
carcinomas are not suitable for being graded with this technique27. 
 
Three morphological parameters are taken into consideration by pathologists while using the 
Elston-Ellis grading technique: the amount of tubule formation, nuclear pleomorphism and 
mitotic activity27. Each parameter is scored 1-3 and then to obtain the overall tumour grade the 
scores for each parameter are added to provide a final score ranging from 3 to 927. Grade 1 or 
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well-differentiated breast cancers have a total score of 3-5, grade 2 or moderately differentiated 




1.1.5 Breast Cancer microenvironment 
 
 
A malignant solid tumour does not only consist of neoplastic cells but also stromal cells. 
Stromal cells have different origin, they can be mesenchymal cells, fibroblasts, myofibroblasts, 
endothelial cells, pericytes and inflammatory cells associated with the immune system28. 
Tumour cells are constantly interacting with the stromal cells and the extracellular matrix 
(ECM) which encircles the tumour29. The tumour microenvironment is composed by these 
numerous stromal cell types and the ECM surrounding the tumour30. 
 
The microenvironment of solid tumours is known to have hostile conditions, usually reflecting 
poor perfusion, oxygen deprivation, nutrient deficiency, severe acidity and elevated interstitial 
fluid pressure (IFP)31. 
 
 
1.1.5.1 Tumour metabolism in breast cancer 
 
 
Tumour metabolism is known to be different from metabolism in normal tissues32. Table 1.1 
displays the main differences between cell metabolism in normal cells and in tumour cells. 
 
Tumour cells grow rapidly forming solid tumour masses. To grow more than 2 mm3 in size, 
new vessel formation occurs (neo-angiogenesis) comprising of a chaotic immature vascular 
system. As the new tumour mass grows, compression and obstruction of these immature blood 
vessels arises. This results in poor oxygen supply especially at the centre of the mass33,34 where 
tumour cells have to adapt to the new hypoxic conditions34. 
 
Under low levels of O2 alternative metabolic pathways are activated in malignant tumours to 
fulfil nutrient demands of growing tumour cells using glycolytic intermediates35 (Figure 1.2). 




Table 1.1 Differences between normal tissue and tumour metabolism37 
 
Normal Tissue Metabolism Tumour Metabolism 
TCA* and ETC* with normal O2 nGlycolysis to derive energy (p
concentration to derive energy (Normal mitochondrial function)   
mitochondrial function)    
90% ATP from glycolysis 50% ATP from glycolysis 
Normal programming Metabolic reprograming- nglucose uptake, 
nLactate production- ntumour cell survival 
(activation of “anaplerotic” pathways) 
Glycolysis-dependant on hypoxia Glycolysis independent of hypoxia36 
*TCA: Tricarboxilic Acid cycle; ETC: Electron Transport Chain. 
 
 
Cells respond to short-term hypoxia (oxygen deficiency) by inducing adaptive reactions 
through the AMP-activated protein kinase (AMPK) pathway, which increases glycolysis by 
the up regulation of catalytic enzymes, such as phosphofructokinase-1 and pyruvate kinase38. 
If the lack of O2 remains, cells stimulate a hypoxia-inducible factor 1 (HIF-1), a heterodimer 
oxygen-sensitive transcription factor composed of alpha and beta subunits that can bind to 
hypoxia-response elements (HREs) activating the transcription of many genes39. Under 
adequate O2 levels, HIF-1 activity decreases by the prolyl hydroxylase-domain protein (PHD) 
which hydroxylates the HIF-1 alpha subunit and enables the interaction with the Von Hippel- 
Lindau protein (pVHL), a tumour suppressor34. 
 
The net result of HIF-1 activation in a hypoxic environment is to shift energy production by 
increasing glycolysis and decreasing mitochondrial function40. HIF-1 increases glycolysis by 
transactivating genes that are able to stimulate the production of glucose transporters, such as 
GLUT1 and GLUT3, responsible for glucose import into the cell and the activation of 
glycolytic enzymes41. Lactate dehydrogenase A (LDHA), responsible for the conversion of 
pyruvate to lactate, is also influenced by HIF-1 alpha41. HIF-1 decreases mitochondrial function 
by transactivating genes such as pyruvate dehydrogenase kinase 1 (PDK1)42,43,44 and MAX 
interactor 1 (MXI1) 43,45. Another mechanism by which HIF-1 controls mitochondrial 
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function in hypoxia is de-activating cytochrome c oxidase in the Electron Transport Chain 
cycle (ETC)44. 
 
HIF-1 alpha stimulation also activates new blood vessel formation in tumours (neo- 
angiogenesis) regulating Vascular Endothelial Growth Factor (VEGF) and its receptors 
(VEGF-R1 and R2). This also promotes the recruitment of endothelial progenitor cells (EPCs) 
from the bone marrow and its differentiation into endothelial cells (ECs) 46,47,48. Both, 




Figure 1.2 Alternative metabolic pathways in the tumour cell activated under hypoxic conditions. Firstly,  
glycolysis increases by the up-regulation of catalytic enzymes participating in this process by the activation of the 
AMP-activated protein kinase (AMPK) pathway, which also stimulates the oxidation of fatty acids. HIF-1 alpha 
can up-regulate glycolytic enzymes. Anaplerotic pathways (pathways that refill the cycle) generate TCA cycle 
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ketoglutarate from glutamine, pyruvate carboxylation which produces oxaloacetate from glucose/pyruvate and 
the oxidation of branched-chain amino acids (BCAAs) like isoleucine, valine and leucine. Carbon from 
macropinocytosis can also enter the TCA cycle and be oxidized to CO2, producing ATP through oxidative 
phosphorylation. Nitric Oxide is a well-known surrogate of oxygen for the activation of cytochrome c oxidase in 
the electron transport chain (ETC). 
 
 
1.1.5.2 Breast cancer vascularity 
 
 
Angiogenesis, the formation of new blood vessels, is a requirement of neoplastic growth, 
proliferation and metastasis from early stages of progression51,52,53. As a general rule, tumours 
do not grow beyond a size of 1 to 2 mm without producing new blood vessels54. New blood 
vessel formation is associated to a process termed “angiogenic switch”, a vascular remodelling 
process which allows cancer cells to invade and grow out their primary niche55. Tumour blood 
vessels display structural and functional abnormalities compared with the normal vasculature 
due to an imbalance between pro and anti-angiogenic factors making them tortuous and leaky56. 
They tend to be elongated, tortuous and have contour irregularities, aberrant branching and 
blind ends31. Similarly, their vascular density is abnormal, and their permeability is high which 
allows significant plasma leakage31. 
 
Angiogenesis is a consequence of microenvironmental factors and the newly formed blood 
vessels are inadequate to meet the demands of the tumour mass55. Angiogenesis is considered 
a target for new cancer treatment strategies because vascular endothelial cells are more 
genetically stable than tumour cells57. 
 
Breast tumours are characterized by an altered general vascular supply, a prominent feeding 
vessel, and increased regional vascularity58. The features and location of the breast tumour are 
factors which influence on the tumour’s vascular supply58. Non-invasive imaging techniques 
of the breasts can monitor the functional fluctuations of tumour vascularity. 
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1.1.5.3 Hypoxia in breast cancer 
 
 
Hypoxia, a deficiency of oxygen resulting from an imbalance between oxygen supply and 
consumption, was firstly described in tumours by Thomlinson and Gray in 195559. Hypoxia 
plays a crucial role in the progression of cancer and can adversely affect patient prognosis. It 
has been shown that hypoxia negatively impacts tumour response to treatment as well as 
reducing patient survival rate60,61,62,63. Tumours that contain large regions of hypoxia are more 
likely to metastasize64-65, a feature that appears to be mediated by several mechanisms, 
including changes in gene expression, inactivation and or activation of genes, and enhanced 
genomic instability64-66. 
 
Hypoxia is a characteristic pathophysiological feature of locally advanced solid tumours, 
including tumours of the breast67 68,69,70,71,72,73, which may exhibit hypoxic areas that are 
heterogeneously distributed within the tumour mass74. 
 
Oxygen is transported to tissues as oxyhemoglobin (HbO2) in the erythrocytes contained in the 
blood, together with other nutrients through blood vessels. Tumour cells are continuously 
growing and they can easily outgrow their vascular supply69,75. Hypoxia can result when the 
diffusion distance of the tumour cells from the nutrient blood vessel is >70 µm (diffusion- 
limited or chronic hypoxia)67,75,76. Furthermore, the characteristic disorganized vascular 
network of cancers with “leaky” fragile capillaries, containing porous fenestrations along the 
endothelial lining, further contributes to the poor delivery of oxygen and nutrients (perfusion- 
limited or acute hypoxia)69. Under these conditions, malignant cells stop growing as quickly as 
before and adapt their growing rate to the new lower levels of oxygen76. Acute hypoxia is often 
called “transient” because tumour blood flow tends to fluctuate in time although, other terms 
are often used, including cyclic, intermittent, repetitive or fluctuating31,77. However, both chronic 
and acute hypoxia can co-exist in tumours62. While cancer cells adapt to hypoxia, they may 
present heterogeneities in O2 distribution78. 
 
1.1.5.3.1 Pathophysiology of hypoxia in breast cancer 
 
 
Hypoxia inducible factor 2 (HIF-2 alpha) is a protein structurally similar to HIF-1 alpha which 
also activates the transcription of many genes distinct from those regulated by HIF-1 alpha79. 
The two hypoxia-inducible factors, HIF-1α and 2α, have been associated with a poor outcome 
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and treatment resistance in the vast majority of cancers, including the breast80. HIF-1α levels 
are not increased in benign fibrocystic disease, but aggressive breast tumours often exhibit 
increased levels of HIF-1α81. 
 
HIF-1α has been associated with an aggressive breast cancer phenotype which includes a large 
tumour size, high grade and levels of proliferation, and lymph-node metastasis81. HIF-1 alpha 
can positively stimulate tumour growth, vascularization, hematogenous and lymphatic 
dissemination of the cancer75. Vascularization is promoted by an increase in the regulation of 
angiogenic factors such as, VEGF, stromal-derived factor 1 (CXCL12), and stem cell factor 
which promotes the migration of bone marrow-derived angiogenic cells to the circulation82. 
 
All breast cancer molecular subtypes have been shown to upregulate HIF-1α and related 
proteins75,83,84. HIF-1 regulates genes implicated in every step of the breast cancer metastatic 
cascade75,85 which can be deconvoluted into a series of discrete steps beginning with the 
epithelial mesenchymal transition (EMT), in which cells lose cell-to-cell contact, become 
motile and locally invade the surrounding stroma85. Local tissue invasion, which requires 
extracellular matrix (ECM) degradation, leads to intravasation that occurs when cancer cells 
penetrate the wall of a blood or lymphatic vessel85. Once breast cancer cells have intravasated, 
they survive within the circulation during transit to distant organs where they have the potential 
to extravasate by repenetrating the vessel wall. The metastatic site must be primed so that it 
presents a suitable microenvironment for cancer cells survival (premetastatic niche)85. 
 
Hypoxia induces activation of unoccupied estrogen receptor alpha in breast cancer cells and 
modulates the level of the receptor expression86,87, which is intimately associated with the 
biology of breast carcinomas. Triple negative breast cancers, one of the most aggressive types 
of breast cancers and thus with worse prognosis88, are associated with basal endoplasmic 
reticulum stress (ERS) which cooperates with hypoxia signaling to promote tumour 
progression and relapse49. 
 
 
1.1.5.4 Other parameters affecting the breast cancer microenvironment 
 
1.1.5.4.1 Interstitial Fluid Pressure (IFP) 
 
Tumour blood vessels fenestrations, which cause leakiness, and the abnormal lymphatic 
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system of cancers89 result on an increased flow of free fluid to the interstitial space. This 
accumulation of fluid in the ECM of the cancer leads to a rise of the interstitial pressure90,91,92. 
Fibrosis and contraction of the ECM can also cause interstitial hypertension93. Values from 50 
to 100 mmHg of IFP have been reported in tumours94. This increase of IFP blocks 
transcapillary transport which affects the uptake of cancer therapeutic agents93. Interstitial fluid 
pressure varies within the same tumour and from one tumour to the other94. It has been shown 






The increase of glycolysis in tumours leads to a rise of lactate production and consequently, to 
tumour acidosis96. In order to maintain homeostasis tumour cells develop mechanisms for 
exporting protons outside the cell, through the cell membrane, which makes the extracellular 
pH (pHe) lower than the intracellular pH (pHi)97,98 whereas, in normal cells, the extracellular 
pH (pHe) is higher than the intracellular pH (pHi)99,100. PH values from 6.5 to 6.9 have been 
reported in the extracellular cancer microenvironment and, by contrast, normal tissues pHe 
values range between 7.2 and 7.5101. In mouse breast cancer models, lower pHe tumour values 
have been found in the range of 6.3-6.9, which may suggest high degree of malignancy102. 
 
Extracellular tumour acidosis has been associated to an increase of tumour aggressiveness103, 
metastasis104,105, chromosomal rearrangements106, and angiogenesis107. Some studies have 




1.2 Importance of understanding the tumour microenvironment 
 
 
As it was previously described, the tumour microenvironment can enhance tumour progression 
and metastasis. Similarly, many factors such as tumour hypoxia, acidosis and interstitial 
hypertension can create resistance to cancer treatment, radiation and/or chemotherapy. A better 
understanding of the microenvironment of breast cancer will guide us towards the development 
of treatment capable of destroying tumour cells in an attempt to improve patient prognosis, by 
increasing disease free survival and overall survival rates. 
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For decades, imaging methods have helped scientists and physicians gain insight into the 
tumour micromilieu and since these methods are non-invasive, patients are able to tolerate them 
more than invasive tissue biopsies. 
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Chapter 2. Imaging the breast cancer microenvironment with MRI and PET 
 
 
Mammography is the most common screening tool to detect breast cancer at an early stage, 
often in conjunction with breast ultrasound, particularly in women under the age of 40 years 
for whom mammography alone is less sensitive due to the abundant fibro-glandular tissue1. 
These conventional imaging modalities have well-documented pitfalls, particularly in missing 
small lesions and measuring tumours while distinguishing them from surrounding breast 
parenchyma2,3,4,5,6. The density of the adjacent parenchyma also poses a major challenge for 
mammography, limiting its overall sensitivity and specificity7,8,9,10,11. The latter has been 
overcome by Tomosynthesis, in which thin slices or images of a volume of tissue are used to 
reconstruct a pseudo 3D image of the breast, to detect breast cancer6,12. Some studies have 
shown that the addition of tomosynthesis to conventional or digital mammography can increase 
detection rates of breast cancer6,13 , whereas tomosynthesis in combination with ultrasound is 
better than mammography alone for the determination of cancer morphology14. Alternative 
methods for imaging breast cancer include breast MRI, which has demonstrated higher 
sensitivity than all other breast imaging techniques for the diagnosis of breast malignancies 
regardless of the density of the parenchyma15,16. Currently, MRI is recognised as a valuable 
addition to the diagnostic work-up of breast mammography and ultrasound1,16,17. 
 
The injection of contrast material to enhance the visualisation of tumours with respect to the 
rest of the breast tissue, is being used in all imaging modalities. In mammography it is known 
as contrast-enhanced mammography (CEM) or digital mammography (CEDM); in 
tomosynthesis as contrast-enhanced tomosynthesis (CET), in tomography (CT) as contrast- 
enhanced CT or angio-CT and in MRI as dynamic contrast-enhanced (DCE) MRI. All contrast 
modalities have higher diagnostic accuracy than non-contrast modalities18. In a study by Chen- 
Pin et al. the diagnostic performance of CEDM with or without CET was equivalent to DCE- 
MRI for breast cancer18. Diagnosis of breast cancer is confirmed with image-guided core 
biopsy and/or fine needle aspiration cytology. 
 
Beyond cancer diagnosis, the interest in visualizing the tumour microenvironment (TME) has 
been increasing not only for the clinical relevance (influence on carcinogenesis and treatment 
resistance) but also because the TME is abundant in comparison to cancer cells and it may 
contribute up to 90% of the tumour volume19. Many imaging techniques have been developed 
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to visualize, quantify and characterise the TME20,21,22,23,24. The most frequently used imaging 




2.1 Breast Magnetic Resonance Imaging (MRI) techniques available for imaging breast 
cancer microenvironment 
 
MR imaging allows identification of the presence and progression (or regression) of disease, 
as well as the morphology of the breast lesion. Breast MRI is a non-invasive imaging technique 
that combines excellent soft tissue contrast with cross-sectional anatomical detail, allowing 
imaging with high spatial resolution and sensitivity25. Unaffected by breast density, MRI can 
show much more accurate delineation of lesion morphology and extent. It offers superiority in 
terms of image acquisition, as volumetric data can be acquired for both breasts simultaneously 
and in any desired plane, typically with sub-millimetre resolution. MRI has improved cancer 
treatment planning and reduced unnecessary biopsy procedures26,27,28,29. 
 
In addition to evaluating the morphological aspect of the breast lesion, MRI can simultaneously 
assess multiple cancer-biological processes or hallmarks of cancer such as vascularity, 
metabolism, hypoxia and cellularity30. The combined assessment of different functional 
(because they are indirect markers of the cancer physiological processes) MRI parameters is 
known as multiparametric resonance imaging (mpMRI) which offers high specificity to image 

















Figure 2.1 T1 post-contrast weighted image of a female patient of 70 years old. The yellow 
square illustrates an NST carcinoma on the right breast, ER and PR-positive, HER2-negative. 
 
 
2.1.1 Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) for imaging 
tumour vascularity and hypoxia 
 
DCE-MRI provides high spatial resolution of tumour vascular organization, perfusion and 
permeability. DCE-MRI refers to a serial acquisition of images at the same spatial location 
before, during and after intravenous administration (preferably by a power injector) of an 
extracellular contrast agent. By observing the uptake and washout of a contrast agent through 
a region-of-interest (ROI) placed on the most enhancing part of the lesion, the behavior and 
extent of the disease can be accurately assessed together with the vasculature. The primary 
effect of administering gadolinium chelates (Gd) is to shorten the T1 relaxation time of the 
hydrogen nuclei where the contrast medium accumulates33. This results in signal hyperintensity 
on T1-weighted images. By subtracting pre-contrast from the post-contrast images, the heart, 
blood vessels and lesions (and their vasculature) are hyper-intense compared to tissues that 
have little or no uptake of contrast. Information from DCE-MRI can be measured qualitatively, 
semi-quantitatively or quantitatively. 
 
The tumour signal intensity information can be converted to contrast agent concentration, 
elucidating key physiological metrics of vascular function such as blood flow and capillary 
permeability, by performing pharmacokinetic modelling. Quantitative analysis of tumour 
vascular function using DCE-MRI is based on these mathematical pharmacokinetic models 
which provide measurements of the distribution of the contrast agent between the intravascular 
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and the interstitial space34. The Tofts’ model (or standard Tofts’ model) and extended Tofts’ 
model have become a standard for the analysis of DCE-MRI35. A study by Sourbron et al35 
suggests that the Tofts’ model should be used in tissues with weak vascularization or low blood 
flow whereas the extended Tofts’ model results more accurate in highly perfused tissues. In 
tissues with intermediate vascularity, neither model offers a good fit to the tissue 
concentrations. The standard Tofts’ model has been recommended for DCE- MRI of the breast 
because it estimates quantitative parameters within an error margin of 20%36. 
 
DCE-MRI quantitative analysis provides a range of pharmacokinetic parameters characterizing 
the movement of the contrast agent across the endothelium, between the intravascular and the 
extravascular space. Such parameters are: Ktrans (min-1), the volume transfer constant of contrast 
agent from the blood plasma to the extravascular-extracellular space (EES); kep, (min-1) the 
transfer rate constant of contrast reflux from the EES to the blood plasma; vp, total blood plasma 
volume, and ve, total EES volume fraction37,38. Owing to the hyperpermeability of the tumour 
vasculature, it is hypothesized that these parameters will be different in pathologic vessels like 
tumour capillaries. Some studies have reported reliable Ktrans values (0.50-0.5639,40), kep (2.5939) 
and ve (0.1539) values for characterizing benign and malignant breast lesions with sensitivity, 
specificity and accuracy over 80%. Huang et al41 demonstrated that low Ktrans values could 
differentiate malignant from benign breast lesions. Other authors have found higher Ktrans, kep 
and ve values in malignant breast tumours in comparison to normal breast parenchyma or 
benign tumours42,43. Pharmacokinetic analysis requires measurement of an arterial input 
function (AIF), which refers to the concentration of the contrast agent in a vessel entering the 
tissue over time38. 
 
Different investigators have demonstrated that Ktrans and kep can differentiate between benign 
and malignant breast lesions and discriminate different breast cancer subtypes25,44. Other 
authors found that percentage changes of Ktrans after the first cycle of NAC, were a good 
predictor of tumour pathological response45. 
 
When the DCE-MRI analysis method does not require characterization of the AIF, it is 
considered semi-quantitative. Semi-quantitative metrics are derived from the time-signal 
intensity (SI) curve38, and examples include the initial area under the curve (iAUC), time to 
peak (TTP) and slope of the washout curve37. 
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The Breast Imaging Reporting and Data System (BI-RADS) lexicon which was developed by 
the American College of Radiology (ACR) in order to standardize breast MRI reports, in 
addition to the evaluation of the lesion morphological features (shape, size and margins), 
includes MRI enhancement characteristics of the tumour such as internal and peripheral 
enhancement (also denominated rim enhancement, a sign of central hypoxia in the tumour46) 
and the analysis of the time-signal intensity curve of the cancer, known as well as tumour 
kinetic curve. 
 
Semi-quantitative methods used in DCE-MRI are based on describing the shape of this time- 
signal intensity curve of Gd-concentration in the lesion47. The tumour enhancement curve helps 
to differentiate malignant tumours from benign lesions48,49,50. The enhancement kinetics curve 
is obtained by plotting the signal intensity values in breast tissue intensity over time after 
contrast material injection. It has two phases, which are assessed separately, an initial phase 
and a delayed phase (Figure 2.2). The initial phase or initial slope occurs within the first 2 mins 
after contrast injection or when the time-signal intensity curve starts to increase. It is slow if 
there is a signal increase of less than 50% compare to the un-enhanced baseline, medium if the 
signal intensity increases from 50 to 100%, and fast if the signal intensity increases more than 
100%. This enhancement rate is calculated according to the following enhancement formula: 
% Enhancement rate = [(SIpost - SIpre)/SIpre] × 10051 where SI refers to signal intensity. 
 
The delayed phase occurs after the first 2 mins post-contrast or after the curve has peaked. A 
persistent increase in signal intensity after contrast injection is considered a type 1 kinetic curve 
and is correlated to tumour benignity. A type 2 kinetic curve has a plateau pattern where there 
is initial contrast uptake followed by a plateau phase and indicates malignancy (however, the 
lesion could be benign or malignant). Type 3 curves are characterized by initial rapid uptake 
followed by rapid signal washout and it is strongly suggestive of malignancy47. Small cancers 
and DCIS usually present with a type 1 kinetic curve or steady enhancement in DCE-MRI 
whereas large tumours present type 3 kinetic curves or washout of the signal enhancement 









Figure 2.2 Phases of the time-signal kinetic curve of breast lesions. SI: Signal Intensity, mins: 
Minutes. A slow initial slope usually precedes a delayed phase of persistent enhancement (type 
1 curve) whereas medium or fast initial slopes tend to be followed by plateau or washout curves 
(type 2 or 3, respectively). 
 
 
DCE-MRI qualitative analysis consists of examining the internal enhancement features of the 
cancer which according to the fifth and last BI-RADS edition53 are as follows: homogeneous 
enhancement, heterogeneous enhancement and rim enhancement49. In routine clinical practice, 
the data from DCE-MRI is analyzed qualitatively, using the BI-RADS lexicon, and semi- 
quantitatively (analysis of the enhancement curves of the lesions). The calculation of DCE- 




DCE-MRI is an evolving tool for determining breast disease and an excellent imaging modality 
to monitor treatment response in breast cancer patients receiving neoadjuvant chemotherapy 
(NAC), allowing visualization of the extent of disease and lesion heterogeneity, detection of 
changes in angiogenic properties before morphological alterations, and prediction of the overall 
response early during treatment. Likewise, gadolinium diethylene-triamine penta- acetic acid-
based (DTPA or gadolinium-pentetate) DCE-MRI has been useful measuring hypoxia: 
Egeland et al54 observed that xenografted tumours of human melanomas showing 
28  
high Ktrans and ve values had low fractions of hypoxic cells on pimonidazole stained specimens, 
whereas tumours showing low Ktrans and ve values had high hypoxic fractions. DCE-MRI has 
also provided measures of tumour hypoxia and IFP in cervical carcinoma55. These studies 
support the current attempts to establish DCE-MRI as an indirect method for assessing the 
presence and extent of hypoxia in human tumours. 
 
 
2.1.2 Diffusion weighted Imaging (DWI) for imaging tumour perfusion and cellularity 
 
 
In biological tissues, diffusion of water molecules follows a pattern according to the 
biophysical characteristics of the tissue such as tissue structure, cell membrane integrity and 
cell density34. In some pathological conditions like cancer, this diffusion pattern is disturbed56. 
Diffusion-weighted MRI (DW-MRI) or DWI is a non-invasive technique that visualizes the 
microstructural characteristics of water diffusion in biological tissues without the 
administration of contrast. The microscopic motion includes blood microcirculation in 
capillary networks, therefore, both, diffusion of water and perfusion are assessed by DWI. 
DWI-MRI has a short acquisition time of 2-3 minutes and it is available on most commercial 
scanners57. The sensitivity of DWI-MRI mainly depends on the degree of diffusion weighting, 
described by the b-value (s/mm2). 
 
To measure the diffusivity of the tissue, the Apparent Diffusion Coefficient (ADC, calculated 
in mm2/s) is generated for each voxel in the image and presented as ADC maps58. The ADC 
can be calculated using two or multiple b-values varying between 0 and 1000 mm2/s57,58,59. In 
malignant breast tumours, due to the high cellular density and abundance of intra and 
intercellular membranes, there is a more restricted diffusion and lower ADC in comparison to 
the normal breast parenchyma and benign lesions60,61,62. There is controversy with respect to a 
cut-off value of ADC to differentiate malignant from benign breast lesions, however, studies’ 
cut-off values of ADC range between 1.1 and 1.3 x 10-3 mm2/s59,63. Recently, body background 
signal suppression (DWIBS) has been added to DWI because it is superior to conventional 
DWI for the visualization of malignant and benign breast lesions64,65,66. 
 
DWI-MRI may reduce false positives and unnecessary biopsies25. It also enables the 
differentiation of breast cancer subtypes, including invasive versus non-invasive 
carcinomas67,68. DWI-MRI together with DCE-MRI of the breast provide higher diagnostic 
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accuracy than DCE-MRI alone69,70. Likewise, DWI is a useful tool for the assessment of 
tumour response after NAC. It has been reported that changes in ADC occur earlier than 
changes in vascularity (DCE-MRI parameters) or tumour size71,72. ADC can be used to identify 
metastatic breast cancer in axillary lymph nodes, and it has shown good correlations with 
prognostic factors of breast cancer (tumour grade and molecular markers such as oestrogen 
receptors and progesterone receptors)73. 
 
2.1.2.1 Intravoxel Incoherent motion Diffusion (IVIM) 
 
 
IVIM results from the “pseudo-perfusion effect” caused by blood flow within a random 
capillary network58,74,75. Intravoxel Incoherent motion DWI is obtained from multiple b-values 
without the injection of contrast material76. It provides measurements of diffusion and 
perfusion separately. Pure diffusion is acquired as tissue diffusion coefficient (Dt)77. Pseudo-
diffusion coefficient (Dp) and microvascular volume fraction (f) are the perfusion parameters78. 
All these parameters allow a non-invasive assessment of the tumour microenvironment. 
 
Many researchers have been able to correlate IVIM parameters with prognostic factors of breast 
cancer and DCE-MRI parameters79,80,77. In those studies, (Dt) values were positively correlated 
to hormonal expression79,80 and Ki-67 expression77. Similarly, Sung et al76 demonstrated positive 
correlations between IVIM-derived ADC and perfusion fraction (f) and DCE-MRI tumour 
kinetic features. 
 
2.1.2.2 Diffusion Tensor Imaging (DTI) 
 
 
Water molecules move in different directions within biological tissues (anisotropy)88. 
Obstacles like cell membranes, can block the movement of molecules going in some directions 
causing molecular displacements89 (the molecule changes its original orientation). Another 
factor which can influence on these molecular displacements is the application of diffusion 
gradients in multiple directions during the MRI examination to improve the analysis of 
diffusion anisotropy90. DTI-MRI detects and visualizes these molecular displacements90. DTI-
derived parameters mean diffusivity (MD, an estimate of the average anisotropy) and fractional 
anisotropy (FA, a measure of the directionality of diffusion anisotropy) correlate well with 
tissue cellularity91 and they can provide information about tumour aggressiveness in breast 
cancer92. 
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A lower diffusion anisotropy has been found in breast cancers in comparison to the normal 
breast parenchyma91. Other researchers have successfully used DTI to differentiate malignant 
from benign breast tumours93,94. Kim et al92 reported associations between DTI- derived 
metrics, MD and FA, and breast cancer histological prognostic factors. Specifically, they 
reported that lower MD and FA values were significantly associated with larger tumour size 
(>2 cm), nuclear grade 3 and lymph node metastasis. In the same study, significant differences 
in MD were observed between invasive breast carcinoma and DCIS. 
 
2.1.2.3 Diffusion weighted Kurtosis (DKI) 
 
 
Water molecules usually diffuse without any restrictions (with a “Gaussian pattern”), however, 
as previously mentioned, in biological tissues water molecules follow the tissue microstructure 
which restricts their free movement and diffusion (non-Gaussian diffusion)81,82. DKI quantifies 
the deviation of water diffusion from a Gaussian pattern83. In 2005, Jensen et al83 proposed a 
DKI model from which parameters such as kurtosis and diffusion coefficients were derived. 
 
DKI has demonstrated higher sensitivity than conventional DWI in the diagnosis of different 
types of cancer, including breast84,85,86,87. These studies have revealed that high grade cancers 
show more heterogeneity in their microstructure than low grade cancers. In a different study82, 
DKI showed higher specificity than conventional DWI for differentiating malignant from 
benign breast lesions. High kurtosis values and low diffusivity coefficients were observed in 
grade 3 breast cancers and cancers with high Ki-67 expression. 
 
There are two known limitations to DKI1: The first one is the long image acquisition time 
compared with that of Diffusion Tensor Imaging (DTI); a minimum of two nonzero b-values 
and 15 diffusion directions need to be acquired to calculate the diffusion and kurtosis tensor. 
This long image acquisition time increases susceptibility to patient motion and decreases 
throughput. Clinically feasible imaging protocols of 7–10 minutes have been suggested for 
DKI2,3. Another limitation of DKI is that the model is more complex (21 independent 
parameters) than DTI (six independent parameters)4.  
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2.1.3 BOLD-MR for imaging tumour hypoxia and perfusion 
 
 
This functional MRI technique has been traditionally used to measure tumour oxygenation, 
however, in brain tumours, it has proved to be able to assess tumour perfusion as well34,95. 
Blood oxygen level-dependent MRI ( BOLD-MRI) can show the hemodynamic fluctuations 
which lead to oxygenation changes95,96,97. BOLD-MRI distinguishes oxygenated hemoglobin 
(oxy-Hb) from deoxygenated hemoglobin (deoxy-Hb) which is paramagnetic (causes signal 
increase on T1-weighted images) and produces a change in the T2*-relaxation rate of the tissue 
(see figure 2.3), therefore, signal loss is observed in T2* weighted images98. Because of this, 
T2*-weighted sequences are used to detect changes in deoxy-Hb which are small and typically 
range between 1-5%. Although T2* weighted images are preferred in most cases to detect 
endogenous deoxy-Hb as contrast agent, a study deriving BOLD contrast from T2 weighted 
images (T2WI) proved that T2WI are trustworthy to detect BOLD contrast in the breast99. 
Since blood flow in tumours is related to a response of the body to oxygen and carbon dioxide 
levels in tissues, BOLD-MRI R2* (1/T2*, apparent relaxation rate or decay rate) could be 
considered an indirect marker of hypoxia100. Interestingly, Li et al101 reported that R2* in 
treatment-naïve breast cancers may be a marker of perfusion whereas in treated breast cancers 
R2* by contrast, seems to be a marker of tumour hypoxia. This is explained by the fact that 
before NAC, the authors observed a relationship between R2*, relative blood flow and relative 
blood volume which it was not observed after NAC treatment. 
 
There have been many reports of BOLD-MRI in the breast: Jiang et al102 used an oxygen- 
breathing challenging BOLD technique in patients with locally advanced breast cancer. A 
preliminary observation was that a greater BOLD response was correlated with better treatment 
response. More recently, Wallace et al103 investigated stimuli combinations for inducing BOLD 
contrast in healthy volunteers and breast cancer patients. Oxygen vs. 5% carbon was found to 
be the most robust stimulus for BOLD imaging in the breast, with heterogeneous results in 
malignant tissue. 
 
BOLD-MRI can provide a non-invasive approach to assess breast tumour physiology, 
nevertheless, there are number of limitations for BOLD imaging: (1) blood flow is only an 
indirect marker of hypoxia; (2) T2*-sequences are susceptible to field inhomogeneity due to 
bone-air interfaces (particularly in the brain), hemosiderin/blood products, rapid flow in large 







Figure 2.3 Physics behind BOLD-MRI98. After termination of the radiofrequency pulse 
transmission, the receiver coil detects a decrease or decay of the T2* and T2 relaxation times of 
the tissues due to signal loss. This T2* decay is detected and measured by BOLD-MRI. RF: 
Radiofrequency; TR: Repetition time (time between one pulse and the next one); TE: Echo time 
(time between consecutive echos). 
 
 
2.1.4 Oxygen-Enhanced MRI (OE-MRI) for imaging tumour hypoxia 
 
An emerging imaging technique is oxygen-enhanced MRI (OE-MRI). This method is based on 
measuring the increase of the longitudinal relaxation rate of protons (R1) after the inhalation of 
oxygen. Since oxygen levels are normally adequate to satisfy mitochondrial demands, excess 
oxygen remains dissolved in plasma and interstitial fluid104. The change of R1 ('R1) is sensitive 
to oxygen concentration in the interstitial fluid and plasma and the relationship between 'R1 
and pO2 has been also shown by a research group105,106. As 'R1 is not dependent upon 
haemoglobin saturation, haemo-dynamic effects of hyperoxic gas breathing would not 
influence on it107. R1 changes produce intensity changes on MRI T1 weighted images which 
typically are d5%108. Other biomarkers of OE-MRI, when used together with DCE-MRI, are 
Oxy-R (or perfused Oxy-R) which highlights the regions of the lesion that are perfused but 
lack oxygen enhancement and Oxy-E, which refers to tumour perfused areas with oxygen 
enhancement109. Oxy-R has provided utility distinguishing hypoxic tumour areas from well- 
oxygenated areas107. 
 
O’Connor et al110 demonstrated that OE-MRI accurately quantifies tumour hypoxia non-
invasively and that this technique could be translatable to the clinic. Similarly, Salem et al111 
showed that OE-MRI could be a good imaging modality to monitor hypoxia changes in non- 
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small cell lung cancer (NSCLC), to predict tumour response to immunotherapy in patients with 
hypoxic tumours and to guide radiotherapy by mapping regional hypoxia. OE-MRI could bear 
potential utility in radiotherapy: This modality was capable to distinguish radiation necrosis 
from high-grade gliomas in mouse models112. The value of OE-MRI continues to be 
investigated by several research groups. 
 
2.1.5 Proton Magnetic Resonance Spectroscopy (1H-MRS) for imaging tumour metabolism 
and pH 
 
Magnetic Resonance Spectroscopy (MRS) provides spatially localized signal spectra of tissues 
in which the structure and concentration of chemical compounds in a certain region of interest 
(ROI) are shown as spectral peaks34. The position of each peak is determined by the chemical 
structure, and the area under each peak is determined by the chemical concentration113. Many 
studies using 1H-MRS in the breast have identified high levels of the metabolite Choline in 
malignant breast tumours compared with benign and normal breast tissue114,115,116. Choline is 
needed to synthesize major phospholipids vital for cell membranes, hence, choline is a well- 
known marker of cell density and proliferation. The Choline peak (tCho, total Choline peak) 
that is located at 3.2 ppm (parts per million), represents different choline-containing 
compounds (free choline, phosphocholine and glycerophospho-choline)25 which can be 
detectable in the normal breast parenchyma as well but at higher signal to noise ratio (SNR) 
levels113,117. 
 
Proton MRS can be very useful to detect cellular anaerobic metabolism since lactate is one of 
the more important compounds assessed on MR spectroscopy. Lactate resonates at 1.3 ppm 
with a characteristic double peak at long echo times (TE)118. It is elevated in necrotic areas 
which are commonly observed in higher grade tumours and infections119. Breast cancers can 
show high concentration of lactate120. Serganova et al121 investigated lactic dehydrogenase A 
(LDH-A) regulation in primary breast cancer. The high lactate levels in small primary tumours 
of the breast were associated with intense pimonidazole staining (an immunohistochemical 
marker of hypoxia). The same authors recommended Lactate-MRS to monitor LDH-A targeted 
therapy and for the surveillance of patients who are at high risk of developing metastasis. 
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1H-MRS can be performed as single or multi-voxel proton MRS. Single proton MRS is the 
most widely used acquisition approach25 and it produces a single chemical spectrum from a 3- 
dimensional cuboid volume (or voxel) placed on the centre of a lesion25,34. On the other hand, 
multivoxel proton MRS produces a spatially resolved grid of spectra from a larger volume of 
voxels using multiple phase-encoding steps25,34. Breast MRS analysis is done qualitatively, 
semi-quantitatively or quantitatively113. The qualitative analysis consists of visually detecting 
the peak of total Choline (tCho). Semi-quantitative analysis focuses on measuring tCho SNR, 
peak height or peak integral. A threshold of tCho SNR >2 is commonly used to distinguish 
malignant from benign breast lesions25. The quantitative analysis of tCho is based on the 
calculation of its concentration using internal referencing to unsuppressed water signal (MRI 
scanners detect and localize the signals from hydrogen nuclei in water and lipids whose peaks 
dominate in-vivo spectra) or external referencing to a phantom with a known chemical 
concentration113. 
 
1H-MRS improves the diagnosis of breast cancer. 1H-MRS Choline concentration has shown 
high specificity for differentiating benign breast lesions from cancers122,123,124. Other 
researchers have reported a high sensitivity and accuracy of 1H-MRS for breast cancer 
detection32,125. On the other hand, different investigators observed low sensitivity of proton 
MRS for detecting choline levels in small breast cancers (<10 mm)113. Choline levels in breast 
cancer may be an early predictive marker of tumour response after treatment since they reflect 
treatment-induced alterations in cell proliferation prior to changes in tumour size126,127,128. 
 
2.1.6 Hyperpolarized carbon-13 Magnetic Resonance Imaging (HP 13C-MRI) for imaging 
tumour metabolism and hypoxia 
 
Hyperpolarized (HP) carbon-13 (13C) MRI is another non-invasive imaging modality which 
allows real-time in-vivo evaluation of cancer metabolism129. Naturally, the MRI signal of 
endogenous 13C nuclei is low due to its low abundance in the human body (only 1.1% of carbon 
in the body is 13C) and to its low nuclear spin polarization (the spins of 13C nuclei are not well 
aligned to the external magnetic field)130. In order to observe 13C alone or labelled to substrates 
such as pyruvate (the most widely used 13C-labelled substrate131,132,133) using MRI, the MRI 
signal needs to be increased by a process called hyperpolarization129, which increases the signal 
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of 13C by more than 10,000 fold134. The basic principle of hyperpolarization is that electrons 
have a high level of polarization (most of the electrons are aligned in the same direction) at low 
temperatures and in high magnetic fields129. This high level of polarization can be transferred 
to 13C-metabolic substrates (increasing their MRI signal) by mixing free electrons with the 13C- 
labelled substrates135. The mixture needs to be placed in a polarizer at a high magnetic field 
(3.0-5.0 T) and at a low temperature. Lastly, the high electron spin polarization is transferred 
to the 13C nuclear spins by microwave irradiation, and then the sample is ready to be injected 
into patients34. 
 
Pyruvate is converted into lactate by the enzyme lactate dehydrogenase (LDH) through a 
catalytic reaction. In tumours, the isoform A of the enzyme is predominantly presented136. HP 
13C-MRI affords high sensitivity to image in real time the spatial distribution of intravenous 
(i.v) hyperpolarized 13C-pyruvate and the hyperpolarized 13C-lactate formed from it137. The 
level of hyperpolarized-13C lactate produced from the metabolism of 13C pyruvate increases 
with cancer grade, reflecting disease aggressiveness130,138, and can provide a rapid assessment 
of treatment response. The latter has been suggested by multiple studies demonstrating an early 
reduction in 13C lactate following therapy139,140. Gallagher et al138, demonstrated the feasibility 
of hyperpolarized 13C MRI in patients with breast cancer. In their study, 13C-pyruvate 
metabolism displayed tumour metabolic heterogeneity in breast cancers where lactate labelling 
correlated with tumour volume, MCT-1 expression (a protein which facilitates the transport of 
lactate across the plasma membrane141) and HIF-1 alpha. Similarly, different authors have 
considered that hyperpolarized 13C-pyruvate may be a useful MRI biomarker of MCT-1 
regulation and malignant transformation in breast cancer cells142. 
 
 
2.2 Positron Emission Tomography (PET) for the evaluation of breast cancer 
microenvironment 
 
Pathological conditions often begin with molecular or biochemical changes occurring in an 
organ or tissue at a cellular level. Positron Emission Tomography (PET) is a highly sensitive 
and accurate nuclear medicine technology which identifies changes in the tissues at an earlier 
stage, before anatomical or structural changes143. PET can detect diseases in early onset 
although it is also used for the functional or metabolic assessment of normal tissues. PET 
detects the gamma-rays from positron-emitting isotopes. Some of
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the most frequently used radioisotopes are carbon-11 (half-life, T1/2 = 20 min), nitrogen-13 
(T1/2 = 10 min), fluorine-18 (T1/2 = 110 min), copper-64 (T1/2 =12.7 h), and iodine-124 (T1/2 = 
4.2 days)143, among others. 
 
 
The physics behind PET can be summarized as follows (see Figure 2.4)144. When the positron- 
emitting radiotracer is administered to patients, the nucleus emits a positron which travels a 
short distance, up to a few millimeters (mean positron range), to meet an electron in the tissue. 
This process is called annihilation (the positron annihilates with the electron). This annihilation 
event produces a pair of 511-KeV photons that are emitted in opposite directions, with an angle 
between them of approximately 180o. The resulting gamma rays (photons with the highest level 
of energy) are the signals detected by the PET scanner and converted to images. PET provides 
images of the quantitative uptake of the injected radiotracer from which the concentration of 
radiotracer can be calculated in becquerels per milliliter (Bq/mL). Radiotracer uptake can also 
be measured semi-quantitatively by calculation of the standardized uptake value (SUV) in a 
static PET image, this means a single point in time. The SUV is calculated by a formula, see 
Figure 2.5145. 
 
Figure 2.4 Annihilation reaction144. This image illustrates the nucleus of the radiotracer 
containing N=neutrons (blue circles) and P=protons (yellow circles) from which the positron 
is emitted after travelling a small distance called the mean positron range. The positron, which 
is positively charged, annihilates with a negatively charged electron while being in motion and 
then, 2 photons are emitted with an angle between them of 180o. This angle may vary 0.5o. The 
gamma rays from the two photons will hit the detectors (sand colour squares) of the PET 
scanner ring. 
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Positron Emission Tomography uses a broad range of radiotracers (molecules or 
radiopharmaceutical drugs labelled with different radioisotopes) which offer many advantages 
for the in-vivo and real-time evaluation of functional processes related to cancer 
pathophysiology. In the area of oncology, PET is being utilized for cancer staging, assessing 
treatment strategies and monitoring the effects of cancer therapy. The most commonly used 
oncologic PET radiotracer is 18Fluoro-2-deoxy-glucose (18F-FDG) and it is the only one 
approved by the Food and Drug Administration (FDA) for routine clinical use. 
 
By combining PET with CT, functional and anatomic images are obtained from the same 
patient. PET-CT is required for differentiating normal from abnormal radiotracer uptake 
because PET provides poor anatomic detail which CT affords. 
 
 
𝑆𝑈𝑉 (𝑔/𝑚𝐿) =  
Tissue radioactivity concentration (Bq/mL)




Figure 2.5 SUV equation. Tracer concentration in the tissue is expressed in becquerels per 




2.2.1 PET for imaging tumour metabolism 
 
 
Like other cells, tumour cells take up the glucose by facilitated transport via glucose 
transporters (GLUTs) and, later through glycolysis, pyruvate is derived from glucose under 
aerobic conditions. However, under anaerobic conditions (under the absence of oxygen), 
pyruvate is converted to lactate by LDHA146. Cancer cells have an increased glucose uptake 
due to upregulation of hexokinase activity146. 18F-fluoro-2-deoxy-D-glucose (18F-FDG) is a 
radiopharmaceutical analogue of glucose that is transported through cell membranes by 
GLUTs, in the same way that glucose. 18F-FDG is then phosphorylated to 18F-FDG-6-
phosphate which cannot undergo glycolysis, unlike glucose-6 phosphate, and hence it is 
trapped within metabolically active cells147. The rate of 18F-FDG uptake by cancer cells is 
proportional to their metabolic activity. 
 
Since most tumour cells have an increased glucose metabolism, 18F-FDG is trapped by all types 
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of cancer including most types of lymphoma, melanoma, breast cancers, ovarian, cervical, head 
and neck, stomach, oesophageal, colorectal, lung, etc148. Many studies have reported that 
changes in 18F-FDG uptake predict tumour response to therapy and that further information 
regarding tumour grade and proliferative status may also be derived from 18F-FDG scans149. 
18F-FDG-positron emission tomography (18F-FDG-PET) is being utilized in breast cancer for 
the detection and differentiation of primary breast tumours, lymph node staging, detection of 
residual and metastatic disease and for the follow-up of patients after surgery, chemotherapy 
and/or external radiotherapy150,151,152. 
 
According to a meta-analysis involving 2,460 breast cancer patients, 18F-FDG-PET 
sensitivities range between 20-100% and specificities between 65-100%153. Another study154 
reported that the sensitivity of 18F-FDG-PET-CT in small breast lesions (<5mm) was 53% 
whereas in large lesions (>20mm) the sensitivity was 92%. The uptake of 18F-FDG may be 
influenced by the phenotype, mitotic index and grade of the primary breast tumour155. 18F-FDG 
has proved to be helpful predicting and monitoring response to neo-adjuvant chemotherapy, 
even early in the course of treatment156,157,158. Some authors157 demonstrated a decrease of more 
than 40% in 18F-FDG SUVmax in responding tumours after NAC, whereas non-responding 
tumours showed an increase, no change, or only a small decrease (of about 24%) in 18F-FDG 
SUVmax. As for lymph node metastases, 18F-FDG-PET is not sensitive enough to detect 
microscopic metastases in non-pathologically enlarged lymph nodes. However, in lymph node 
metastases larger than 3 cm, the sensitivity and specificity of 18F-FDG-PET-CT at 97% and 
100% has been reported159,160. 
 
Recent studies have shown the advantage of delayed or dual-time point imaging (DTPI) with 
18F-FDG-PET to distinguish malignant from benign 18F-FDG uptake161,162. Delayed scan time- 
points may improve 18F-FDG-PET image quality due to the greater tumour to background 
contrast163,164. 
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2.2.2 PET for imaging tumour perfusion 
 
 
For years 15O-labeled water (15O-H2O)-PET has been considered the gold standard method to 
quantify blood flow in humans165. However, not many imaging centres can perform these PET 
studies because an on-site cyclotron to produce 15O-H2O is required. Since the half-life of 15O 
is so short (only 122 seconds165), the radioactive activity of 15O-H2O would decay shortly after 
the radiotracer is produced. 15O-H2O-PET is a promising diagnostic tool for the assessment of 
tumour aggressiveness166. In prostate cancer, absolute quantification values of tumour 
perfusion measured by 15O-H2O-PET have been highly correlated to post-prostatectomy 
tumour Gleason grades167. In breast cancer patients, 15O-H2O-PET has proved to be effective 
for the early detection and quantitative analysis of sub-clinical post-radiotherapy changes in 
heart perfusion168,169. 
 
Different PET radiotracers produced with other radioisotopes are being used to quantify tumour 
blood flow. Since 1989, when the FDA allowed its use in clinical studies, 82Rubidium (82Rb)- 
PET has proved to accurately quantify myocardial (MBF) blood flow166,170. 82Rubidium, is a 
potassium analogue which is trapped within cells in metabolically active tissues at a rate 
proportional to tissue blood flow170,171 and as it is retained longer than 15O in the tissues, 82Rb 
allows quantitative measurements of blood flow using kinetic modelling and semi-quantitative 
measurements using SUV in late uptake images166. Few years ago, 82Rb’s potential to measure 
tumour blood flow (TBF) started to be evaluated. Mads R Jochumsen et al166 demonstrated that 
82Rb-PET-CT was a diagnostic tool for quantitative tumour blood flow imaging after 
comparing its performance with the one of the gold standard method 15O-H2O-PET-CT. 
Likewise, they proved that 82Rb-PET SUV was associated with prostate cancer aggressiveness 
and they could also show its potential to estimate TBF in this type of cancer. The same authors 
observed higher uptake of 82Rb in the cancer than in the normal prostate tissue. Ali Shafiq et 
al172. reported a case of a male old patient in whom 82Rb- cardiac PET helped to diagnose breast 
cancer metastasis in the lungs. The potential of 82Rb-PET to diagnose breast cancer metastasis 
in the brain has also been explored by Lu et al173. In his study, 82Rb-PET-MRI showed better 
tumour-to-noise ratio than 18F-FDG-PET-MRI. The lesion was positive in both, 18F-FDG and 
82Rb PET brain studies. To my knowledge, no studies have been done with 82Rb-PET on 
primary breast cancers. 
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2.2.3 PET for imaging tumour hypoxia 
 
 
Positron Emission Tomography can directly quantify oxygen levels by employing radiotracer 
labelled molecules which allow the non-invasive and three-dimensional evaluation of oxygen 
levels within the tumour in a more direct manner174. 18F-FDG can be upregulated under hypoxic 
conditions, however, it is not specific for hypoxia. Therefore, since the1980s a great number 
of PET tracers have been developed for the identification of hypoxia in living tissues and solid 
tumours, starting with the 2-nitroimidazole family of compounds175,174,176. Only few of these 
compounds have been used to study breast cancer. 
 
18Fluorine-Fluoromisonidazole (18F-FMISO) is a radiolabelled analogue of the hypoxic radio 
sensitizer drug, misonidazole. 18F-FMISO is the predominant PET tracer among the tracers of 
the 2-nitroimidazoles group and it has been extensively investigated for noninvasively 
detecting hypoxia in vivo using PET imaging177. It freely diffuses into cells and under normal 
oxidative conditions, freely exits. When entering hypoxic cells, 18F-FMISO is reduced and 
retained through accumulation of the 2-nitroimidazole metabolites and irreversibly bound to 
intracellular thiol-rich proteins178 (Figure 2.6). 18F-FMISO accumulation in hypoxic tumours 
increases over a period of approximately four hours, while the efflux from normoxic tissues 
starts at 30 minutes post-injection. Imaging times suggested range from 2 to 4 hours post 
injection179. 
 
Figure 2.6 18F-FMISO metabolism under hypoxic conditions: 18F-FMISO enters the cell by 
passive diffusion and under a hypoxic environment (pO2 ≤10 mmHg) it is reduced by the nitro 
reductase enzyme and becomes irreversibly trapped by intracellular proteins. 
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18F-FMISO-PET is a highly sensitive and specific non-invasive technique for the evaluation of 
the hypoxic breast tumour microenvironment180,181 and it has demonstrated potential in 
treatment selection and treatment response prediction182,183. By using 18F-FMISO PET, 
Yamane et al (2016)183 demonstrated that tumour hypoxia may play an important role in the 
differentiation of breast cancer subtypes183. Sorace et al182 showed the potential of 18F-FMISO- 
PET in predicting response to anti-HER2 therapy. In a recent study, baseline 18F-FMISO-PET 
showed that HER2-negative breast cancers do not benefit from neo-adjuvant Nintedanib184 (a 
potent multityrosine kinase receptor inhibitor and also VEGF receptor inhibitor185). 
Furthermore, 18F-FMISO was studied in a triple negative human breast cancer xenograft where 
it could detect hypoxic status in TNBC cells at a macroscopic level186. 
 
Based on published information, 18F-FMISO is the only nitroimidazole compound that has 
been used for the assessment of hypoxia in clinical research of breast cancer. Other non- 
nitroimidazole compounds like for example, 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) 
(64Cu-ATSM) have been examined in different tumour types which do not include breast 
cancer175. Lopci et al (2014)175 in their work about PET radiopharmaceuticals for imaging 
tumour hypoxia stated that evidence-based data favours the use of 18F-FMISO, but the issue of 
sub-optimal tumour to background ratio persists. 
 
Despite its high hypoxic selectivity, 18F-FMISO suffers from a slow kinetic profile and limited 
clearance from normoxic tissue and blood which may result in moderate hypoxic-to-normoxic 
tissue contrast. However, very recently a new method to improve the tumour to background 
ratio of 18F-FMISO imaging was published by Goos et al187. This method consists of pH 
responsive polymers designed for improving the delivery and retention of 18F-FMISO into 
hypoxic cells. 
 
PET imaging using 18F-FMISO has been shown to identify hypoxic tumour sub-volumes and 
track spatiotemporal dynamics188. Efforts have been made to develop fluorinated hypoxia 
markers with improved pharmacokinetic properties. Examples include: 18F- fluoroazomycin 
arabinoside (18F-FAZA), 18F- fluoroerythronitroimidazole (18F-FETNIM), and flortanidazole, 
3-[18F] fluoro-2-(4-((2-nitro-1H-imidazol-1-yl) methyl)-1H-1,2,3-triazol-1-yl)-propan-1-ol) 
18
F-HX4. Nevertheless, none of these compounds have been used to study breast cancer. 
 
One study5 comparing 
18
F-HX4 with 18F-FMISO and 18F-FAZA for PET imaging of hypoxia 
found higher tissue clearance for 
18
F-HX4 than for 18F-FMISO. The absolute tracer activity in 
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tissue 4 hours post injection was highest for 18F-FMISO and lowest for 18F-HX4. Simulated 
contrast at four hours post injection was highest for 8F-HX4 (2.39), while 8F-FMISO and 18F-
FAZA were comparable (1.67 and 1.75, respectively). Currently, 18F-FAZA and 18F-HX4 are 
not available in the UK. 
 
2.2.4 PET for imaging tumour proliferation 
 
 
18F-Fluorothymidine (18F-FLT)-PET enables the quantification of cell proliferation in 
tumours189,190,191,192. 18F-FLT is a structural analogue of the DNA constituent thymidine. It 
enters proliferating cells by active transport and partly via passive and/or facilitative 
diffusion190. Within the intracellular space, 18F-FLT is phosphorylated by the enzyme 
thymidine kinase 1 (TK1), which is a key enzyme in DNA precursor synthesis193,194. The 
presence of TK1 in cells is an indicator of active cell proliferation because TK1 is upregulated 
during the S phase of the cell cycle194. Phosphorylation of 18F-FLT into 18F-FLT-phosphate 
leads to the intracellular retention of the radiotracer (18F-FLT-phosphate forms undergo 
minimal incorporation into DNA). As phosphorylation by TK1 is the rate limiting step in the 
18F-FLT metabolic pathway, 18F-FLT accumulation in cells is proportional to the activity of 
TK1 and therefore, to sustained cellular proliferation195. The accumulation of 18F-FLT in 
tumours has shown good correlations with cell proliferation measurements from in vitro 
assays196, pre-clinical animal studies197 and human studies198,199,200,201. Furthermore, 18F-FLT- 
PET has shown high specificity in the diagnosis of primary tumours199, 202 and it can also depict 
response to chemotherapy.203,204 
 
In breast cancer, 18F-FLT-PET SUV and tumour-to-reference tissue ratios have been correlated 
to the histochemical proliferation index Ki-67 in preliminary studies205,206,207. A recent 
systematic review and meta-analysis about 18F-FLT-PET imaging in which the association 
between Ki-67 expression and 18F-FLT-PET SUV was examined in various types of cancer, 
confirmed significant correlations overall and particularly in breast cancer208. In a study 
included in this meta-analysis209, the sensitivity and specificity of 18F-FLT to predict 
chemotherapy response in breast cancer was shown. 18F-FLT-PET has also demonstrated 
specificity in the diagnosis of primary breast tumours and loco-regional metastases210,211. 18F- 
FLT SUV measurements have been reported highly reproducible in the breast (test-retest 
correlation co-efficient ≥ 0.97205) and changes in 18F-FLT SUV measured early after the 
initiation of treatment were found to be potentially predictive of eventual response to 
chemotherapy189,190,212. 
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. The added clinical value of hybrid F-FDG- 
There are many other PET radiotracers that are currently being used for the evaluation of other 
physiological processes such as neuroinflammation, angiogenesis, etc. Every day scientists 
strive to develop new radiotracers by labelling new molecules or the same molecules with other 
radioisotopes until finding a radiotracer that proves to be safe and reliable to be used in clinical 
studies. All of this with the purpose of continuing exploring the cancer microenvironment 
through the in-vivo assessment by PET. 
 
 
2.3 Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) 
 
Positron emission tomography – Magnetic Resonance Imaging (PET-MRI) is a hybrid imaging 
technology that incorporates MRI and PET information acquired simultaneously. The most 
relevant fields where PET-MRI is being used are oncology213,214,215, cardiology216 and 
neurology217. The technique emerged as a result of the limited soft-tissue contrast resolution of 
CT, especially in the pelvis, head and neck, even when full-dose radiation exposure and 
contrast medium are employed. As it is well recognized, MRI provides higher soft tissue 
contrast and spatial resolution than CT218. The use of breast PET-MRI combined with other 
MRI parameters has shown promise in reducing unnecessary breast biopsies that would be 
recommended based on DCE-MRI examinations219. 
This hybrid technique is highly specific for the diagnosis of nodal breast cancer metastasis 
compared to conventional imaging methods220,221 
18
 
PET-MRI compared to conventional imaging in breast cancer management has been assessed 
by Goorts et al (2017)221. They reported that PET-MRI results helped to prolong or reduce 
treatment in 8/40 (20%) patients with breast cancer by identifying more or fewer malignant  
lymph nodes and distant metastasis. In another study, PET-MRI outperformed PET-CT at a 
lower radiation dose for breast cancer patients in need of whole-body staging or post-treatment 
surveillance222. 
PET-MRI is unlikely to become part of the breast clinical routine due to cost, radiation dose, 
imaging post-processing, and exam reading times. PET-MRI may be more relevant in breast 
cancer research especially before and during NAC treatment, where all the MRI and PET 
parameters can be converted into radiomics that may lend increased precision to breast cancer 
treatment. 
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Fusion of MR and PET images (fused or combined PET-MRI) may confer clinical advantages 
over PET-CT; however, it also carries out some limitations. 
 
The following are some of the advantages combined PET-MRI has over PET-CT: 
x Simultaneous acquisition of PET and MRI provides an insight into the structural and 
biochemical features of the cancer in only one exam per patient, shortening the 
diagnostic cycle of neoplastic diseases (it is only one exam instead of many others). 
x PET-MRI provides better methodological analysis of the tumour characterization than 
PET-CT and MRI separately, currently done only for research. Since the patient is in 
the exact same position for the PET and MRI scanning, it is easier to correlate imaging 
parameters extracted from the same ROI (region of interest) than from two different 
ROIs located in two different studies (on the PET-CT and the MRI). 
x Combined PET-MRI affords more reliable correlations between imaging biomarkers 
depicting different physiological processes (like for example, correlations between 
imaging biomarkers of tumour vascularity and hypoxia). Because tissue blood flow and 
oxygenation may vary over time (seconds and/or minutes), hybrid PET-MRI can help 
avoiding the confounding effects of intermittent hypoxia or fluctuating perfusion in the 
analysis of radiomics. 
x The availability of sophisticated MRI sequences, such as diffusion and DCE-MRI or 
MRI spectroscopy, which can provide important information additionally to the 
information extracted from PET. 
 
Limitations of PET-MRI: 
 
x Attenuation correction223: Even though the attenuation of PET photons by biological 
tissues allows the generation and differentiation of contrasts (scale of grays) on PET-
CT images, it also affects adequate quantification of PET parameters because photon 
attenuation (less photon detection by the detectors of the scanner) may cause 
underestimation of actual radiotracer activity in lesions or normal tissues. Therefore, 
to perform attenuation correction of PET images is required. MRI is unable to measure 
attenuation since there is no relation between MRI signal intensity and photon 
synthesis or absorption. Different methods of attenuation, like Dixon resonance 
sequence that is the most commonly used, are used to  create attenuation maps from MR 
images. 
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x PET-MRI studies are usually longer and more uncomfortable than PET-CT studies. 
Hence, they are less acceptable for patients and more expensive as fewer studies can 
be performed per day. 
The contraindications of PET/MRI are the same as those of MRI and PET (metallic devices 
incompatible with magnetic field, claustrophobia and pregnancy or breastfeeding, 
respectively.) 
 
2.3.1 PET-MRI as a method of measuring hypoxia in breast cancer 
 
 
Simultaneous PET and MRI assessment of the breast cancer micromilieu has been limited in 
human studies, perhaps, because of the low availability of PET-MRI systems which may be 
product of the higher costs of PET-MRI scanners in comparison to PET-CT scanners224. 
 
Combined PET-MRI scans can avoid spatial and temporal shifts in the hypoxic status of the 
cancer (cycling hypoxia) due to fluctuations of the tumour blood flow225. Similarly, the 
molecular and phenotypic diversity demonstrated between same breast cancer subtypes and 
within each cancer (intra-tumoral and inter-tumoral heterogeneity)226 illustrates the potential 
role of simultaneous multi-modality imaging in detecting or examining hypoxic breast cancers, 
improving therefore breast cancer treatment selection and efficacy. 
 
The main aim of this thesis was to provide a better understanding of breast cancer 
pathophysiology using simultaneous PET and multi-parametric MRI. In particular, this work 
aimed to explore relationships between imaging biomarkers of tumour vascularity measured 
by dynamic contrast-enhanced (DCE) MRI, cellularity using diffusion-weighted imaging 
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Chapter 3. Relationship between hypoxia and vascularity in breast cancer 
by using PET-MRI  
 
In Chapter 1 we introduced breast cancer as a clinical problem and in Chapter 2 imaging 
techniques for the detection and characterisation of breast tumours were presented. This 
Chapter investigates the breast cancer microenvironment with specific emphasis on 
relationships between imaging descriptors of vascularity and oxygenation in breast 
malignancies.  
 
It is widely accepted that hypoxia is associated with poor clinical outcome and metastasis in 
breast cancer. However, temporal fluctuations in hypoxia (cycling hypoxia) and perfusion can 
confound interpretation of imaging results. To remove the confounding effect of temporal 
fluctuations in hypoxia and perfusion, the relationship between these two parameters was 
investigated using combined PET-MR imaging with 18F-fluoromisonidazole (18F-FMISO).  
 
A large portion of this work has been recently published in European Radiology1 and presented 
at national and international conferences. 
 
3.1 Objective 
To examine the association between hypoxia, perfusion and cellularity in treatment-naïve 
breast cancers using combined 18F-FMISO-PET/MRI. 
 
3.2 Hypothesis 
It was hypothesised that breast cancers with poor perfusion, as measured by DCE-MRI, or high 




Hypoxia is a common characteristic of the microenvironment of solid tumours and arises as a 
consequence of a dysregulated metabolism and the  structurally and functionally aberrant 
microcirculation found in cancers2-4. Adaptation to hypoxia is achieved by propagating 
molecular signalling cascades to promote metabolic reprogramming towards glycolysis and 
restore oxygen and nutrient supply to the tumour via the formation of new vessels 
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(angiogenesis). In breast cancer, the presence of hypoxia has been confirmed via pO2 
histography in both pre-invasive and invasive tumours and has been shown to occur regardless 
of histological type, molecular sub-type, grade, size or patient characteristics3,4. In vitro studies 
have shown that hypoxia promotes a dedifferentiated phenotype in ductal carcinoma in situ 
(DCIS)5 and downregulates the expression and function of oestrogen receptor-α (ERα)6,7. 
Furthermore, several immunohistochemical studies of breast tumour specimens have 
demonstrated that overexpression of hypoxia-associated proteins, such as hypoxia-inducible 
factor 1α (HIF-1α) and carbonic anhydrase IX (CAIX) are associated with an aggressive 
phenotype8, poor prognosis9, increased risk of metastasis and resistance to treatment10,11. 
Though tumour hypoxia can be broadly categorised as chronic (diffusion-limited) or acute 
(perfusion-limited), it is generally accepted that the tumour microenvironment is a highly 
dynamic entity, exhibiting temporally-varying perfusion patterns and heterogeneous oxygen-
tension gradients in neoplastic cell subpopulations12. Experimental evidence suggests that 
oxygenation levels in tumours continually fluctuate, with several cells oscillating between 
hypoxia and variable oxygenation states owing to transient changes in perfusion13,14. These 
perfusion and oxygenation abnormalities serve in inducing a variety of gene expression profiles 
and the definition of a unique microenvironment in tumours that is pivotal for growth and 
metastatic dissemination15.  
 
Imaging methods, like PET and MRI have been used to non-invasively probe 
pathophysiological aspects of the tumour microenvironment, including hypoxia and 
neovascularisation. As discussed in Chapter 2, DCE-MRI has an established role in the 
diagnosis and management of breast cancer and has demonstrated utility in the characterisation 
of tumour vascular features related to perfusion and vascular permeability in several clinical 
studies16,17,18. DWI-MRI has also been utilised to provide surrogate measures of breast cancer 
cellular density and information on the integrity of cell membranes19,20. On the other hand, PET 
with 18F-labelled nitroimidazoles can provide specific measures of intracellular hypoxia. In 
breast cancer, 18F-fluoromisonidazole (18F-FMISO) – the most extensively studied PET 
hypoxia biomarker – has been used for the evaluation of response to anti-angiogenic and 
HER2-targetted treatment in both clinical studies21,22 and preclinical models of disease23,24,25 
and shown potential utility as a predictor of response to primary endocrine therapy26,27. 
Additionally, high 18F-FMISO uptake at baseline has been associated with shorter disease-free 
survival28 and disease-specific death29. 
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Despite in vitro evidence regarding the link between tumour hypoxia and vascular function, 
multi-modal imaging approaches for the characterisation of this aspect of the tumour 
microenvironment have been limited in the clinical setting22,29,30. Given the dynamic nature of 
processes like hypoxia and perfusion, sequential multi-modal imaging investigations may not 
be able to effectively assess relationships between these parameters, as similar tumour status 
cannot be guaranteed at different time points of the imaging sessions. Simultaneous assessment 
of the hypoxia and perfusion status in tumours can mitigate confounders associated with the 
dynamic character of these processes, and thus allow additional pathophysiological 
characterisation of breast cancer. To this end, imaging with a combined PET/MRI system 







Between February 2017 and November 2018, a total of 32 women with treatment-naïve, 
pathologically confirmed primary breast cancer, were prospectively enrolled from 
Addenbrooke’s Hospital, Cambridge, UK. Patients aged >18 years, with a tumour >10 mm 
diameter on mammography and/or ultrasound were considered eligible for the study. 
Pregnancy, lactation, history of serious breast trauma within three months prior to diagnosis, 
previous surgery or radiotherapy for cancer or benign breast disease, inadequate renal function, 
previously known allergies to gadolinium-based contrast agents and contraindications to MRI 
were exclusion criteria for the study.  
 
All patients gave written, informed consent before participating in the study.  The research was 
approved by a National Research Ethics Committee (14/EE/0145) and the Administration of 
Radioactive Substances Advisory Committee (ARSAC), UK. 
 
3.4.2 PET/MRI acquisition 
18F-FMISO-PET/MR scans were performed on a SIGNA PET/MR scanner (GE Healthcare, 
Milwaukee, WI), University of Cambridge, UK. 18F-FMISO was provided by the 
Radiopharmaceutical Unit, Wolfson Brain Imaging Centre, University of Cambridge, UK. 
 
 69 
Participants underwent a 60-min simultaneous PET/MR scan of the breasts in the prone 
position, using a 16-channel bilateral breast array coil (RAPID Biomedical, Rimpar, Germany) 
120 min (median [range]: 120.2 [119.8–127.5] min) after injection of 306 ± 14 MBq 18F-
FMISO. The uptake period post injection (p.i.) was used to enhance hypoxic-to-normoxic 
tissue-contrast and allow the free 18F-FMISO concentrations in tissue and blood to reach 
equilibrium23,24 a requirement for influx-rate constant (Ki) determination by Patlak analysis25. 
Participants were not required to fast before the PET/MR examination. 
 
3.4.2.1 PET acquisition:  Emission data from 120-180 min p.i. (12×5-min frames) were 
reconstructed into a 192×192×89 matrix with 3.12×3.12×2.78 mm voxels, using time-of-flight 
ordered-subsets expectation-maximisation (TOF-OSEM) with 4 iterations and 28 subsets. 
Corrections for normalisation, dead-time, random events, scatter, attenuation, sensitivity and 
isotope decay were applied as implemented on the scanner, together with an isotropic 4-mm 
FWHM Gaussian filter post reconstruction. Plasma radioactivity concentration from two 
venous blood samples, acquired immediately before and after the end of the PET/MR 
examination, were employed for scaling an 18F-FMISO population-based arterial input 
function (AIF) derived from existing data (Appendix A-1 and appendix figure A-1), permitting 
calculation of the Patlak influx rate constant Ki, as previously reported31. 
 
3.4.2.2 MRI acquisition: The MRI protocol included: the manufacturer’s 2-point Dixon 
sequence for PET attenuation correction, T1 and T2-weighted images, DWI, and a DCE series. 
Sequences for measuring B1+ transmission-field inhomogeneity (B1-mapping), using a Bloch-
Siegert method, and baseline T1 (T1 mapping), as required for pharmacokinetic analysis of DCE 
data were also acquired32. For DCE acquisition, a dose of 0.1 mmol/kg of bodyweight of 
Gadovist (Bayer Healthcare, Germany) was administered intravenously as a bolus with an 
automated injector at 3 mL/s followed by a saline flush. DCE acquisition involved five pre-
contrast image volumes followed by 43 phases after contrast injection. Details of MR sequence 







Table 3.1 MRI acquisition parameters 









   
Sequence 3D SPGR 2D SPGR  3D SPGR 2D SE-EPI 
FOV diameter (mm) 350 350 350 360 
Image Matrix 256×256 128×128 512×512 140×192 
Slice thickness (mm) 2.8 7.0 2.8 
(interpolated to 1.4) 
4.0 
No. of slices 112 22 112 26 
b-values (s/mm2) n/a n/a n/a 0, 900 
Pixel size 1.4×1.4 2.7×2.7 0.6×0.6 2.6×1.9 
Fat suppression No No Yes† Yes‡ 
ASSET factor 2 n/a 2.5 2 
TR (ms) 4.2 24 7.1 6.0 
TE (ms) 2.1 13.7 3.8 94.9 
RF excitation (degrees) 2, 3, 5, 10, 15 20 12 90 
No. of averages 1 1 0.5 5 
Bandwidth (kHz) 62.5 15.6 125 250 
Acquisition time 33 s 
(per flip angle) 
2 m 20 s 8 m 5 s 10 m 48 s 
     
VFA: variable flip angle; VIBRANT-TRICKS: volume image breast assessment–time-resolved imaging of 
contrast kinetics; 3D SPGR: three-dimensional spoiled gradient recalled echo; 2D SPGR: two-dimensional 
spoiled gradient recalled echo; DWI: Diffusion weighted imaging; 2D SE-EPI: two-dimensional spin echo–echo-
planar imaging; FOV: field-of-view; ASSET: array spatial sensitivity encoding technique; n/a: not applicable. 
† Spatial-spectral water excitation 
‡ Spatial-spectral water excitation with water spatial pre-saturation 
 
 
3.4.3 Image analysis 
 
Region-of interest delineation: Tumour regions of interest (ROIs) were manually delineated in 
OsiriX, version 8.0.2 (Pixmeo SARL, Switzerland) by three radiologists in consensus (one, 
three and >20 years of experience in breast MRI respectively). Regions were drawn on the 
peak-enhancing volumes of the DCE-MRI series (approximately corresponding to phase 19 of 
the DCE-MRI series) and included all consecutive axial sections encompassing the enhancing 
tumour mass and including multifocal/multicentric disease. For ROI delineation on the DCE 
images, care was taken to visually exclude normal breast parenchyma, fat, necrotic areas (void 
of signal within the tumour) and large vessels. To guide region definition, subtraction images 
were created in Osirix by subtracting pre-contrast images from the peak-enhancing phase of 
the DCE image series (~2 min from the start of enhancement). For the exclusion of large 
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vessels, maximum-intensity projection (MIP) images were also generated from the subtraction 
image-set and used as an additional reference for ROI delineation. In cases of multifocality or 
multicentricity on the MRI, region determination was based on the pathological review. 
Synchronous bilateral cancers were regarded as independent lesions33. 
 
For DWI analysis, whole tumour regions were demarcated on all axial slices encompassing the 
tumour on the b=900 s/mm2 image, using the DCE post-contrast images as guidance, and 
subsequently imported on the corresponding apparent diffusion coefficient (ADC) map for 
each lesion. For ROI delineation, care was taken to avoid tumour boundaries, non-enhancing 
lesion voxels, necrotic and cystic areas34. Additionally, the ADC value of the darkest part of 
the tumour (dp-ADC) was measured, using a 5 mm circular ROI in the visually darkest (and 





Figure 3.1 ADC map of 45-year-old female patient with an invasive ductal carcinoma 
(hormone receptor-positive/HER2-; grade 3) in the posterior aspect of the left breast. Regions 
of interest encompassing the entire lesion are shown in green and blue color and a small 5-mm 
diameter circular region encompassing the darkest area within the lesion is shown in orange 
color.  
 
DCE-MRI: Pharmacokinetic analysis of the DCE-MRI series was performed in MIStar, version 
3.2.63 (Apollo Medical Imaging, Melbourne, Australia) using the extended Tofts’ model37 to 
calculate the forward volume transfer constant, Ktrans, efflux rate constant, kep, extracellular-
extravascular volume fraction ve and plasma volume fraction vp. Modelling utilised the 
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modified Fritz-Hansen arterial input function38,39. During model fitting, thresholds were 
applied, and all parameters were restricted to positive values with ve ≤1. Ktrans values >5 
mL/cm3/min were regarded as non-physiological17.  
 
Before pharmacokinetic analysis, a cuboid region encompassing the entire tumour across the 
DCE-MRI series was motion corrected using a 3D affine model implemented in MIStar, which 
utilised the peak-enhancing phase of the DCE image series as reference for the registration. 
Transmission-field inhomogeneity on DCE-MR images was corrected by generating B1+ 
correction maps, using in-house software implemented in Matlab R2016b (Mathworks Inc., 
Natick, MA). Computation of B1+ maps included smoothing by a 3×3×3 median filter. T10 maps 
were subsequently generated in MIStar, utilising the B1+-field maps to correct for spatial 
variations in flip angle30. 
 
Ktrans values in the most vascularised area of the tumour (hotspot Ktrans) were calculated by 
averaging pixel values within a 9-pixel square region of interest placed around the area 
exhibiting the highest Ktrans value on the Ktrans parametric maps34. The region encompassing the 
hotspot Ktrans area was subsequently superimposed on the corresponding co-registered Ki map 
to calculate the mean Ki values within the hotspot area. 
 
DWI-MRI: Calculation of ADC maps was performed in OsiriX, using b-values of 0 and 900 
s/mm2.  
 




                                                           (1)                                                      
where S0 and S1 are the signal intensities in images obtained with b0=0 s/mm2 and b1=900 
s/mm2. 
 
PET: To reduce the impact of patient motion during acquisition, 18F-FMISO dynamic image 
series were non-rigidly registered to the first frame using the Advanced Normalization Tools 
(ANTs) package (http://stnava.github.io/ANTs/). Registered frames from 150–180 min p.i. 
were averaged, rigidly registered to the peak-enhancing phase of the DCE-MRI series and 
subsequently employed for the determination of 18F-FMISO uptake as mean and maximum 
standardised uptake values normalised by body-weight (SUVmean, SUVmax), maximum tumour-
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to-plasma (Tmax/P) and tumour-to-muscle (Tmax/M) ratios within the tumour regions defined on 
the DCE-MRI. For Tmax/M calculations, the mean radioactivity concentration in a bilateral 
region in the pectoral muscle was used to represent normoxic tissue. The quality of the 
registrations was visually inspected by a breast radiologist. In two cases where lesions were 
located directly adjacent to pectoral muscle, regions were only placed in the contralateral 
muscle. Given that increased tracer uptake may represent high tracer delivery to a region rather 
than trapping under hypoxic conditions, the influx rate of 18F-FMISO (Ki) into the trapped 
tissue compartment was determined as a more specific measure of tumour hypoxia. Ki maps 
were produced by Patlak-plot analysis, using in-house software implemented in Matlab 
R2016b. Hypoxic fractions (%HF) in tumour ROIs were calculated as the percentage of voxels 
with Ki values >2×standard deviations (SD) of the mean Ki in the normoxic muscle. Image 
analysis was performed using Analyze 12.0 (AnalyzeDirect Inc.,). 
 
3.4.4 Histology 
Histopathological information including tumour histological subtype, grade, oestrogen 
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 
(HER2) status were obtained from core biopsies or surgical tumour specimens. Cancers with 
positive ER or PR expression were classified as hormone-receptor (HR) positive. 
Histopathological classification of breast tumours was performed following the WHO 
classification for breast tumours40. Tumours were graded according to the Elston-Ellis scoring 
system34.  
 
3.4.5 Statistical analysis 
Statistical analysis was performed in IBM SPSS Statistics for MacOS, v25.0 (IBM Corp.) or 
Matlab 2016b. Continuous data were assessed for normality using the Anderson-Darling test. 
Correlations between continuous variables were assessed using the Pearson correlation (r) or 
Spearman correlation (ρ) coefficients. t-tests were used for comparison between means of two 
groups, and ANOVA when more than two groups were compared. Where data was not 
normally distributed, or normality could not be assessed, Mann-Whitney U and Mood’s median 
or Kruskal-Wallis H tests were employed for comparisons between two or more groups, 







A total of 32 women were enrolled into the study. Two participants withdrew before the 
PET/MR examination. PET and MRI data from one participant were excluded owing to 
inadequate acquisition of the DCE-MRI series that did not permit delineation of a tumour ROI. 
Additionally, DCE-MRI from a further patient was excluded due to poor quality of the images. 
In total, data from 29 participants was analysed with 32 biopsy-confirmed primary breast 
cancers on PET-MRI and 31 on DCE-MRI. ADC calculations included data from 18 patients 
(19 lesions), who successfully completed the DWI examination. Clinical information about the 
patient cohort is provided in Table 3.2. 
 
Table 3.2 Clinical characteristics of the patient population (n=29).  
Characteristic n (%) 
Age at diagnosis (years)a 57 [37-78] 
  
Menopausal status  
Pre-menopausal 10 (35) 
Post-menopausal 19 (65) 
  
Clinical management  
Primary surgery 21 (72) 
Neo-adjuvant therapy 8 (28) 
  
Lesion presentation  
Unilateral 26 (90) 
Unilateral (synchronous) 1 (3) 
Bilateral (synchronous) 2 (7) 
  
Lesion lateralityb [n=32 lesions]  
Right breast 16 (50) 
Left breast 16 (50) 
aData presented as median [range]. 
bLesion numbers include synchronous bilateral carcinomas, which were regarded as independent lesions. 
 
Two-thirds of the lesions (21/32; 66%) were invasive ductal cancers (IDC), while 6/32 (19%) 
were invasive lobular carcinomas (ILC). The majority of cancers (29/32; 91%) were either 
grade 2 or 3. HR-positive expression was noted for 31/32 (97%) lesions, with 24/32 (77%) 
cancers being HER2-negative. Tumour characteristics are summarised in Table 3.3. Of the 19 
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cancers included in comparisons with DWI, 14 (74%) were IDC, three (16%) ILC, and two 
were classified as mucinous and mixed cancers respectively. All tumours were HR-positive, 
with 13 (68%) lesions also being negative for HER2.  
 
Table 3.3 Tumour characteristics (n=32). 
Characteristic  n (%) 
Lesions 32 
  
Pathological size (mm)a,b 26 [10-142] 
  
Lesion longest diameter on MRI  
≤20 mm 10 (31) 
>20 mm 22 (69) 
  
Histopathological subtype  
Ductal (IDC) 21 (66) 
Lobular (ILC) 6 (19) 
Mucinous (IMC) 2 (6) 
Mixedc 3 (9) 
  
Histological graded  
1 3 (9) 
2 16 (50) 
3 13 (41) 
  
Hormone-receptor statuse  
Positive (ER or PR) 31 (97) 
Negative 1 (3) 
  
HER2 statusf  
Positive 7 (22) 
Negative 25 (78) 
aData presented as median [range]. 
bPathological size measured on tumor specimens from patients undergoing primary surgery (n=21). 
cInvasive carcinomas with presence of both lobular and ductal components on histology.  
dNottingham combined histologic grade. 
eTumours classified as ER or PR-positive, if >10% of the cells demonstrated nuclear staining by 
immunohistochemistry. 
fTumours classified as HER2-positive, if they scored 3+ on immunohistochemistry, or if they carried gene 






3.5.1 Correlation between clinical data and 18F-FMISO-PET/MRI parameters 
 
Linear regression analysis was used to investigate the effect of age, patient menopausal status 
and the interaction between age and menopausal status on 18F-FMISO and DCE-MRI 
parameters. This analysis did not reveal any statistically significant association with the 
imaging parameters (Table 3.4). Menopausal status and the interaction of age and menopausal 
state showed statistically significant associations with both mean lesion ADC and dp-ADC 
(Table 3.4). However, the statistical significance of these associations was not upheld after 
false discovery rate (FDR) correction for multiple comparisons (Menopausal status: ADC: 
p=0.24 dp-ADC: p=0.28; Age*Menopausal Status: p=0.36 dp-ADC: p=0.36).  
 
Injected activity did not significantly correlate with 18F-FMISO hypoxia parameters (Table 
3.5). Similarly, lesion laterality did not yield significant differences in DCE-MRI metrics 
(Table 3.6). Comparisons of mean lesion ADC and dp-ADC values between right and left-
sided breast cancers trended towards statistical significance (p=0.05; Table 3.6). However, it 
should be noted that the group of right-breast cancers included a mucinous carcinoma. IMC 
have been demonstrated to yield higher ADC than cancers of other histologic subtypes or 
benign breast tumours41. Removing the one mucinous lesion from this analysis reduced the 















Table 3.4 Linear regression coefficients (β) with standard errors (SE) and p values for age, 
menopausal status and an interaction effect between age and menopausal status as regressors 
for regional DCE-MRI and PET values. 
 Age Menopausal statusa Age*Menopausal status 
Parameters β, [SE], p β, [SE], p β, [SE], p 
Lesions (n) 31 
Ktrans -0.028, [0.025], 0.27 -1.924, [1.340], 0.16 -0.043, [0.027], 0.13 
kep -0.004, [0.003], 0.25 0.028, [0.178], 0.88 0.001, [0.004], 0.80 
ve -0.022, [0.011], 0.07 -1.351, [0.611], 0.37 0.029, [0.013], 0.27 
ln(vp)b -0.085, [0.055], 0.14 -3.371, [3.002], 0.27 0.086, [0.061], 0.17 
Lesions (n) 19 
ADC (×10-3) -0.016, [0.015], 0.31 -2.079, [0.848], 0.02* 0.039, [0.017], 0.03* 
dp-ADC (×10-3) -0.016, [0.016], 0.33 -1.931, [0.884], 0.046* 0.035, [0.018], 0.06 
Lesions (n) 32 
Ki (×10-3) -0.038, [0.037], 0.32 -2.200, [2.000], 0.27 -0.047, [0.041], 0.26 
(1/%HF)b 1.058, [1.058], 0.32 108.1, [56.9], 0.09 -2.001, [1.173], 0.12 
SUVmax -0.016, [0.020], 0.42 0.180, [1.108], 0.87 0.007, [0.022], 0.75 
SUVmean -0.016, [0.013], 0.25 -0.591, [0.732], 0.47 0.017, [0.016], 0.27 
Tmax/M -0.016, [0.015], 0.31 -0.071, [0.844], 0.93 0.008, [0.017], 0.65 
Tmax/P -0.015, [0.012], 0.23 -0.149, [0.673], 0.83 0.007, [0.014], 0.62 
a0 = Pre-menopausal; 1 = Post-menopausal 
bDue to the non-normality of residuals, as indicated by Shapiro-Wilk tests and Q-Q plots, ve values were 
transformed using the natural logarithm, whereas the reciprocal of %HF was taken before linear regression.  
 
 
Table 3.5 Spearman correlation coefficient (ρ) and p value between PET parameters and 
injected activity (MBq). 
 Injected Activity (MBq) 
Parameter ρ p 
Lesions (n) 32 
Ki (×10-3) 0.07 0.73 
HF (%) -0.09 0.66 
SUVmax 0.20 0.31 
SUVmean 0.01 0.95 
Tmax/M 0.15 0.44 




Table 3.6 MRI and PET parameters with respect to lesion laterality. Data are presented as 
median [range] or mean ± standard deviation (SD) as appropriate. 
 Laterality  
Parameters Right Left p 
Lesions (n) 16 15  

















Lesions (n) 10 9  








Lesions (n) 16 16  
Ki (×10-3) 0.188 ± 0.566 0.085 ± 0.646 0.63 
HF(%) 0 [0-2.19] 
0 
[0.-4.74] 0.41 
SUVmax 1.61 ± 0.36 1.51 ± 0.36 0.45 
SUVmean 1.20 ± 0.36 1.13 ± 0.36 0.40 
Tmax/M 1.07 ± 0.20 1.08 ± 0.31 0.89 




3.5.2 Relationship between 18F-FMISO-PET and DCE-MRI parameters  
 
Scatter plots indicating the relationships between DCE-MRI parameters and Ki or %HF are 
illustrated in Figure 3.2. An inverse relationship was observed between mean lesion Ki and 
Ktrans, ve, and vp (Figure 3.2a-3.2d), which was statistically significant for Ki vs. Ktrans (r=-0.38, 
p=0.04), but not for Ki vs. ve (r=-0.30, p=0.10) or vp (r=-0.28, p=0.12). Associations between 
%HF and DCE-MRI parameters followed similar trends, also indicating a decrease in hypoxia 
with increasing Ktrans, ve, and vp (Figure 3.2e-3.2h). Similarly, a weak negative correlation was 
observed between Ki and Ktrans in the hotspot area of the tumour (r=-0.16, p=0.40; Figure 3.3). 
Statistically significant correlations were observed between %HF and both Ktrans (r=-0.33, 
p=0.04) and ve (r=-0.38, p=0.03). No correlation was observed between kep and either Ki 
(r=0.08, p=0.65) or %HF (r=0.02, p=0.90). 
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Figure 3.4 presents axial slices through Ki and Ktrans parametric maps of four tumours of 
different histological subtype, indicating heterogeneous spatial relationships between hypoxia 
and perfusion; other DCE-MRI parametric images are given in Figure 3.5. 
 
 
Figure 3.2 18F-FMISO-PET Ki and hypoxic fraction (%) vs. the following DCE-MRI 
parameters: (a,e) contrast influx rate, Ktrans (mL/g/min); (b,f) contrast efflux rate, kep (min-1); 
(c,g) fractional volume of extravascular-extracellular space, ve; (d,h) plasma fractional volume, 
vp. IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; IMC: invasive mucinous 
carcinoma; Mixed: carcinoma of mixed ductal and lobular type. 
 
 
Figure 3.3 Scatterplot and regression line of Ki (mL/cm3/min) vs. Ktrans (mL/g/min) in the most 




Figure 3.4 Axial images of four representative patients with: (a) invasive ductal carcinoma 
(IDC); (b) invasive lobular carcinoma (ILC); (c) invasive mucinous carcinoma (IMC); and (d) 
carcinoma of mixed ductal and lobular type (Mixed). (Left-to-right) DCE-MRI image at peak 
enhancement; Ktrans map representing tumour perfusion for the lesion ROI overlaid on the peak 
enhancing DCE-MRI image; Ki map representing tumour hypoxia for the lesion ROI overlaid 
on the peak enhancing DCE-MRI image; scatter plot and regression line of Ki vs. Ktrans voxel-
values within the tumour. Ktrans: contrast influx rate (mL/g/min); Ki: 18F-FMISO influx rate 






















































































































































































































































































Figure 3.6 Dot plots of hypoxic fraction (%) by (a) histological type and (b) nuclear grade. 
 
 
3.5.3 18F-FMISO-PET and DCE-MRI parameters vs. tumour histology and grade 
 
Hypoxic fractions >1% were observed in 6/32 (19%) cancers with an additional 8/32 (25%) 
lesions displaying hypoxic fractions greater than zero but less than 1%; the remaining 18/32 
(56%) tumours had no measurable %HF. Dot plots of %HF vs. tumour histological subtype 
and grade are presented in Figure 3.6. Ki, %HF and 18F-FMISO uptake parameters showed no 
significant difference between different histological subtype or grade (Tables 3.7 and 3.8). 
Similarly, no significant differences were observed between histological groups or grades for 
the DCE-derived parameters (Tables 3.7 and 3.8), except for the efflux rate-constant kep, which 
displayed differences among grade 2 and 3 cancers that were trending towards statistical 
significance  after FDR correction of p-values for multiple comparisons was done (median 
[range]: 0.25 [0.13-0.34] vs. 0.30 [0.10-0.35] min-1; punc=0.009; pcor=0.1). Furthermore, 
analysis of hypoxia and Ktrans values in the most vascularised area of the tumour (hotspot on 
DCE-MRI) yielded no significant differences among different histological subtypes or grades 









Table 3.7 MRI and 18F-FMISO-PET parameters with respect to tumour histology. Data are 
presented as median [range] or mean ± standard deviation (SD) as appropriate. 
 Histology  
Parameter IDC ILC Mixed IMC p-value 
Lesions (n=31) 20 6 3 2  


































Lesions (n=19) 14 3 1 1  
















Lesions (n=32) 21 6 3 2  
Ki (×10-3) 0.00 ± 0.52 0.37 ± 0.65 0.08 ± 0.61 0.97 ± 0.91 0.26c 








SUVmax 1.53 ± 0.41 1.77 ± 0.16 1.60 ± 0.21 1.25 ± 0.12 0.31c 
SUVmean 1.14 ± 0.26 1.27 ± 0.18 1.17 ± 0.16 1.07 ± 0.15 0.65c 
Tmax/M 1.02 ± 0.24 1.30 ± 0.29 1.09 ± 0.22 0.95 ± 0.02 0.12c 
Tmax/P 0.87 ± 0.22 0.83 ± 0.33 0.87 ± 0.09 0.84 ± 0.09 0.99c 
aMood’s median test 
bMann-Whitney U test for malignancies of type IDC and ILC only (mixed and IMC lesions were not included in 
the comparison) 
cOne-way analysis of variance (ANOVA)  
IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; Mixed: invasive carcinoma with presence of 
lobular and ductal components; IMC: invasive mucinous carcinoma; Ktrans: contrast influx rate (mL/g/min); kep: 
contrast efflux rate (min-1); ve: fractional volume of extravascular-extracellular space; vp: plasma fractional 
volume; ADC: apparent diffusion coefficient (mm2/s); dp-ADC: ADC (mm2/s) in the darkest part of the tumour; 
Ki: 18F-FMISO influx rate (mL/cm3/min); %HF: percentage hypoxic fraction; SUV: standardised uptake value 







Table 3.8 MRI and 18F-FMISO-PET parameters with respect to nuclear grade. Data are 
presented as median [range] or mean ± standard deviation (SD) as appropriate. 
  Grade   
Parameter 1 2 3 p-value 
Lesions (n=31) 3 15 13  


























Lesions (n=19) 1 9 9  












Lesions (n=32) 3 16 13  
Ki (×10-3) -0.18 ± 0.52 0.25 ± 0.58 0.06 ± 0.65 0.47c 






SUVmax 1.28 ± 0.29 1.55 ± 0.29 1.66 ± 0.46 0.28c 
SUVmean 0.98 ± 0.09 1.18 ± 0.19 1.18 ± 0.29 0.37c 
Tmax/M 0.96 ± 0.02 1.04 ± 0.17 1.56 ± 0.36 0.36c 
Tmax/P 0.78 ± 0.08 0.81 ± 0.20 0.85 ± 0.25 0.21c 
aKruskal-Wallis H  
bMann-Whitney U test for grade 1 and 2 cancers only (grade I lesions were not included in the comparison). 
cOne-way analysis of variance (ANOVA)  
dSignificant difference between grade 2 and 3 cancers (p=0.01). Pairwise multiple comparison analysis utilized 











Table 3.9 Hotspot Ktrans (mL/g/min) and 18F-FMISO-PET parameters with respect to tumour 
histology. Data are presented as mean ± standard deviation (SD) or median [range] as 
appropriate. 
aOne-way analysis of variance (ANOVA) 
bMood’s median test 
Ktrans: contrast influx rate (mL/g/min); Ki: 18F-FMISO influx rate (mL/cm3/min); SUV: standardised uptake value 
(g/mL); T/P: tumour-to-plasma ratio. 
 
 
Table 3.10 Hotspot Ktrans (mL/g/min) and 18F-FMISO-PET parameters in the hotspot area with 
respect to nuclear grade. Data are presented as median [range] or mean ± standard deviation 
(SD) as appropriate. 
  Grade   
Parameter 1 2 3 p-value 
Lesions (n=31) 3 15 13  






Hotspot Ki (×10-3) -0.43 ± 0.42 0.57 ± 0.97 -0.16 ± 1.31 0.153‡ 
Hotspot SUVbw 0.66 ± 0.09 0.96 ± 0.25 0.94 ± 0.27 0.168‡ 






† Kruskal-Wallis H  
‡ One-way analysis of variance (ANOVA)  
 Histology  
Parametera IDC ILC Mixed IMC p-value 
Lesions (n=31) 20 6 3 2  
Hotspot Ktrans 2.50 ± 0.95 2.67 ± 0.35 1.68 ± 1.05 2.24 ± 1.58 0.46a 
Hotspot Ki (×10-3) -0.03 ± 1.14 0.54 ± 0.79 0.69 ± 1.59 0.39 ± 1.77 0.65a 
Hotspot SUV 0.90 ± 0.26 0.91 ± 0.41 0.90 ± 0.48 1.14 ± 0.75 0.68a 









3.5.4 Effect of tumour size on 18F-FMISO-PET and DCE-MRI parameters 
 
Table 3.11 presents correlations between imaging parameters and tumour size as measured by 
longest diameter on MRI or pathological size. No or weak negative correlations were observed 
between tumour size and DCE-MRI parameters. Conversely, 18F-FMISO-PET parameters 
correlated positively with size; %HF significantly correlated with pathological size (r=0.63, 
p=0.001), while 18F-FMISO-PET uptake metrics displayed associations of moderate strength 
with longest diameter on MRI. 
 
Table 3.11 Pearson correlation coefficients r (p-value) between tumour size (obtained from 
MRI and pathological specimens) and 18F-FMISO-PET/MRI parameters. 
 Tumour size (mm) 
Parameter Longest diameter on MRI Pathological size 
Lesions (n) 31 21 
Ktrans -0.15 (0.42) -0.16 (0.48) 
kep -0.04 (0.84) -0.15 (0.48) 
ve -0.04 (0.83) -0.27 (0.22) 
vp -0.13 (0.50) -0.09 (0.70) 
Lesions (n) 19 11 
ADC (×10-3) 0.08 (0.72) 0.56 (0.07) 
dp-ADC (×10-3) 0.06 (0.79) 0.23 (0.40) 
Lesions (n) 32 21 
Ki (×10-3) 0.15 (0.29) 0.21 (0.48) 
HF (%) 0.26 (0.16) 0.63 (0.001**) 
SUVmax 0.48 (0.02*) 0.26 (0.24) 
SUVmean 0.42 (0.006**) 0.39 (0.07) 
Tmax/M 0.45 (0.01*) 0.32 (0.14) 
Tmax/P 0.43 (0.02*) 0.49 (0.02*) 
*p<0.05; **p<0.01. 
aPathological size as measured on tumour specimens from patients undergoing primary surgery (n=21). 
 
 
3.5.5 ADC vs. 18F-FMISO-PET and DCE-MRI parameters 
Positive correlations were observed between mean lesion ADC and DCE-MRI indices (Ktrans: 
r=0.24, p=0.34; ve: r=0.29, p=0.25; vp: r=0.20, p=0.43), except for kep which correlated 
negatively with mean lesion ADC (r=-0.15, p=0.56; Figure 3.7); none of which were 
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statistically significant. No correlations were observed between mean lesion ADC and Ki or 
%HF (Ki: r=0.05, p=0.84; %HF r=0.04, p=0.88; Figure 3.7). Representative ADC maps are 
given in Figure 3.8.  
 
Similarly, mean ADC of the darkest part of the tumour (dp-ADC) showed weak positive 
correlations with Ki and %HF (Figure 3.9) which were not statistically significant. Similar to 
mean lesion ADC, dp-ADC correlated positively to DCE-MRI Ktrans and negatively to kep.  No 
association was observed between dp-ADC, ve and vp (Figure 3.10). Correlations between dp-
ADC and DCE-MRI parameters (Ktrans, Kep, Ve, Vp) were not statistically significant. 
 
 
Figure. 3.7 18F-FMISO-PET parameters vs. mean whole tumour apparent diffusion coefficient 
(ADC): (a) influx rate Ki and (b) hypoxic fraction (%). IDC: invasive ductal carcinoma; ILC: 
invasive lobular carcinoma; IMC: invasive mucinous carcinoma; Mixed: carcinoma of mixed 






Figure 3.8 Axial images of two patients with: (a) invasive ductal carcinoma (IDC); (b) invasive 
lobular carcinoma (ILC). (Left-to-right) DCE-MRI image at peak enhancement; Ktrans map 
representing tumour perfusion for the lesion ROI; Ki map representing tumour hypoxia for the 
lesion ROI; ADC map of the lesion. Ktrans: contrast influx rate (mL/g/min); Ki: 18F-FMISO 
























Figure 3.9 Scatterplot and regression line of (a) influx rate Ki (mL/cm3/min) and (b) hypoxic 









Figure 3.10 Scatterplot and regression line of DCE-MRI parameters vs. apparent diffusion 
coefficient of the darkest part of the tumour (dp-ADC [mm2/s]): (a) contrast influx rate, Ktrans 
(mL/g/min); (b) contrast efflux rate, kep (min-1); (c) fractional volume of extravascular-
extracellular space, ve; (d) plasma fractional volume, vp. 
a b 




This study explored the relationship between tumour hypoxia and vascular function in breast 
cancer using combined 18F-FMISO-PET/MRI. Hypoxic fractions and Ki measured on 18F-
FMISO-PET showed inverse relationships with the DCE-MRI perfusion parameter Ktrans, 
consistent with the generally accepted view that tumour hypoxia is a consequence of 
inadequate oxygen supply to the tumour42. Previous clinical studies in cervical and head-and-
neck carcinomas have demonstrated significant negative correlations between contrast 
enhancement or pharmacokinetic parameters from DCE-MRI and polarographic pO2 
measurements or pimonidazole immunohistochemistry41,43. These findings are consistent with 
these results in breast cancer.  
 
However, PET and DCE-MRI parametric images exhibited largely heterogeneous intra-
tumoural patterns with hypoxic islands on Ki maps often colocalising with areas of increased 
Ktrans. This spatially discrepant relationship between hypoxia and perfusion has been previously 
documented, with the co-existence of hypoxic and hyperperfused tumour sub-volumes44. 
Various biological mechanisms, including HIF-1α-induced angiogenesis, interstitial fluid 
pressure, a fluctuating haemodynamic response, increased oxygen diffusion distances from the 
microvasculature, and the presence of longitudinal oxygen gradients across tumour vessels 
have all been proposed to explain the occurrence of hypoxia in highly perfused areas45,46. Thus, 
although the general trend of our results would support the widely accepted view that hypoxia 
develops in hypo perfused breast tumours, the diverse relationships observed in individual 
tumour sub-volumes indicate heterogeneity in hypoxia-perfusion patterns and reflect the 
variety of pathophysiological mechanisms occurring in cancers.   
 
The weak relationship between PET hypoxia parameters with kep suggests that the degree of 
tumour hypoxia is more strongly influenced by vascular flow rather than vessel permeability. 
Li et al47 have previously suggested that kep is a much more sensitive measure of vessel 
permeability than Ktrans, as the latter represents a combined measure of blood flow, vessel 
permeability and capillary-surface area. Our findings broadly agree with previous research in 
cervical and head-and-neck carcinomas, which illustrated weaker correlations between 
hypoxia and permeability-surface-area product than between hypoxia and blood flow41,48. The 
relationship between Ktrans and regional hypoxia observed in our study suggests this is due to 
fluctuations in tumour vascular flow rather than capillary permeability.  
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No or weak positive correlations were found between static 18F-FMISO parameters (SUVmean, 
SUVmax, Tmax/M, Tmax/P) and DCE-MRI metrics. In contrast, in human head-and-neck cancer, 
where hypoxia is often marked, 18F-FMISO SUV measurements were negatively correlated 
with both Ktrans and kep18. A plausible explanation for this disparity is the higher level of hypoxia 
typically encountered in head-and-neck cancer, which will lead to uptake values being more 
dominated by hypoxia-specific 18F-FMISO trapping rather than non-specific tracer 
accumulation. Due to the higher contribution of non-specific 18F-FMISO accumulation at low 
hypoxia levels49, the use of uptake values in cancers without marked hypoxia may not 
accurately reveal relationships between hypoxia and perfusion. 
 
No significant correlation was observed between PET hypoxia parameters and tumour grade 
or subtype. Our sample size of non-IDC cases was small for evaluating the impact of histology 
on tumour hypoxic status, but the presence of non-zero hypoxic fractions was observed in all 
histological subtypes studied. Hypoxic fractions and higher Ki were noted in both grade 2 and 
3 tumours, and less so in grade 1 cancers. These findings are concordant with previously 
reported small differences in hypoxia between low and high-grade breast malignancies50. 
Correlations between DCE-MRI functional parameters and pathological size or MR tumour 
diameter yielded moderate negative relationships and conversely positive associations between 
18F-FMISO-PET hypoxia parameters and size. The size-related hypoxia changes could be 
ascribed to diffusion-limited hypoxia, concomitant decreased perfusion or increased interstitial 
fluid pressure51. 
 
ADC has been shown to inversely correlate with cellular density52, and therefore a reduction 
in whole tumour ADC should theoretically be accompanied by an increase in tumour hypoxia. 
Our findings indicated no association between mean whole tumour ADC and PET hypoxia 
parameters. This result could be explained by the molecular subtype of lesions in our sample, 
which predominantly consisted of ER-positive/HER2-negative cancers. Due to lower blood 
flow, ER-positive or HER2-negative lesions exhibit lower ADC values than ER-negative or 
HER2-positive cancers53,54. As ADC is affected not only by tissue cellularity but several 
pathophysiologic processes including blood flow, membrane permeability and the geometric 
architecture of the interstitial space55,56 it is likely that the lack of association between the PET 
hypoxia parameters and mean whole tumour ADC is a consequence of the combined effect of 
cellularity, perfusion and micro-vessel structure on ADC. This assertion is further supported 
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by the weak correlations between DCE-MRI indices and ADC (mean WTu and Dptu) observed 
in this study. It should be noted however that inconsistent correlations between mean ADC and 
DCE-MRI parameters have been reported in tumours, including breast cancer57,58,59. 
 
ADC measurement approach using a small region of interest (ROI) in the visually assessed 
lowest ADC area of the tumour has been found to be the most practical and diagnostically 
accurate measurement in mass lesions in comparison to whole-lesion ROIs36,60. Likewise, 
small-ROI ADC measurement has been more frequently associated with tumour prognostic 
factors60, although this study did not reveal significant correlations between tumour prognostic 
factors (such as histological tumour type, grade and size) and ADC measured in the darkest 
part of the lesion. In this study, mean ADC of the part of the tumour with more restricted 
diffusion presented poor positive correlations with PET hypoxia parameters and as previously 
mentioned, this may be due to the influence of other hallmarks of the cancer. Small-ROI ADC 
(from the part of the lesion with more restricted diffusion), like whole tumour ADC, correlated 
weakly to DCE-MRI quantitative parameters. 
 
We calculated hypoxic fractions based on a specific parameter for hypoxia namely influx rate-
constant Ki. Despite the higher variability associated with kinetic parameter estimates, our 
choice was based on two considerations. First, several authors have reported lack of correlation 
between 18F-FMISO uptake ratios and pO2 measurements casting doubt on the accuracy of 
thresholds derived from static PET imaging for hypoxic quantification61,62. Kinetic parameters, 
including Ki, have provided superior correlations with physiological measures of hypoxia from 
pO2 histography and immunohistochemistry61,62. Second, these thresholds have mostly been 
defined on measurements from head-and-neck cancers and are not necessarily applicable to 
other tumour types, including breast cancer. 
 
The main limitations of our study are the small sample size and that the majority of cancers 
were HR-positive ductal carcinomas. Though our findings cannot be generalised to the full 
spectrum of histological/molecular subtypes encountered in breast cancer, our study indicates 
the presence of hypoxia in all histological subtypes studied independent of nuclear grade. 
While the majority of lesions (56%) examined were found to be non-hypoxic, it should be 
noted that breast tumours are generally less hypoxic than cancers of the head-and-neck, cervix 
or lung and show greater variability in hypoxia among molecular subtypes, with basal-like 
subtypes being the most hypoxic63.  
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3.7 Conclusion and clinical impact 
 
Our demonstration of in vivo simultaneous measurement of perfusion and hypoxia is clinically 
important for three reasons. First, previous reports have indicated that tumours with a high 
hypoxia-perfusion ratio (i.e. hypoxia due to low perfusion) have a poorer prognosis and 
suboptimal treatment response64,65. In breast cancer, studies have described differences in the 
response to perfusion-related hypoxic exposure between molecular subtypes66,67, emphasising 
the need for combined hypoxia-perfusion measurements to provide more accurate prognostic 
information or tailor treatment. Second, preoperative radiotherapy or radio-chemotherapy 
regimes in early or locally advanced breast cancer have reported beneficial clinical 
outcomes68,69. Hypoxia and hypoperfusion are known to reduce the effectiveness of 
radiotherapy and chemotherapy, therefore knowing the hypoxia-perfusion status of tumours at 
baseline could allow optimisation of these regimens. Third, tumour hypoxia can occur 
independently of hypoperfusion as evidenced in the oncology literature44,45,64,65 and our 
findings. As such, the data presented here can be viewed as providing further indication of the 
benefit of non-invasive multi-modal assessment of the tumour microenvironment for disease 
characterisation. 
 
In conclusion, we found a negative relationship between tumour hypoxia, measured by 18F-
FMISO-PET, and markers of perfusion and vascular function from DCE-MRI, endorsing the 
hypothesis of perfusion-driven hypoxia in breast cancer. No associations were observed 
between 18F-FMISO-PET parameters and tumour histology or grade, but hypoxic fractions 
increased with lesion size. The intra-tumoral heterogeneity observed in hypoxia and perfusion 
images is consistent with the known complex relationship between perfusion and the hypoxic 
tumour micromilieu. The combined assessment of hypoxia-perfusion status of tumours may 
need to be considered in determining treatment efficacy or informing therapy selection in breast 
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Measurement of 18F-FMISO radioactivity concentration in blood samples and scaling of 
the population-based arterial input function (AIF) 
 
The 18F-FMISO population-based AIF used in this study was generated by averaging measured 
arterial input functions derived from six healthy volunteers scanned at the Wolfson Brain 
Imaging Centre, University of Cambridge as part of a study in stroke and normalised by body 
weight.   
 
For each scan the 18F-FMISO population-based AIF was scaled by two venous blood samples 
(~2 mL each) collected following arteriovenous equilibrium [29], prior to (107 ± 6.4 min p.i) 
and after the end (186.9 ± 6.5 min p.i) of the PET/MR acquisition. Immediately after collection, 
each blood sample was aliquoted into a sample tube and centrifuged (6000 rpm; 5 min) to 
separate plasma, of which ~0.5 mL was apportioned for measuring radioactivity using a 
Triathler gamma counter (HIDEX, Turku, Finland). The radioactivity concentration (Bq/mL) 
in each plasma sample was subsequently calculated accounting for radioisotope decay between 
the time of measurement and injection. Given the low levels of metabolism and protein binding 
of 18F-FMISO in human plasma, no correction for 18F-FMISO plasma metabolites or protein 
binding was performed [29-31]. To determine the scale factor applied to the 18F-FMISO 
population-based AIF for each patient, the ratio between the measured 18F-FMISO 
radioactivity concentration in each venous plasma sample and the population-derived AIF at 













Appendix Figure A-1: 18F-FMISO population-based arterial input functions (AIFs) for four 












Chapter 4. The relationship between tumour radiological features, whole-
breast vascularity and PET/MR imaging parameters of hypoxia and 
vascular function 
 
Chapter 3 examined the relationship between hypoxia and vascular function in treatment-naïve 
breast cancer using 18FMISO-PET/MRI. At the tumour level, hypoxia as measured by 18F-
FMISO-PET was found to be negatively correlated with perfusion measured by DCE-MRI, 
supporting the hypothesis of perfusion-driven hypoxia in breast cancer.  
 
This chapter aims to expand upon this finding by exploring associations between radiological 
descriptors of peri-tumoral and whole-breast vascularity, and quantitative metrics of hypoxia 






Tumour enhancement kinetics obtained from dynamic contrast enhanced magnetic resonance 
imaging (DCE-MRI) have been  important for breast cancer diagnosis and management1,2. 
These features of the lesion are included in the American College of Radiology Breast Imaging 
Reporting and Data system (BI-RADS) lexicon. This lexicon was initially developed in 1993 
with the purpose of standardizing imaging reports and facilitating communication among 
physicians3. Likewise, it allows a better description of the morphological features of breast 
cancers (shape, margins and internal enhancement characteristics). The fifth and most recent 
BI-RADS edition, published in 2016, improved and expanded the lexicon for mammography, 
breast ultrasonography (US) and breast MRI3. The MR imaging lexicon of the fifth edition 
added for first time descriptors for the amount of fibro glandular tissue and background 
parenchymal enhancement. Additionally, terms used to describe mass and non-mass 
enhancements were consolidated in the new edition. 
 
In addition to contrast enhancement kinetics of the cancer (quantitative vascular parameters 
and kinetic curve), other vascular features obtained from DCE-MRI have been extensively 
studied such as background parenchymal enhancement, whole breast vascularity, tumour 
internal enhancement and the adjacent vessel sign4. Blood-vessel analysis of breast cancers on 
contrast-enhanced magnetic resonance images (CE-MRI) dates back to 1997 when Siewert et 
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al5 demonstrated the diagnostic value of  the adjacent vessel sign to differentiate benign from 
malignant breast lesions. The adjacent vessel sign refers to the presence of one or more 
prominent vessels adjacent to a breast mass6 and can be considered as an indicator of tumour 
vascularity. Previous reports have found a strong significant correlation between the total 
number of adjacent feeding vessels (AFV), tumour size and features from histopathology7,8. 
 
 
4.1.1 Local and whole breast vascularity assessment 
 
Although most studies have focused on the vascular function and microcirculation properties 
of breast tumours, the vascularity of the ipsilateral breast has also been shown to increase in 
women with breast cancer2,9. Associations between breast cancer and increased vascularity of 
the cancer-bearing breast have been demonstrated with contrast-enhanced MRI2,9,10, laser 
Doppler imaging11, CT angiography12 and PET13, with studies also indicating an overall 
increase in the blood flow of the ipsilateral breast. Aside from the  neo-angiogenesis stimulated 
by breast cancer, other reasons explaining this association could be the reduced flow resistance 
in the tumour neo-vessels as well as an increased tumour metabolism14. Prominent increased 
whole-breast vascularity has also been associated with poor prognosis. 
 
Subtracted dynamic MR images or maximum-intensity-projection (MIP) reconstruction of 
subtracted dynamic MR images are often used to measure breast and cancer vascularity 
simultaneously. Breast vascularity is frequently assessed by visually analyzing the contrast 
enhancement of the breast parenchyma (background parenchymal enhancement) and grouping 
it into different categories according to the level of enhancement (minimal, mild, moderate or 
marked) and to its distribution (symmetric or asymmetric)3. However, Sardanelli et al2. 
proposed a different method for breast vascularity assessment which was used in this study. 
The method is based on counting the number of breast blood vessels, arteries and veins, with 
3 cm long or longer and 2 mm or greater in maximal diameter. 
 
Given the association between ipsilateral whole-breast vascularity and tumour blood flow and 
the negative association between tumour hypoxia and perfusion, it would be reasonable to 
hypothesise that vascular blood flow within the cancer-bearing breast may also be a surrogate 
marker of the perfusion and hypoxia status of tumours. This chapter evaluates the relationship 
between parameters of tumour hypoxia and perfusion from 18FMISO-PET/MRI with 
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morphological features of the cancer and qualitative measures of whole breast and tumour 
vascularity, including the number of adjacent feeding vessels (AFV). To the best of our 
knowledge, DCE-MRI features of whole-breast and peritumoral vascularity, specifically, 
signal-intensity curve type and tumour adjacent feeding vessels have not been previously 






The patient population for the study consisted of 29 women with 32 newly diagnosed and 
biopsy-confirmed primary breast cancers on PET-MRI and 31 on DCE-MRI. ADC calculations 
included data from 18 patients (19 lesions). The inclusion and exclusion criteria for the study, 
as well as further clinical information about the patient population are provided in Chapter 3, 
Section 3.4.1 and Table 3.1, respectively. 
 
4.2.2 PET/MR acquisition 
A detailed description of the PET/MR acquisition protocol is presented in Chapter 3, Section 
3.4.2. MR sequence information is given in Chapter 3, Table 3.1.  
 
4.2.3 Image analysis 
 
4.2.3.1 Radiological evaluation 
Three radiologists reviewed the MR images and identified lesions in each patient in consensus, 
using information from the post-contrast T1-weighted and subtraction images. For each 
PET/MR examination, the following lesion characteristics were evaluated: location, size, 
morphology, and enhancement kinetics. The readers were blinded to the pathological findings 
at the time of image evaluation.  
 
Lesion size: For size assessment, the longest diameter (LD) in the axial plane was taken as 
tumour size measurement. In cases of multifocality or multicentricity, all foci were measured, 
and the sum of all longest diameters was calculated15. In addition, total tumour ROI volume 
was calculated by summing tumour volumes across all slices encompassing the cancer and 
multiplying by the slice thickness (i.e. 1.4 mm). 
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Morphology and enhancement kinetics: Morphology and kinetic curve assessment used 
descriptors from the Fifth Edition of the ACR BI-RADS Atlas3 and included the following:  
i. Shape – oval, round, irregular 
ii. Margins – circumscribed, not-circumscribed: irregular, spiculated 
iii. Internal enhancement characteristics – homogeneous, heterogeneous, rim enhancement 
iv. Signal intensity (S/I) curve description 
a. Initial phase – slow, medium, fast 
b. Delayed phase – persistent (Type 1), plateau (Type 2), washout (Type 3) 
 
Breast vascularity assessment: Whole-breast vascularity was evaluated according to the 
method of Sardanelli et al2 using axial and coronal maximum intensity projections (MIPs) from 
subtracted MR images. The total number of significant vessels, i.e. arteries or veins, which 
were ≥3 cm in length and ≥2 mm in maximal diameter, were recorded for each breast. A score 
ranging from 0 to 3, corresponding to low and high breast vascularity respectively, was 
assigned to each breast according to the following criteria: 
i. Score 0 - Absence or very low vascularity: Complete absence of vessels ≥3 cm in length 
and ≥2 mm in maximal diameter or presence of vessels <3 cm in length and <2 mm in 
maximal diameter 
ii. Score 1 – Low vascularity: Presence of 1 vessel ≥3 cm in length and ≥2 mm in maximal 
diameter 
iii. Score 2 – Moderate vascularity: Presence of 2-4 vessels ≥3 cm in length and ≥2 mm in 
maximal diameter 
iv. Score 3 – High vascularity: Presence of ≥5 vessels that were ≥3 cm in length and ≥2 
mm in maximal diameter. 
A vascularity score for each patient was subsequently calculated by averaging the vascularity 
scores for the two breasts. To facilitate statistical analysis, breast vascularity was further 
classified as either low (scores 0 and 1) or high (scores 2 and 3). 
 
Asymmetries in breast vascularity were assessed by taking the difference in the number of 
significant vessels between the two breasts. Vascular asymmetry was considered present in 
cases where the difference in the number of vessels between the two breasts was ≥2. In women 
with unilateral disease and presence of vascular asymmetry (i.e. patients with one-sided 
increased vascularity), the side of vascular asymmetry (ipsilateral or contralateral) was 
recorded and also, the breast with the highest number of vessels (ipsilateral or contralateral). 
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Furthermore, the presence and number of enlarged vessels, defined as vessels ≥3 cm in length 
and ≥3 mm in maximal diameter, was also recorded for each breast in patients. For this analysis 
of whole-breast vascularity and comparisons between the ipsilateral and contralateral breast, 
women with bilateral cancers were excluded. 
 
Tumour adjacent feeding vessel count: MIPs of subtraction images were used for counting 
adjacent feeding vessels (AFV) in tumours16. Either all vessels leading to the enhancing tumour 
mass or in contact with the edges of the lesion on the DCE-MR images were considered as 
AFV17. In cases of multifocal or multicentric breast cancers, the aggregate AFV count was 
calculated.  
 
4.2.3.2 Quantitative analysis 
Tumour region of interest delineation: Tumour regions were manually delineated in OsiriX, 
version 8.0.2 (Pixmeo SARL, Switzerland) by three radiologists in consensus as previously 
described (Chapter 3, Section 3.4.3). In brief, regions were drawn on the peak enhancing phase 
of the DCE-MRI series (phase 19) on all consecutive axial sections encompassing the 
enhancing mass and including multifocal/multicentric disease. Bilateral breast cancers were 
treated as individual lesions18. 
 
DCE-MRI: Pharmacokinetic analysis of DCE-MRI data was performed in MIStar, version 
3.2.63 (Apollo Medical Imaging, Melbourne, Australia) using the extended Tofts’ model to 
calculate the volume transfer constant, Ktrans, efflux rate constant, kep, extravascular-
extracellular volume fraction ve, and plasma volume fraction, vp. B1+ maps and T1 maps were 
also computed as outlined in Chapter 3.4.2.2. In addition to pharmacokinetic analysis, the 
enhancing tumour volume (ETV) was calculated for each patient using the signal enhancement 
ratio method19. Early percent enhancement (PEe) and signal-enhancement ratio (SER) maps for 
each lesion were derived from pre-contrast images (S0), early post-contrast (SE, phase 19 of the 
DCE series) and late post-contrast (SL) images, phase 46 of the DCE series; using the following 
equations: PEe = 100×(SE – S0)/S0 and SER = 100×(SE – S0)/(SL– S0) respectively. ETV was 
subsequently calculated by summing all image voxels within the tumour ROI above thresholds 
for PE and SER, followed by connectivity test to eliminate single voxels or exceedingly small 
regions. For ETV calculations, thresholds of 70% and 100% were used for PE and SER 
respectively19. 
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DWI-MRI: Calculation of apparent diffusion coefficient (ADC) maps was performed in OsiriX, 
using b-values of 0 and 900 s/mm2, as previously described in Chapter 3, Section 3.4.3. Aside 
from the whole lesion mean ADC, mean ADC from the darkest part of the tumour (dp-ADC) 
was measured, using a 5 mm circular region in the visually darkest area of the tumour20,21 
(Chapter 3, Section 3.4.3). 
 
PET: Image frames from 120-180 min p.i were averaged, registered to the peak-enhancing 
phase of the DCE-MRI series and subsequently employed for the determination of 18F-FMISO 
uptake as standardised uptake values normalised by body weight (SUVbw), tumour-to-plasma 
(Tmax/P) and tumour-to-muscle (Tmax/M) ratios using the ROIs defined on DCE-MRI. The 
influx rate of 18F-FMISO into the trapped (hypoxic) tissue compartment (Ki) was determined, 
as a more specific measure of tumour hypoxia. Ki maps were produced by using the Patlak-
plot analysis, for which a population-based arterial input function was utilised. Hypoxic 
fractions (%HF) in tumour ROIs were calculated as the percentage of voxels with Ki values 
higher than 2×standard deviations (SD) of the mean Ki in the normoxic muscle.  
 
4.2.3.3 Histology 
Histopathological information including tumour type, grade, oestrogen receptors (ER), 
progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) were 
obtained from core biopsies and/or surgical tumour specimens. Tumours were graded using the 
Elston-Ellis scoring system22. Cancers with positive ER or PR expression were classified as 
hormone-receptor (HR) positive. Expression of hormones and HER2 were measured by 
immunohistochemistry (Chapter 3. Section 3.4.4). 
 
4.2.3.4 Statistical analysis 
Statistical analysis was performed in IBM SPSS Statistics for MacOS, v25.0 (IBM Corp., 
Armonk, NY) or Matlab 2016b. Continuous data was assessed for normality using the 
Anderson-Darling test and is presented as mean ± SD or median [range] as appropriate.  
 
Correlations between continuous variables were assessed using the Pearson (r) or Spearman 
(ρ) correlation coefficient, whereas Kendall’s τb was used to measure correlations between 
ordinal variables. Associations between nominal variables were assessed using chi-squared (χ2) 
tests and Cramer’s V. t-tests were used for comparison between means of two groups, and 
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ANOVA when more than two groups were compared. Where data was not normally 
distributed, or normality could not be assessed, Mann-Whitney U and Mood’s median or 
Kruskal-Wallis H tests were employed for comparisons between two or more groups 
respectively. Linear regression was utilised for assessing the relationships between continuous 
variables or between continuous and categorical variables, whereas associations between lesion 
and patient metrics were examined using mixed effects models with random intercepts for 
subjects. In cases where the ensuing residuals from linear regression or mixed models were not 
normally distributed as indicated by normality tests and Q-Q plots, dependent variables (i.e. 
quantitative PET and MRI parameters) were transformed using the natural logarithm to yield 
more normally distributed residuals. Factors affecting parameter associations were identified 
through separate univariate analyses and included into the models if p-values were ≤ 0.1. In all 
analyses, p-values <0.05 were considered statistically significant, unless otherwise indicated. 
 
4.3  Results 
Twenty-nine patients with 32 pathologically confirmed breast cancers were analysed. The 
majority of lesions were NST or invasive ductal carcinomas (21/32; 66%), grade 2 (16/32; 
50%) and positive for hormone receptors (31/32; 97%). Clinical information about the patient 
population can be found in Table 4.1. Further clinical details can be found in Chapter 3, Table 
3.2. Lesion histological characteristics are summarised in Table 4.2.   
 
Table 4.1: Clinical characteristics for the patient population (n=29 patients).   
Characteristic n (%) 
Age at diagnosis (years)a 57 [37-78] 
  
Menopausal status  
Pre-menopausal 10 (35) 
Post-menopausal 19 (65) 
  
Clinical management  
Primary surgery 21 (72) 
Neo-adjuvant therapy   8 (28) 
  
Lesion presentation  
Unilateral 27 (93) 
Bilateral (synchronous) 2 (7) 
aData presented as median [range]. 
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Table 4.2: Tumour characteristics (n=32 lesions).   
Histological features n (%) 
Lesions (n) 32 
  
Histological sub-type   
Ductal (IDC) 21 (66) 
Lobular (ILC)   6 (19) 
Mixeda 3 (9) 
Mucinous (IMC) 2 (6) 
  
Histological Grade  
1 3 (9) 
2 16 (50) 
3 13 (41) 
  
Molecular subtype   
HR+/HER2- 24 (75) 
HR+/HER2+ 7 (22) 
HR-/HER2- 1 (3) 
  
Lesion lateralityb   
Right breast 16 (50) 
Left breast 16 (50) 
aInvasive carcinomas for which histology indicated the presence of both lobular and ductal components.  
HR: hormone receptor; HER2: Human epidermal growth factor receptor 2. 
 
 
A summary of the morphological and enhancement characteristics of the cancers in this sample 
is given in Table 4.3. The median lesion diameter on MRI was 24 [10 – 117] mm, with 22/32 
(69%) cancers measuring >2 cm in the longest diameter, while the median tumour volume was 
2.44 [0.29 – 27.74] cm3. Thirty-one breast cancers (31/32; 97%) depicted irregular shape, 
whereas one cancer showed an oval shape (1/32; 3%). All 32 lesions had non-circumscribed 
margins, with 17/32 cancers (53%) presenting with irregular margins and 15/32 (47%) with 
spiculated margins.  
 
All masses showed rim enhancement. Initial phase enhancement was classified as fast for all 
lesions, with 29/31 (93%) cancers showing either plateau (type 2) or washout (type 3) curves. 
Two breast tumours (2/31; 7%) displayed persistent enhancement (type 1), although they were 
malignant lesions. The median ETV was 2.29 [0.29 – 22.02] cm3. 
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Table 4.3: Tumour morphological and enhancement characteristics (n=32 lesions).   
Characteristic n (%) 
Longest diameter (LD) on MRI (mm)a 24 [10 - 117]  
≤20 mm 10 (31) 
>20 mm 22 (69) 
  
Adjacent feeding vessels (AFV)a  10.5 [1 – 58] 
  
Volume (cm3)a 2.44 [0.29 – 27.74] 
  
Enhancing tumour volume (ETV; cm3)a 2.29 [0.29 – 22.02] 
  
Shape  
Oval 1 (3) 
Irregular 31 (97) 
  
Margins   
Non-circumscribed  32 (100) 
Irregular 17 (53) 
Spiculated 15 (47) 
  
Internal enhancement characteristicsb  
Rim enhancement 31 (100) 
  
Signal intensity (S/I) curve descriptionb  
Initial phase  
Fast 31 (100) 
Delayed phase  
Persistent (Type 1) 2 (7) 
Plateau (Type 2) 14 (45) 
Washout (Type 3) 15 (48) 
aData presented as median [range]. 












Table 4.4: Breast vascularity assessment for the patient population (n=29 patients). 
Characteristic n (%) 
Breast vascularity   
Absent (score 0) 4 (14) 
Low (score 1) 3 (10) 
Moderate (score 2) 20 (69) 
High (score 3) 2 (7) 
  
Significant breast vessels (number)a 4 ± 3 
  
Vascular asymmetry  
Absence 18 (62) 
Presence  11 (38) 
  
Vascular asymmetry side [n=27 patients]b   
One-sided increased vascularity 9 (33) 
Contralateral 2 (7) 
Ipsilateral 7 (26) 
No vascular asymmetry 18 (67) 
  
Enlarged vessels [n=29 patients]  
Absence 14 (48) 
Presence 15 (52) 
Numberc 0 [0 – 3] 
aData presented as mean ± standard deviation (SD). 
bData given for patients with unilateral disease (n=27), patients with bilateral disease (n=2) were excluded. 
cData presented as median [range]. 
 
 
4.3.1 Local and whole-breast vascularity assessment 
The median number of tumour AFV was 11 [1 – 58] vessels (Table 4.3) in all patients, whereas 
the mean number of significant blood vessels in the breasts, vessels ≥ 3 cm in length and ≥ 2 
mm in maximal diameter, was 4 ± 3 vessels (Table 4.4). Breast vascularity was characterised 
as moderate (score 2) or high (score 3) for 22/29 (76%) patients, with 11/29 (38%) women also 
exhibiting vascular asymmetry between the two breasts (Table 4.5). The median number of 
significant breast vessels in women with vascular asymmetry was 6 [3 – 9] vessels. Presence 
of enlarged vessels was noted in 52% (15/29) of all patients.   
 
Among women with unilateral disease (n=27), vascular asymmetry was observed in 9/27 
(33%) patients (Table 4.4).  In general, there was a tendency for a higher number of significant 
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breast vessels (and subsequently a higher vascular score) in the ipsilateral rather than the 
contralateral breast (Table 4.5); however, differences in the number of significant breast vessels 
between the two breasts did not reach statistical significance (ipsilateral vs contralateral: 2 [0 
– 7] vs 2 [0 – 5] vessels, p=0.08). The correlation between the number of significant breast 
vessels in the ipsilateral and contralateral breast was positive (ρ=0.5, p=0.01), like it was the 
correlation between ipsilateral and contralateral breast vascularity scores (τb=0.6, p<0.001).  
  
Table 4.5: Individual breast vascularity assessment for patients with unilateral tumours (n=27 
patients). 
Characteristic n (%) 
Ipsilateral breast 
Breast vascularity   
Absent (score 0) 4 (15) 
Low (score 1) 4 (15) 
Moderate (score 2) 17 (63) 
High (score 3) 2 (7) 
Significant breast vesselsa 2 [0 – 7] 
Enlarged breast vesselsa 1 [1 – 3] 
  
Contralateral breast 
Breast vascularity   
Absent (score 0) 6 (22) 
Low (score 1) 7 (26) 
Moderate (score 2) 13 (48) 
High (score 3) 1 (4) 
Significant breast vesselsa 2 [0 - 5] 
Enlarged breast vesselsa 1 [1 - 3] 




Table 4.6: Ipsilateral vs contralateral breast vascularity scores for women with unilateral 
disease (n=27). Two patients with bilateral cancers were excluded from ipsilateral vs 
contralateral breast comparisons. Vascularity scores of 0 and 1 were classified as low 
vascularity, whereas vascularity scores of 2 and 3 were classified as high vascularity. 




(n = 13) 
High 
(n = 14) 
Low (n = 8) 7 1 




Notably, in approximately three-quarters of the patients (20/27; 74%), there was 
correspondence in the vascularity score between the two breasts (Table 4.6). Patient vascularity 
scores were significantly associated with the presence (Cramer’s V=0.42, p=0.04) and number 
of enlarged breast vessels (τb=0.45, p=0.01). Analogous relationships were observed between 
the presence of vascular asymmetry and the presence (Cramer’s V=0.33, p=0.13) or number of 
enlarged vessels (presence vs absence of vascular asymmetry: 0 [0 – 2] vs 1 [0 – 3] vessels, 
p=0.07), but these relationships did not achieve statistical significance. Additionally, there was 
no significant difference in the number of enlarged vessels between the ipsilateral and 
contralateral breast in patients with unilateral disease (ipsilateral vs contralateral: 1 [1 – 2] vs 
1 [1 – 3] vessels, p=0.23).  
 
The number of AFV in tumours did not significantly correlate with the number of breast 
significant vessels in either the ipsilateral (ρ=0.20, p=0.28) or contralateral breast1 (ρ=-0.30, 
p=0.12). Similarly, weak associations were observed between whole-breast or patient 
vascularity scores and AFV (ipsilateral breast: τb=0.13, p=0.36; contralateral breast1: τb=-0.14, 
p=0.38; patient: τb=0.15, p=0.33). Additionally, no correlations were observed between AFV 
and the number of enlarged breast vessels (ρ=0.06, p=0.77). Patients with vascular asymmetry 
had a higher number of AFV than patients with no asymmetry (presence vs absence: 18 [4 – 
32] vs 9 [1 - 58] vessels, p=0.045), while the presence or absence of enlarged breast vessels did 
not yield any statistically significant difference in the number of AFV (presence vs absence: 
12 [1 – 37] vs 15 [4 - 58] vessels, p=0.65).   
 
 
4.3.2 Correlations between clinical data and morphological DCE-MRI descriptors 
 
There was no statistically significant correlation between patient age and tumour size, 
measured as the longest lesion diameter on MRI (ρ=-0.28, p=0.14). In contrast, the correlation 
between tumour volume and patient age was close to statistical significance (ρ=-0.37, p=0.05). 
No association was observed between tumour size metrics (LD and volume) with patient body 
mass index (LD: ρ=0.08, p=0.67; volume: ρ=0.08, p=0.67)2, menopausal status (pre-
 
1 Correlations between the number of AFV and significant breast vessels or breast vascularity scores in the 
contralateral breast excluded two patients with bilateral tumours. 
2The Spearman correlation coefficients between BMI and tumour longest diameter or volume were 0.079 
(p=0.669) and 0.078 (p=0.671) respectively. Both correlation coefficients and the respective p values were 
rounded to the second decimal point.   
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menopausal vs post-menopausal – LD: 20.5 [9.8 – 117] vs 24 [10 – 60] mm, p=0.71; volume: 
2.12 [0.5 – 27.7] vs 2.4 [0.3 – 21.2] cm3, p=0.74) or lesion laterality (right vs left breast – LD: 
29.5 [10 – 117] vs 20 [9.8 – 71] mm, p=0.13; volume: 2.5 [0.5 – 27.8] vs 2.3 [0.4 – 22.3] cm3, 
p=0.78). Additionally, the type of margins (irregular vs spiculated) was not associated with any 
of these clinical parameters (age: 56 ± 11 vs 61 ±13 years, p=0.28; BMI: 27.3 ± 4.9 vs 28.8 ± 
5.8 kg/cm2, p=0.28; lesion laterality: Cramer’s V = 0.19, p=0.29). 
In a similar manner, delayed phase patterns of the time-signal intensity tumour curve were not 
significantly associated with menopausal status (Cramer’s V = 0.36, p=0.14) or lesion laterality 
(Cramer’s V = 0.1, p=0.85).  No statistically significant difference was found in the age (Type 
1 vs Type 2 vs Type 3: 66 [66 – 66] vs 63 [37 – 78] vs 50 [37 – 75] years old, p=0.19) or BMI 
(Type 1 vs Type 2 vs Type 3: 27.5 [26.0 – 29] vs 29 [24 – 39] vs 24.5 [20 – 36] kg/cm2, p=0.30) 
of patients with lesions presenting type 1, 2 or 3 kinetic curves. Tumour enhancing volumes 
showed similar correlations with clinical variables as other tumour size metrics, displaying a 
negative correlation with patient age that was close to statistical significance (ρ=-0.31, p=0.09); 
no association with patient BMI (ρ=0.04, p=0.83) and no difference between pre and post-
menopausal women (1.3 [0.32 – 22.0] vs 2.4 [0.29 – 13.0] cm3, p=0.98) .  
 
With respect to local tumour vascularity, there was no significant correlation between the total 
number of tumour AFV and patient age (ρ=-0.04, p=0.83) or BMI (ρ=0.15, p=0.45). Likewise, 
no statistically significant difference in AFVs was observed between pre or post-menopausal 
women (pre-menopausal vs post-menopausal: 11 [2 – 58] vs 10 [1 - 31], p=0.84), and right or 
left-sided lesions (right vs left breast: 10 [4 – 32] vs 12 [1 – 58], p=0.91). In terms of whole 
breast vascularity, no significant association was found between breast vascularity scores and 
age (τb=0.09, p=0.55), BMI (τb =0.21, p=0.17), menopausal status (χ2=1.48, p=0.69) or lesion 
laterality (χ2=6.53, p=0.09). Furthermore, the presence of vascular asymmetry was not related 
to any of the aforementioned clinical characteristics (presence vs absence – age: 57 ± 13 vs 57 
± 11 years, p=1.0; BMI: 28.5 ± 6.8 vs 27.2 ± 4.2 years, p=0.79; menopausal status: Cramer’s 
V = 0.18, p=0.33). 
 
4.3.3 Relationships between tumour morphological and enhancement descriptors 
Tumours with irregular margins were larger than those with spiculated boundaries, suggesting 
a potential interaction effect between margin type and tumour size (measured as either the 
longest diameter on MRI or volume) in this sample of cancers (Table 4.7.A). Similarly, there 
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was a statistically significant difference in ETV between cancers with irregular and spiculated 
margins (Table 4.7.B). Although relationships between tumour size and delayed-phase kinetic 
curve patterns were not statistically significant (LD: τb=0.27, p=0.07; volume: τb=0.20, p=0.18; 
ETV: τb=0.23, p=0.13), breast cancers with type 3 kinetic curves tended to be larger than those 
displaying type 1 or type 2 curves (Table 4.8.A).  
 
Table 4.7: Size (A), enhancement (B) and vascularity (C) parameters according to the type of 
tumour margins (n=32 lesions). Data are presented as median [range]. Lesions included for 
DCE-MRI analysis (n=31). 
  Margins  






Lesions (n=32) 17 15  
LD 
33.5  
[14 – 117] 
20  




[0.5 – 27.7]  
1.7 










Lesions (n=31) 16 15  
ETV 
3.4 
[0.3 – 22.0] 
1.7 
[0.3 – 5.8] 
0.03*a 
Kinetic curve type 
3 
[1 – 3] 
2 










Lesions (n=31) 16 15  
AFV 
15 
[4 – 58] 
10 
[1 – 31] 
0.38a 
aMann-Whitney U test 
bChi-squared (χ2) test 
*p<0.05; **p<0.01 
LD: tumour longest diameter (LD, mm); volume: tumour volume (cm3); ETV: enhancing tumour volume (cm3); 
AFV: adjacent feeding vessels (count). 
 
 
The association between kinetic curve delayed phase enhancement patterns and margin types 
was also statistically significant in this data set (χ2=7.81, p=0.02), with 11/16 (69%) lesions 
with irregular margins displaying type 3 enhancement and 11/15 (73%) cancers with spiculated 




4.3.4 Local and whole-breast vascularity vs tumour morphology and delayed phase 
enhancement patterns 
There was a significant positive correlation between the number of AFV and tumour longest 
diameter (ρ=0.48, p=0.01), volume (ρ=0.37, p=0.04), or ETV (ρ=0.46, p=0.01), indicating a 
tendency for larger tumours or tumours with a larger enhancing component to display a higher 
number of feeding vessels. There was no statistically significant difference in the median 
number of AFV between cancers with irregular and spiculated margins (Table 4.7.C) or lesions 
displaying different delayed-phase enhancement patterns (Table 4.8.C). 
 
Table 4.8: Size (A), enhancement (B) and vascularity (C) parameters with respect to delayed-
phase enhancement patterns. Data are presented as mean [95% confidence interval]. Lesions 
included for DCE-MRI analysis (n=31). 
















[8 – 43] 
21 
[16 – 29] 
32 




[0.33 – 11.7] 
2.00 
[1.04 – 3.83] 
4.02 















[0.18 – 5.54] 
1.7 
[0.91 – 3.17] 
3.09 











Lesions (n=31) 2 14 15  
AFV 
11 
[3 – 40] 
10 
[6 – 16] 
10 
[6 – 16] 
0.98a 
a p values were estimated using by linear regression of each parameter for the effect of delayed-phase enhancement 
type. Due to no non-normality of residuals, dependent variables were transformed using the natural logarithm 
before being inserted into the model. The table presents untransformed mean estimates and 95% confidence 
intervals of DCE-MRI parameters.  
LD: tumour longest diameter (LD, mm); volume: tumour volume (cm3); ETV: enhancing tumour volume (cm3); 




Table 4.9: Fixed effects estimates (β), 95% confidence intervals [CI] and p values for the 
association of log-transformed values of the tumour longest diameter (LD; mm), volume (cm3) 
and enhancing tumour volume (ETV; cm3) with vascularity scores for the ipsilateral breast, 
contralateral breast and patient overall breast vascularity score.  
 Vascularity score 
 Ipsilateral breast Contralateral breasta Overall 
Parameter β,[CI],p 
ln(LD) 0.15,[-0.02 – 0.32],0.13 0.11,[-0.18 – 0.40],0.13 0.18,[-0.11 – 0.46],0.24 
ln(Volume) 0.39,[-0.05 – 0.82],0.11 0.08,[-0.49 – 0.65],0.79 0.25,[-0.33 – 0.83],0.41 
ln(ETV) 0.47,[0.18 – 0.77],0.05 -0.04,[-0.62 – 0.54],0.90 0.19,[-0.39 – 0.76],0.53 
aAssociations between vascularity scores for the contralateral breast and DCE-MRI parameters were computed 
for patients with unilateral cancers (n=27). Two patients with bilateral lesions were excluded from these 
associations.  
 
Table 4.10: Fixed effects estimates (β), 95% confidence intervals [CI] and p values for the 
association of log-transformed values of the tumour longest diameter (LD; mm), volume (cm3) 
and enhancing tumour volume (ETV; cm3) with the number of significant breast vessels for 
the ipsilateral and contralateral breast. 
 Significant vessels 
 Ipsilateral breast Contralateral breasta 
Parameter β,[CI], p 
ln(LD) 0.07,[-0.02 – 0.16],0.17 0.03,[-0.15 – 0.21],0.74 
ln(Volume) 0.16,[-0.07 – 0.38],0.19 -0.01,[-0.37 – 0.34],0.94 
ln(ETV) 0.23,[0.09 – 0.38],0.06  -0.09,[-0.45 – 0.27],0.63 
aAssociations between the number of significant vessels in the contralateral breast and DCE-MRI parameters were 
computed for patients with unilateral cancers (n=27). Two patients with bilateral lesions were excluded from these 
associations.  
 
Table 4.11: Fixed effects estimates (β), 95% confidence intervals [CI] and p values for the 
association of log-transformed values of the tumour longest diameter (LD; mm), volume (cm3) 
and enhancing tumour volume (ETV; cm3) with the presence of vascular asymmetry, and the 
presence or number of enlarged vessels. 
 Vascular asymmetry Enlarged vessels 
 Presence Presence Number 
Parameter β,[CI], p β,[CI], p 
ln(LD) -0.02,[-0.02 – 0.32],0.13 0.54,[0.12 – 0.56],0.02* 0.27,[0.01 – 0.54],0.05 
ln(Volume) 0.07,[-0.88 – 1.00],0.88 1.11,[0.29 – 0.94],0.01* 0.55,[0.02 – 1.07],0.05 
ln(ETV) 0.16,[-0.79 – 1.11],0.74 0.91,[0.04 – 1.78],0.05 0.43,[-0.11 – 0.97],0.13 
aAssociations between vascular asymmetry and DCE-MRI parameters were computed for patients with unilateral 




The fixed-effect estimates together with confidence intervals and p-values for the association 
between whole-breast or patient vascularity scores with tumour LD, volume and ETV are 
presented in Tables 4.9 – 4.11. Vascularity scores, the number of significant vessels in each 
breast and presence of vascular asymmetry were positively associated with tumour LD or 
volume, but these associations were not significant (Tables 4.9 – 4.11 respectively). In contrast, 
the presence or number of enlarged vessels was significantly associated with larger cancers 
(Table 4.11). Furthermore, ETV displayed positive associations with the vascularity score and 
number of significant breast vessels for the ipsilateral breast (Tables 4.9 and 4.10 respectively). 
There was also a positive association between ETV and the number or presence of enlarged 
vessels (Table 4.11) which was close to statistical significance.  
 
Table 4.12: Mean [95% confidence interval (CI)] for the association of tumour histology with 
the tumour longest diameter (LD; mm), volume (cm3), enhancing tumour volume (ETV; cm3) 
and number of adjacent feeding vessels (AFV). Lesions included for DCE-MRI analysis 
(n=31). 
  Histology 
 Parameter IDC ILC Mixed IMC p 
 Lesions 





e  LD 
23 
[18 – 31] 
35 
[21 – 58] 
26 
[13 – 54] 
20 




[1.30 – 3.67] 
6.73 
[2.56 – 17.71] 
3.94 
[1.00 – 15.46] 
0.87 










t  Lesions 
(n=31) 20 6 3 2  
ETV 
1.83 
[1.07 – 3.14] 
4.65 
[1.75 – 12.39] 
2.44 
[0.61 – 9.75] 
0.87 














[7 – 15] 
15 
[7 – 30] 
6 
[2 – 16] 
5 
[2 – 18] 
0.33b 
ap values were estimated using by linear regression of each parameter for the effect of tumour histological subtype. Due to no 
non-normality of residuals, dependent variables were transformed using the natural logarithm before linear regression analysis. 
IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; IMC: invasive mucinous carcinoma; Mixed: invasive 
carcinomas for which histology indicated the presence of both ductal and lobular components. 
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4.3.5 The influence of tumour histology and grade on descriptors of tumour 
morphology, enhancement and vascularity 
Tables 4.12, 4.13 and 4.14 present tumour morphology, enhancement, and vascularity 
parameters with respect to histological subtype, molecular subtype and nuclear grade, 
respectively. Regarding tumour size and ETV, no statistically significant differences were 
observed in tumours of different histology, molecular subtype or nuclear grade (Tables 4.12 – 
4.14, respectively).  Though size and ETV comparisons between HR+/HER2- and 
HR+/HER2+ lesions were not statistically significant3, HR+/HER2- lesions were on average 
larger in size than HR+/HER2+ cancers, while also displaying a larger enhancing volume 
(Table 4.13). It should be noted however, HR+/HER2- cancers constituted the majority in this 
sample of tumours.  
 
Table 4.13: Median [range] for the tumour longest diameter (LD; mm), volume (cm3), 
enhancing tumour volume (ETV; cm3) and number of adjacent feeding vessels (AFV) 
according to molecular subtype. Lesions included for DCE-MRI analysis (n=31). 
  Molecular subtype  
 Parameter HR+/HER2- HR+/HER2+ HR-/HER2- p 







[10 – 117] 
19 
[10 – 34] 
31 




[0.39 – 27.74] 
1.71 
[0.29 – 2.46] 
3.55 











Lesions (n=31) 24 6 1  
ETV 
3.13 
[0.32 – 22.02] 
1.50 
[0.29 – 2.36] 
2.29 










Lesions (n=31) 24 6 1  
AFV 
12 
[1 – 58] 
11 
[4 – 18] 
5 
[ – ] 
0.57a,b 
aThe single HR-/HER2- cancer was excluded from statistical comparisons. 




3 The single triple-negative cancer in this dataset was excluded from statistical comparisons but is reported in 
Table 4.13 for completeness. 
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Overall, an increase in tumour size metrics, ETV and number of AFV could be observed with 
higher tumour grade (Table 4.14). Grade 3 cancers exhibited a larger size and ETV, and 
consequently a larger number of feeding vessels, than lower grade lesions. However, 
correlations between nuclear grade and tumour size or ETV did not reach statistical 
significance (LD: τb=0.19, p=0.20; volume: τb=0.24, p=0.10; ETV: τb=0.20, p=0.17; Table 
4.15). Additionally, no significant association was observed between kinetic-curve types and 
tumour histology (χ2=6.30, p=0.39), molecular subtype (χ2=1.66, p=0.79) or grade (τb=0.26, 
p=0.13).  
 
Associations between tumour prognostic factors and breast vascularity characteristics are given 
in Table 4.15 and Figure 4.1. Whole-breast and patient vascularity scores or the number of 
significant breast vessels in the cancer-bearing or contralateral breast were not associated with 
tumour histology, molecular subtype or grade (Table 4.15; Figure 4.1 (a), (c) and (e) 
respectively). Similarly, no differences were observed in the number of AFV between cancers 
of different histology (Table 4.12), molecular subtype (Table 4.13) or grade (Table 4.14).  
 
Table 4.14: Mean [95% confidence interval] for the association of tumour grade with the 
tumour longest diameter (LD; mm), volume (cm3), enhancing tumour volume (ETV; cm3) and 
number of adjacent feeding vessels (AFV). Lesions included for DCE-MRI analysis (n=31). 
  Grade  
 Parameter 1 2 3 p 







[11 – 45] 
23 
[17 – 31] 
29 




[0.42 – 7.44] 
2.12 
[1.14 – 3.95] 
3.99 











Lesions (n=31) 3 15 13  
ETV 
1.36 
[0.33 – 5.57] 
1.72 
[0.92 – 3.23] 
3.09 










Lesions (n=31) 3 15 13  
AFV 
8 
[3 – 22] 
10 
[6 – 15] 
11 
[7 – 18] 
0.84a 
ap values were estimated using by linear regression of each parameter for the effect of tumour histological subtype. 
Due to no non-normality of residuals, dependent variables were transformed using the natural logarithm before 
linear regression analysis. *p<0.05; **p<0.01 
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Table 4.15: Associations and respective p values between whole breast and patient vascularity 
scores or number of significant breast vessels and tumour histology, molecular subtype, or 
grade. Parameter associations or correlations were assessed using chi-squared (χ2) tests, linear 
regression analysis for the effect of tumour histology or molecular subtype, or Kendall’s τb. 
Parameter Histology Molecular subtype Grade 
Vascularity Score χ2, p χ2, p τb, [CI], p 
Ipsilateral breast 5.26, 0.81 3.64, 0.73 -0.06, [-0.43 – 0.27], 0.81 
Contralateral breast 8.01, 0.53 6.59, 0.36 -0.14, [-0.52 – 0.20], 0.43 
Overall score 6.13, 0.73 4.70, 0.58 -0.04, [-0.42 – 0.28], 0.55 
Significant breast vessels R2, p R2, p τb, [CI], p 
Ipsilateral breast 0.02, 0.89 0.05, 0.45 -0.04, [-0.37 – 0.32], 0.81 
Contralateral breast 0.13, 0.32 0.04, 0.62 -0.12, [-0.55 – 0.17], 0.43 






Figure 4.1: Number of significant vessels and whole-breast vascularity scores vs tumour histological 
subtype (a, b), molecular subtype (c, d) and grade (e, f) [n=29 patients]. Average numbers of significant 
breast vessels and 95% upper confidence intervals (CI) are presented for the ipsilateral and contralateral 
breast together with the total number of breast vessels observed in a patient. Median (upper range limit) 




































































































































Table 4.16: DCE-MRI, DWI and PET parameters according to the type of margins. Data are 
presented as median [range] or mean ± standard deviation (SD) as appropriate.  
  Margins  








Lesions (n=31) 16 15  
Ktrans 0.395 
[0.129 – 1.978] 
0.535 
[0.099 – 1.285] 
0.52a 
hs-Ktrans 2.646 ± 0.449 2.760 ± 0.435 0.18b 
kep 0.254 [0.103 – 0.307] 
0.286 




[0.213 – 0.838] 
0.491 
[0.259 – 0.949] 
0.36a 
vp 0.0 [0.213 – 0.838] 
0.491 






Lesions (n=19) 10 9  
ADC 
0.949 
[0.423 – 1.549] 
1.079 




[0.471 – 2.120] 
0.842 
[0.250 – 1.097] 
0.35 
 Lesions (n=32) 16 15  




[0.00 – 2.58]  
0.00 







SUVmean 1.19 ± 0.21 1.14 ± 0.25 0.86a 
 
SUVmax 1.64 ± 0.27 1.40 ± 0.45 0.96a 
 
Tmax/M 1.11 ± 0.20 1.04 ± 0.31 0.42a 
 
Tmax/P 0.88 ± 0.22 0.83 ± 0.23 0.35a 
aMann-Whitney U test 








4.3.5 18F-FMISO-PET and MRI parameters vs descriptors of tumour morphology, 
enhancement and local or whole-breast vascularity  
There was no significant difference between MRI and 18F-FMISO parameters in cancers with 
irregular vs spiculated margins or tumours displaying different delayed enhancement curve 
patterns, with the exception of kep, which showed significant differences between cancers with 
irregular or spiculated margins, and ve in lesions with type 2 and 3 kinetic curves (Tables 4.16.A 
and 4.17.A, respectively). As expected, cancers with kinetic curves type 2 and 3 were 
significantly associated with lower ve values (Table 4.18). No correlation was observed 
between kinetic-curve type and other DCE-MRI pharmacokinetic parameters or PET hypoxia 
metrics (Table 4.18).  
 
Axial images of two patients with 2 breast carcinomas of the same histological subtype (IDC) 
are presented in Figure 4.2. Linear regression analysis between DCE-MRI parameters and 
lesion AFV, adjusting for the effects of tumour LD or volume on AFV (see Section 4.3.4), 
resulted in significant positive associations between the number of adjacent feeding vessels, 
Ktrans and ve (Tables 4.19.A and 4.20.A; Figure 4.3), whereas no association was observed with 
other MRI metrics (Figure 4.3-4.4). Conversely, negative associations were found between 
AFV and hypoxic fraction or 18F-FMISO Ki (Tables 4.19.C and 4.20.C; Figure 4.5), providing 
further evidence for a negative association between tumour vascularity and hypoxia. For Ktrans 
and ve there was an average increase of 4.3 – 6.7% and 1.8 – 2.4% per feeding vessel 
respectively when either LD or tumour volume were included as regressors in the model, with 
reductions of 4.0 – 5.8% and 2- 4% per feeding vessel in Ki and %HF respectively. Associations 
between AFV and other MRI or PET metrics were positive (Figures 4.3 – 4.5), but none of 
these relationships were statistically significant.  
 
Except for hs-Ktrans, kep and ADC, MRI parameters were significantly associated with the 
number of significant breast vessels in the ipsilateral breast, while no association was observed 
with the number of significant breast vessels in the contralateral breast (Table 4.21). Patient 
vascularity scores and the presence or number of enlarged vessels showed no or weak 
associations with MRI parameters (Tables 4.21 and 4.22 respectively). On the other hand, there 
were significant associations between whole-breast vascularity descriptors and Ki or %HF 
(Table 4.21.C). Interestingly, Ki and %HF were the only parameters which displayed 
significant negative associations with the number of significant breast vessels in the 
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contralateral breast (Table 4.21.C) or the number of enlarged vessels (Table 4.22.C). Finally, 
the presence of vascular asymmetry showed positive associations with ve and vp, and conversely 
a negative relationship with 18F-FMISO Ki. No other statistically significant correlations were 





Figure 4.2. Ktrans and adjacent feeding vessels (AFVs) of two invasive ductal carcinomas. The 
cancer in figure 4.2.a is bigger in size than the lesion in figure 4.2.b and therefore, it had more 
AFVs. Both cancers showed high Ktrans in their periphery (area in red on Ktrans maps) and lower 
Ktrans in their centre (area in blue and purple on Ktrans maps). Significant breast vessels can be 

















Table 4.17: DCE-MRI, DWI and PET parameters according to delayed-phase enhancement 
characteristics. Data are presented as median [range] or mean ± standard deviation (SD) as 
appropriate.  

















Lesions (n=31) 2 15 14  
Ktrans 0.163 
[0.099 – 0.227] 
0.571 
[0.129 – 1.285] 
0.374 
[0.144 – 1.978] 
0.35b 
hs-Ktrans 5.633 ± 7.188 6.488 ± 3.636 6.461 ± 3.031 0.83c 
kep 
0.179 
[0.170 – 0.187] 
0.284 
[0.192 – 0.351] 
0.272 




[0.411 – 0.637] 
0.571 
[0.259 – 0.949] 
0.387 




[0.015 – 0.028] 
0.128 
[0.013 – 0.367] 
0.063 






Lesions (n=19) 1 9 8  
ADC (×10-3) 
1.021 
[ – ] 
1.079 
[0.423 – 2.464] 
0.895 




[ – ] 
0.842 
[0.250 – 2.120] 
0.780 







Lesions (n=32) 2 15 14  
Ki (×10-3) 
0.367 
[0.319 – 0.415] 
0.084 
[-0.621 – 0.001]   
-0.056 




[0.00 – 0.13] 
0.00 
[ 0.0 – 4.74] 
0.20 
[ 0.0 – 3.07] 
0.06b 
SUVmean 1.11 ± 0.15 1.20 ± 0.26 1.12 ± 0.21 0.42c 
SUVmax 1.50 ± 0.16 1.64 ± 0.44 1.48 ± 0.28 0.24d 
Tmax/M 1.03 ± 0.01 1.08 ± 0.30 1.08 ± 0.25 0.98d 
Tmax/P 0.59 ± 0.29 0.84 ± 0.22 0.91 ± 0.21 0.39d 
aDue to low number of cancers with persistent enhancement, p values are given for comparisons between type 2 
and 3 kinetic curves. 
bMann-Whitney U test 
cStudent’s t test 





Table 4.18: Kendall’s τb and 95% confidence intervals (CI) for the correlation between kinetic 
curve type and imaging parameters from DCE, DWI-MRI and PET. 








Lesions (n=31)   
Ktrans 0.01, [-0.31 – 0.40] 0.97 
hs-Ktrans 0.04, [-0.18 – 0.51] 0.79 
kep -0.04, [-0.37 – 0.33] 0.77 
ve -0.34, [-0.67 – -0.08]  0.02* 





Lesions (n=19)   
ADC (×10-3) -0.15, [-0.61 – 0.29] 0.46 






Lesions (n=32)   
Ki (×10-3) -0.20, [-0.43 – 0.28] 0.18 
HF (%) 0.29, [-0.19 – 0.50] 0.07 
SUVmean -0.07, [-0.44 – 0.28] 0.64 
SUVmax -0.15, [-0.48 – 0.22] 0.32 
Tmax/M 0.07, [-0.33 – 0.40] 0.63 



























































































































































































































































0.065, [0.002 – 0.129], 0.04* 








0.044, [-0.021 – 0.110], 0.18 










-0.002, [-0.007 – 0.004], 0.55 
-5.21×
10










0.024, [0.008 – 0.039], 0.004** 










0.049, [-0.004 – 0.167], 0.06 













0.006, [-0.058 – 0.070], 0.83 














-0.006, [-0.064 – 0.052], 0.82 













-0.058, [-0.106 – -0.103], 0.02* 
-0.011, [-0.027 – 0.006], 0.19 




-0.04, [-0.14 – -0.062], 0.04* 
-0.004, [-0.037 – -0.030], 0.82 





0.008, [-0.011 – 0.028], 0.41 












0.019, [-0.011 – 0.049], 0.22 












0.011, [-0.010 – 0.032], 0.28 











0.003, [-0.015 – 0.021], 0.72 








*p<0.05; **p<0.01; ***p<0.001  






















































































































































































































































0.043, [0.000 – 0.086], 0.04* 
0.010, [-0.051 – 0.070], 0.74 
-0.003, [-0.005 – -0.070], 0.04* 
hs-K
trans 
0.033, [-0.018 – 0.084], 0.19 
0.079, [0.007 – 0.150], 0.03* 
-0.002, [-0.005 – 0.01], 0.17 
k
ep  
-0.004, [-0.022 – 0.013], 0.62 










0.018, [0.008 – 0.028], 0.001** 










0.054, [-0.003 – 0.111], 0.06 















0.015, [-0.015 – 0.046], 0.30 














0.010, [-0.028 – 0.048], 0.59 













-0.04, [-0.07 – -0.02], 0.04* 
-0.03, [-0.08 – 0.02], 0.20 




-0.02, [-0.08 – 0.01], 0.20 
0.03, [-0.07 – 0.12], 0.58 





0.007, [-0.006 – 0.020], 0.30 












0.013, [-0.009 – 0.034], 0.23 












0.008, [-0.005 – 0.022], 0.30 











0.002, [-0.011 – 0.014], 0.77 








*p<0.05; **p<0.01; ***p<0.001  





























































































































































































































































0.125, [0.040 – 0.209], 0.005** 
-0.050, [-0.263 – 0.162], 0.63
a 




0.072, [-0.125 – 0.745], 0.46 
0.083, [-0.196 – 0.362], 0.54 
0.208, [-0.219 – 0.635], 0.35 
k
ep  
-0.011, [-0.023 – 0.001], 0.08 
-0.011, [-0.027 – 0.006], 0.21 
-0.027, [-0.054 – 0.001], 0.05 
v
e  
0.046, [0.005 – 0.088], 0.03* 
-0.026, [-0.152 – 0.100], 0.68
a 




0.034, [0.011 – 0.058], 0.006** 
-0.054, [-0.356 – 0.249], 0.72
a 









1.08, [0.99 – 1.18], 0.1
a 
0.003, [-0.137 – 0.143], 0.96
a 








0.047, [-0.055 – 0.150], 0.34 
-0.072, [-0.238 – 0.093], 0.29 







-0.13, [-0.26 – -0.59], 0.04* 
-0.201, [-0.363 – -0.391], 0.02* 




-0.32, [-0.54 – -0.10], 0.006** 
-0.33, [-0.65 – -0.003], 0.048* 





0.06, [0.01 – 0.11], 0.02* 
-0.01, [-0.07 – 0.05], 0.73 





0.07, [-0.01 – 0.15], 0.06 
-0.02, [-0.12 – 0.09], 0.73 





0.01, [-0.049 – 0.069], 0.73 
-0.02, [-0.11 – -0.06], 0.56 




0.00, [-0.05 – 0.05], 0.87 
-0.03, [-0.08 – -0.03], 0.35 




ith bilateral cancers w
ere excluded from






ber of significant vessels in the contralateral breast. 
bFixed-effects estim
ates for the association betw

















ally distributed as indicated by norm
ality tests, dependent variables w
ere transform
ed using the natural logarithm
 (ln). 
*p<0.05; **p<0.01; ***p<0.001  






























































































































































































0.109, [-0.454 – 0.673], 0.71
c 
0.056, [-0.284 – 0.396], 0.75
a 




0.557, [-0.454 – 0.673], 0.11 
0.281, [-0.127 – 0.688], 0.19 




-0.030, [-0.072 – 0.011], 0.16 
-0.030, [-0.054 – -0.006], 0.02* 
-0.023, [-0.069 – 0.023], 0.33 
v
e  
0.030, [-0.124 – 0.185], 0.71 
-0.023, [-0.213 – 0.167], 0.88
c 
0.187, [0.031 – 0.344], 0.03* 
v
p  
0.244, [-0.498 – 0.986], 0.53
c 
0.248, [-0.292 – 0.788], 0.38
c 









0.017, [-0.306 – 0.340], 0.92
c 
-0.023, [-0.195 – 0.149], 0.80
c 








-0.030, [-0.434 – 0.373], 0.89
c 
-0.089, [-0.301 – 0.122], 0.42
c 







-0.367, [-0.783 – 0.047], 0.09 
-0.026, [-0.509 – -0.013], 0.048* 
0.555, [-0.001 – -1.234], 0.02* 
H
F 
-0.207, [-1.137 – 0.723], 0.65 
-0.156, [-0.709 – 0.397], 0.57 





0.072, [-0.094 – 0.238], 0.40 
0.017, [-0.085 – 0.119], 0.33 





0.091, [-0.172 – 0.355], 0.50 
0.027, [-0.134 – 0.188], 0.74 





0.084, [-0.106 – 0.273], 0.38 
0.043, [-0.070 – 0.156], 0.46 




0.025, [-0.136 – 0.186], 0.77 
0.013, [-0.084 – 0.111], 0.79 
-0.004, [-0.158 – 0.151], 0.96 
aFixed-effects estim
ates for the association betw












 intercepts for subjects w




















ally distributed as indicated by norm
ality tests, dependent variables w
ere transform
ed using the natural logarithm
 (ln). 
*p<0.05; **p<0.01; ***p<0.001  
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Figure 4.3. Scatter plots and regression lines of DCE-MRI parameters vs the number of 
adjacent feeding vessels (AFV) and patient vascularity scores. Regression lines of DCE-MRI 
metrics vs AFV indicate models adjusted for the tumour longest diameter (blue line) or volume 
(red line). Where normality tests indicated not normally distributed regression residuals, 
dependent variables (i.e. Ktrans and vp) were log-transformed. 






























































































































Figure 4.4. Scatter plots and regression lines of apparent diffusion coefficient in the whole 
lesion (ADC) and the darkest part of the tumour (dp-ADC) vs the number of adjacent feeding 
vessels (AFV) or patient vascularity scores. Regression lines of ADC and dp-ADC vs AFV 
indicate regression models adjusted for the tumour longest diameter (blue line) or volume (red 




Figure 4.5. Scatter plots and regression lines of the 18F-FMISO influx rate constant (Ki) and 
hypoxic fraction (%) vs the number of adjacent feeding vessels (AFV) or patient vascularity 
scores. Regression lines of Ki and hypoxic fraction vs AFV indicate regression models adjusted 
for the tumour longest diameter (blue line) or volume (red line).  
 
















































































































To the best of our knowledge, this was the first study in which 18F-FMISO-PET quantitative 
parameters of tumour hypoxia were assessed together with vascular morphological and 
enhancement characteristics of breast cancers extracted from dynamic-contrast-enhanced 
magnetic resonance imaging (DCE-MRI) following the BI-RADS 5th edition lexicon. Despite 
not being included in the BI-RADS, we decided to add adjacent feeding vessels count (AFVs) 
to our analysis as it is an MRI feature which is closely related to the cancer vascular function 
and not studied in depth until now. Similarly, we correlated imaging parameters of tumour 
hypoxia and vascularity with vascular metrics of whole-breast vascularity which were obtained 
from DCE-MRI using Sardanelli et al method.  
 
Increased vascularity in one breast is an MR imaging finding frequently associated with 
ipsilateral invasive cancer and early disease recurrence2,23,24. In this study, thirty-eight percent 
of the study participants showed increased vascularity in the ipsilateral breast in comparison to 
the other one.  Seventy percent of cancer- bearing breasts depicted higher vascularity than 
“normal” or contralateral breasts. Enlarged breast vessels were noted in 52% of all patients. 
Patient vascularity scores were significantly associated with the presence and number of 
enlarged breast vessels; therefore, we could infer that the presence of enlarged breast vessels 
is an indicator of increased breast vascularity. Ipsilateral breast vascularity score and high 
number of significant breast vessels were associated with bigger cancers like the presence and 
number of enlarged breast vessels. 
 
The median number of tumours AFV in these patients was 11 [1 – 58] vessels), whereas the 
mean number of significant breast blood vessels (vessels ≥ 3 cm in length and ≥ 2 mm in 
maximal diameter) was 4 ± 3 vessels. Local peri-tumoral vascularity, measured as tumour 
AFV, showed a non-significant positive correlation with whole-breast vascularity, measured 
as the number of breast vessels in the ipsilateral breast which means that high vascularity in 
the ipsilateral breast is associated to high peri-tumoral vascularity. Previous authors25 have 
reported an increased sensitivity, specificity, accuracy and predictive value of the adjacent 
vessel sign (which refers to the presence of an adjacent feeding vessel but not to the total 
number of them) for breast cancer diagnosis in comparison with ipsilateral increased breast 
vascularity. However, no previous studies were found about the relationship between the 
number of tumour AFVs and ipsilateral increased breast vascularity. We observed that women 
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with vascular asymmetry between their breasts had a higher number of tumour AFV than 
women without asymmetry. 
 
A previous study by Li et al26 found that malignant breast lesions have 2 or more feeding 
vessels whereas, benign breast lesions have no or only one blood vessel. All cancers in our 
sample displayed more than two adjacent feeding vessels, which was in agreement with the 
results published by Li et al. Furthermore, in concordance with published literature7, a 
statistically significant positive correlation was observed between tumour size  (LD, ETV and  
ROI volumes) and the number of adjacent feeding vessels in the cancer. The higher prevalence 
of AFV with increasing cancer size could be explained by the higher degree of vascularisation 
in such lesions owing to increased metabolic demands7,27. In our study, there was no 
statistically significant difference in the median number of AFV between cancers with irregular 
and spiculated margins. Other authors28 have reported that tumours with irregular or spiculated 
margins have significantly higher vascularity than tumours with smooth margins. We also 
observed that AFVs did not significantly vary between lesions displaying different delayed-
phase curve enhancement patterns, though tumours with a higher number of feeding vessels 
tended to display a more aggressive kinetic-curve pattern.   
 
No significant correlation was observed between the number of adjacent feeding vessels and 
tumour histology or molecular subtype. In general, there was a tendency for higher grade 
cancers to exhibit a higher number of AFV, however, associations between AFV and tumour 
grade were not statistically significant. Although this sample of cancers was likely small to 
evaluate differences in AFV in tumours of different histological/molecular subtype and grade, 
the results presented here are concordant with those of Dietzel et al7, who did not observe a 
significant difference in the presence of the adjacent vessel sign between ductal and lobular 
carcinomas or a correlation with tumour grade. Histopathological features of the cancers did 
not show any association with whole-breast vascularity (presence and number of significant 
breast vessels, enlarged breast vessels or vascularity scores) in neither the ipsilateral nor the 
contralateral breast. 
 
In this study, tumour histopathological prognostic factors (histology, molecular subtype or 
nuclear grade) did not significantly influence the tumour size (LD and ETV).  However, 
HR+/HER- lesions were larger in size than HR+/HER2+ cancers, while also displaying a larger 
enhancing volume. It should be noted that HR+/HER- cancers constituted the majority in this 
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sample of tumours. High grade cancers also demonstrated larger size and ETV than low grade 
lesions. Stierer et al29 found that high histologic grade, mitotic rate and high nuclear 
polymorphism were significant predictors for recurrence and survival in breast tumours less 
than 10mm.  
 
Peripheral rim-enhancement was observed in all breast cancers examined. All time-signal 
intensity curves from these cancers demonstrated a rapid initial phase, which means rapid 
signal increase during the first 2 mins after contrast injection30. Almost half of the analysed 
breast cancers (48%) presented a kinetic curve with washout pattern (type 3), 45% of the 
cancers displayed a plateau pattern of the time-signal intensity curve (type 2 curve) and only 
7% showed persistent signal intensity increase (type 1 kinetic curve). Relationships between 
tumour size metrics and delayed-phase kinetic curve patterns were not statistically significant, 
however breast cancers with type 3 kinetic curves tended to be larger than those displaying 
type 1 or type 2 curves. Aversely, there was a statistically significant difference in enhancing 
tumour volumes between cancers with irregular and spiculated margins. As previously stated 
in the literature31,32, lesions with irregular or ill-defined margins should be considered 
malignant regardless of their size or enhancement pattern. 
 
After comparing DCE-MRI quantitative parameters among lesions with different types of 
margins and kinetic curves, we observed that kep was the only DCE-MRI parameter which 
showed significant differences between cancers with irregular or spiculated margins, and ve 
between lesions with type 2 and 3 kinetic curves. Ve was significantly lower in cancers showing 
a delayed washout pattern, as it has also been shown before33. Like in a previous study33, whole-
lesion Ktrans did not differ significantly between cancers showing delayed plateau and washout 
curve patterns and either hotspot-Ktrans.. To the best of my knowledge, previous researchers 
have not correlated hotspot Ktrans with tumour signal intensity curve types. Kep was slightly 
higher in breast cancers with a delayed plateau curve in comparison to cancers showing delayed 
washout. Conversely, Yi et al33. found significant higher values of kep in breast cancers with 
kinetic curve type 3. Breast cancers with a delayed plateau pattern showed higher median vp 
than cancers exhibiting persistent signal increase and washout pattern, although these 
associations were not significant. With respect to DWI-MRI, ADC from the darkest part of the 
cancer showed a significant association with the type of tumour kinetic curve, opposite to 
whole lesion ADC. Breast cancers having delayed washout showed the lowest dp-ADC. 
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As far as we know, no studies have yet been published commenting about the relationship 
between 18F-FMISO/PET imaging parameters of hypoxia and tumour signal-intensity curves. 
Overall, there were not significant differences of 18F-FMISO parameters between cancers with 
irregular and spiculated margins or cancers with different patterns of kinetic curve. Median 
percentage of tumour hypoxic fractions, analysed on a voxel basis, were higher in breast 
cancers with a kinetic curve type 3 (or delayed washout) than in cancers with a kinetic curve 
type 2 and 1. The association between tumour hypoxic fractions and kinetic curve type came 
close to reaching statistical significance. 18F-FMISO SUVs (mean and max) were higher in 
lesions with a kinetic curve type 2 than in lesions with different type of curves. The highest 
mean 18F-FMISO tumour to blood ratio (T/B) was observed in breast cancers with delayed 
washout. Mean 18F-FMISO T/B ratio did not change notably between breast cancers with a 
kinetic curve type 1 and a type 2 curve whereas, 18F-FMISO tumour to muscle ratio (T/M) 
showed an in crescendo pattern between lesions with a kinetic curve type 1, 2 and 3; 
respectively. 
 
From what we know of previous literature, there have not been studies reporting correlations 
between the number of tumour AFVs and DCE-MRI quantitative parameters in breast cancer. 
In this study, there were statistically significant associations between the number of tumour 
AFVs and whole-lesion Ktrans and ve. According to these results, we ought to expect to find 
higher perfusion and/or blood-vessel permeability in those breast cancers displaying more 
feeding vessels on DCE-MRI examinations. By contrast, there were no significant associations 
between tumour AFVs and other DCE or DWI-MRI parameters. The mixed effect statistical 
model revealed that the interaction between tumour size (LD and ROI volumes) and the number 
of AFVs could significantly influence on whole-lesion Ktrans and ve.. Quantitative parameters 
of the tumour vascular function (whole-lesion Ktrans, ve and vp) were also significantly associated 
with metrics of the whole-breast vascularity in the ipsilateral breast.  
 
This study for first time (because it has not been done before) correlated 18F-FMISO-PET 
hypoxia parameters of breast cancers with the number of tumour adjacent feeding vessels. 
Significant negative associations were found between tumour AFV and 18F-FMISO Ki and 
hypoxic fractions, providing evidence for an inverse association between peri-tumoral 
vascularity and hypoxia. Similarly, significant negative associations were observed between 
metrics of the whole-breast vascularity (number of significant breast vessels in the ipsilateral 
and contralateral breasts and vascularity score in the ipsilateral breast) and 18F-FMISO 
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parameters of tumour hypoxia (Ki and hypoxic fractions). Therefore, it seems that the 
vascularity of the contralateral breast may influence on breast cancer hypoxic status as much 
as the vascularity of the ipsilateral breast. The explanation for this may be that in response to 
high tumour metabolic demands, the organism will supply more blood not only to the cancer 
bearing breast but also to the contralateral breast.   
 
One of the main limitations of our study was the failure of the fat saturation (FAT-SAT) 
technique in one case’s DCE-MRI which made the vascular characteristics of the patients’ 
breasts and tumour unanalysable. Therefore, only 31 breast cancers were included for the 
quantitative and qualitative analysis of DCE-MRI whereas 32 breast cancers were analysed in 
18F-FMISO-PET/MRI. Additionally, a larger sample of patients could have provided stronger 
correlations between DCE-MRI tumour and breast vascular features and quantitative 





These results showed that the peri-tumoral vascularity is significantly related to the ipsilateral 
whole-breast vascularity. Since tumour AFVs presented a significant association with tumour 
size, the vascularity of the whole breast may indirectly influence the size of the malignant 
tumour. Tumour prognostic factors such as histology, molecular subtype and grade seem to not 
be related to the peri-tumoral (number of adjacent feeding vessels) or whole-breast vascularity, 
however, future studies with a bigger sample size may be needed to corroborate our results. 
 
As expected, there was a significant association between the number of tumour AFVs, a 
qualitative marker of the tumour vascularity, and DCE-MRI quantitative parameters (whole-
lesion Ktrans and ve) of the cancer vasculature. Similarly, whole-lesion Ktrans, ve and vp showed 
significant correlations with metrics of the whole-breast vascularity. 18F-FMISO parameters of 
tumour hypoxia, Ki and hypoxic fractions, showed significant negative associations with 
parameters of tumour and breast vascularity which confirms the negative relationship between 
tumour vascularity and hypoxia. Kep significantly differentiated between lesions of irregular 
and spiculated margins and ve between lesions with type 2 and 3 kinetic curves, like DWI-MRI 
dp-ADC. PET quantitative parameters of tumour hypoxia did not vary significantly between 
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Chapter 5. Correlations between immunohistochemistry and 18F-FMISO-




The direct measurement of oxygen pressure in tumours using polarographic oxygen electrodes 
is considered the gold standard method for detecting tumour hypoxia1. However, this method 
is invasive and often fails to detect the whole regions of hypoxia due to its limited sampling 
capability and the known heterogeneity of tumours2. Furthermore, oxygen probes can fail to 
discriminate between viable hypoxic tissue and areas of necrosis, therefore not always 
providing accurate information about tumour oxygenation. 
 
Hypoxia can also be measured in tissue specimens by assessing protein expression with 
immunohistochemistry (IHC) using either endogenous or exogenous markers3. Exogeneous 
markers typically involve nitroimidazole compounds, such as pimonidazole and EF-52, which 
are biochemically reducible and accumulate in cells under hypoxic conditions. On the other 
hand, endogenous markers represent genes or proteins that are specifically upregulated in 
hypoxia. One of the most extensively studied endogenous hypoxia marker is hypoxia-inducible 
factor-1 alpha (HIF-1α), which regulates genes involved in angiogenesis, cell metabolism and 
apoptosis4. Expression levels of HIF-1α as measured by IHC are typically higher in more 
aggressive breast cancers since HIF-1α increases with tumour pathologic stage5. Furthermore, 
its expression has been related to increased proliferation and expression of oestrogen receptors 
(ER) and vascular endothelial growth factor (VEGF)6.  
 
Other endogenous markers, including membrane-bound hypoxia-related proteins have also 
been used for measuring hypoxia in tumours7. Those more relevant to breast cancer are 
carbonic anhydrase-IX (CAIX),  glucose transporter 1 (GLUT 1), C-X-C chemokine receptor 
type-4 (CXCR4)8 and insulin-like growth factor-1 receptor (IGF1R)9,10. Previous studies have 
shown different expression rates for these proteins on the surface of breast cancer cells, with a 
rate of 35% for CAIX7. 
 
Studies comparing 18F-FMISO-PET with hypoxia endogenous markers show controversial 
results. In squamous cell carcinoma, Sato et al11 showed a correlation between 18F-FMISO PET 
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uptake and HIF-1α expression. In head and neck cancer, Norikane at al12 reported a weak 
correlation between 18F-FMISO hypoxic tumour volumes and HIF-1α obtained on 
immunohistochemical examinations. In clinical glioma studies12,13, the correlation between 18F-
FMISO uptake and expression of HIF-1α was not demonstrated. This lack of correlation in 
gliomas may be due to the fact that in addition to hypoxia, many non-hypoxic stimuli such as 
cytokines and growth factors, can also activate HIF-1α14. Another explanation is that the up-
regulation of HIF-1α is dependent on the duration and degree of hypoxia in the tumour12.  
 
Imaging methods, such as Positron Emission Tomography (PET) and MRI can provide a non-
invasive and three-dimensional assessment of the pathophysiological properties of cancers, in 
principle permitting a more direct evaluation of intra-tumoral hypoxia and vascularity. PET is 
the preferred method for the evaluation of tumour hypoxia15 and 18F-FMISO is one of the most 
extensively used PET radiotracers and was the first one to be used in the clinical practice to 
assess tumour hypoxia. Given the inconsistencies in results of comparisons between 18F-
FMISO/PET, polarographic measurements and endogenous biomarkers in different types of 
solid tumours, we decided to establish comparisons between 18F-FMISO/PET parameters and 
endogenous biomarkers in breast cancer. Furthermore, we aimed to establish comparisons 
between DCE-MRI vascular parameters and IHC markers of tumour vascularity.  
 
Like imaging parameters of hypoxia, vascular parameters obtained from Dynamic Contrast 
Enhanced (DCE) MRI have also been compared to immunohistochemical biomarkers of neo-
angiogenesis, such as micro-vessel density and vascular endothelial growth factor (VEGF)16,17 
to further understand the pathophysiological basis for dynamic contrast enhancement in breast 
cancer18,19,20,21. CD31, located in tumour endothelial cells, is one of the best known endogenous 
biomarkers for examining tumour micro-vessel density and for quantifying tumour blood 
vessels22. Its immunohistochemical expression as well as that of  CD105, which is also 
expressed in endothelial cells of tumour capillaries23,  is a prognostic indicator of long-term 
outcome in breast cancer patients23,24. CD31 immunostaining seems to be more accurate than 
CD105 immunostaining24. 
 
Previous chapters studied the relationship between 18F-FMISO-PET/MR parameters of 
hypoxia and vascularity in breast tumours. The purpose of this study was to determine if 
functional imaging parameters extracted from combined 18F-FMISO-PET/MRI and DCE-
MRI correlate with endogenous immunohistochemical markers of hypoxia and vascularity in 
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breast malignant lesions in order to assess the ability of tumour imaging markers to 
adequately identify hypoxia in breast cancer. Likewise, I was interested in correlating IHC 
markers of hypoxia and vascularity with each other. Other pathological features of the tumour 
such as percentage of tumour cells and stromal tumour infiltrating lymphocytes (TILs) were 
also analysed in this chapter due to their clinical relevance. Tumour-infiltrating lymphocytes 
are regarded as significant prognostic markers in patients with breast cancer25 and they have 
been previously related to tumour angiogenesis, as measured by micro vessel density26. 
Information on the percentage of tumour cells is considered essential for a correct 
interpretation of the results from molecular testing by pathologists27 and, previous authors28 
have reported an increase of tumour growth factors which leads to increased tumour cell 





This study was approved by a National Research Ethics Committee (14/EE/0145) and the 
Administration of Radioactive Substances Advisory Committee (ARSAC), UK. Patients aged 
>18 years old with biopsy-confirmed primary breast cancer and a tumour diameter >10 mm on 
mammography and/or ultrasound were eligible for the study. The inclusion and exclusion 
criteria are provided in Chapter 3, Section 3.4. For correlations with immunohistochemistry, 
only patients undergoing primary surgery as part of their clinical management were included 
in this analysis. 
 
5.2.2 PET/MRI acquisition 
18F-FMISO-PET-MR examinations were performed on a SIGNA PET-MR scanner (GE 
Healthcare, Waukesha, WI). Patients underwent a 60-min simultaneous PET/MR scan of the 
breasts 120 min after injection of a target activity of 300 MBq of 18F-FMISO. The MRI protocol 
included a 2-point Dixon sequence for PET attenuation correction, T1 and T2-weighted images, 
DWI and a DCE series. MR sequence information is given in Chapter 3, Table 3.1. A detailed 






5.2.3 Image analysis 
 
5.2.3.1 Qualitative image analysis 
Three radiologists reviewed the MR images and identified malignant lesions in each patient in 
consensus, using information from the post-contrast T1-weighted and subtraction images as 
previously described in Chapter 3, Section 3.4.3. For each cancer observed on PET/MR 
examinations, the following tumour characteristics were evaluated: location, size (longest 
diameter and tumour volume), morphology, and enhancement kinetics.  
 
Lesion morphology and enhancement kinetics: Morphology and kinetic curve assessment used 
descriptors from the Fifth Edition of the ACR BI-RADS Atlas29 as explained in Chapter 4, 
Section 4.2.3.1. 
 
Tumour region of interest (ROI) delineation: Tumour regions were manually delineated in 
OsiriX, version 8.0.2 (Pixmeo SARL, Switzerland) on the peak-enhancing phase of the DCE-
MRI series (phase 19) on all consecutive axial images encompassing the enhancing mass and 
including multifocal/multicentric disease. Bilateral breast cancers were treated as individual 
lesions30. The readers were blinded to the pathological findings at the time of image evaluation.  
 
Tumour adjacent feeding vessel count: MIPs of subtraction images were used for counting 
adjacent feeding vessels (AFV) in tumours31. Either all vessels leading to the enhancing tumour 
mass or in contact with the edges of the lesion on the DCE-MR images were considered as 
AFV32. In cases of multifocal or multicentric breast cancers, the aggregate AFV count was 
calculated.  
 
5.2.3.2 Quantitative image analysis 
 
Quantitative analysis of DCE-MRI and PET series was performed using the methodology 
detailed in Chapter 3, Section 3.4.3. A brief description is provided below. 
 
DCE-MRI: Pharmacokinetic analysis of DCE-MRI data was performed in MIStar, version 
3.2.63 (Apollo Medical Imaging, Melbourne, Australia) using the extended Tofts’ model to 
calculate the: volume transfer constant, Ktrans, efflux rate constant, kep, extravascular-
extracellular volume fraction ve, and plasma volume fraction, vp. Modelling utilised a 
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population-based arterial input function based on the modified Fritz-Hansen model. In addition 
to pharmacokinetic analysis, the enhancing tumour volume (ETV) was calculated for each 
patient using the signal enhancement ratio method33 (Chapter 4, Section 4.2.3.2).  
 
DWI: Calculation of apparent diffusion coefficient (ADC) maps from DWI data was performed 
in OsiriX, using b-values of 0 and 900 s/mm2 (Chapter 3, Section 3.4.3). Mean ADC values 
for the whole lesion and for the darkest part of the tumour (dp-ADC) were calculated. dp-ADC 
measurements used a 5-mm circular region in the visually darkest area of the tumour34,35 
(Chapter 3, Section 3.4.3). 
 
PET: The last six of the registered frames of the 18F-FMISO dynamic series were averaged, 
registered to the peak-enhancing phase of the DCE series and employed for the determination 
of 18F-FMISO uptake as standardised uptake values normalised by body weight (SUVbw), 
tumour-to-plasma (Tmax/P) and tumour-to-muscle (Tmax/M) ratios in the ROIs defined on the 
DCE-MRI. The influx rate of 18F-FMISO into the trapped (hypoxic) tissue compartment (Ki) 
was determined as a more specific measure of tumour hypoxia by using Patlak-plot analysis. 
Hypoxic fractions (%HF) in tumour regions were calculated as the percentage of voxels with 
values >2×standard deviations (SD) of the mean Ki in normoxic muscle on PET images. PET 
image analysis was performed in Analyze 12.0 (AnalyzeDirect Inc., Overland Park, KS). Ki 
maps were generated using in-house software implemented in Matlab R2016b (Mathworks 
Inc., Natick, MA). 
 
5.2.4 Histology 
Histopathological information including type, grade, oestrogen receptors (ER), progesterone 
receptors (PR) and human epidermal growth factor receptor 2 (HER2) were obtained from 
surgical tumour specimens. Tumours were graded using the Elston-Ellis scoring system36. 
Cancers with positive ER or PR expression were classified as hormone-receptor (HR) positive. 
Hormone and HER2 expressions were measured by IHC. 
 
5.2.5 Immunohistochemistry  
Following surgical excision, sections of formalin-fixed and paraffin-embedded (FFPE) tumour 
samples were cut at 3 µm and baked for 1 hour at 60°C before deparaffinization and rehydration 
on a Leica ST5020 (Leica Biosystems) as standard. All sections were subsequently loaded onto 
a BOND III instrument (Leica Biosystems) and pre-treated using epitope retrieval solution 1 
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(Cat. No. AR9961, Leica Biosystems) at 100°C for 20 minutes.  Immunohistochemical staining 
was performed on sections containing sufficient tumour tissue using a polymer refine detection 
system (Cat No. DS9800, Leica Biosystems) with diaminobenzidine (DAB) enhancer (Cat No. 
AR9432, Leica Biosystems). Endogenous peroxidase was blocked with a 3% hydrogen 
peroxide solution for 5 minutes and sections were counterstained with haematoxylin and eosin. 
 
Table 5.1 Characteristics of the antibodies used for the IHC analysis. 
Cat. No.: Catalogue number 
 
Samples were stained with CD31, HIF-1α and CAIX using previously optimised conditions 
(see Table 5.1 for specific details). Staining for haematoxylin and eosin (H&E) was performed 
at a concentration of 0.1%. Following immunohistochemistry, slides were removed from the 
BOND III instrument, rehydrated and cleared on the Leica ST5020, and finally mounted on a 
Leica CV5030 (Leica Biosystems). 
 
All stained tumour sections were visually evaluated by an expert breast histopathologist 
blinded to the clinicopathological and PET/MR imaging variables. The distribution of 
immunostaining was classified as either homogeneous or heterogeneous: uniform staining 
throughout the tumour tissue was considered homogeneous staining, whereas accentuated 
staining in either the central area or the periphery of the lesion was considered heterogeneous. 
For HIF-1α and CAIX immunohistochemistry, staining intensity assessment was based on a 4-
point scale from 0 to 3, representing no, mild, moderate and marked immunostaining, 
respectively. The extent of staining was recorded as a percentage of the target tumour sample 







































that had positive expression of HIF-1α or CAIX. CD31-stained slides were digitalised at 
microscopic resolution and the following histopathological parameters were obtained using in-
house software: the total number of micro-vessels, the median vessel diameter (μm), and micro-
vessel density (MVD; number of vessels per mm2). Additionally, tumour cell and stromal TIL 
percentages37 were derived from all available H&E-stained slides. For tumours where more 
than one consecutive IHC sections were available, median parameter values were calculated 
and used in statistical analyses. 
 
5.2.6 Statistical analysis 
Statistical analysis was performed in IBM SPSS Statistics for MacOS, v25.0 (IBM Corp., 
Armonk, NY) or Matlab 2016b. Continuous data were checked for normality using the 
Anderson-Darling test. Correlations between continuous variables were assessed using Pearson 
(r) or Spearman (ρ) correlation, whereas Kendall’s τb was used to measure correlations between 
ordinal or ordinal and continuous variables. Associations between nominal variables were 
assessed using chi-squared (χ2) tests.  Linear regression analysis was utilised for assessing the 
relationship between continuous imaging parameters. t tests were used for comparison between 
means of two groups, and ANOVA when more than two groups were compared. Where data 
were not normally distributed, or normality could not be assessed, Mann-Whitney U and 
Mood’s median or Kruskal-Wallis H tests were employed for comparisons between two or 
more groups respectively. p-values <0.05 were considered statistically significant, unless 
otherwise indicated.  
 
5.3 Results 
The patient population for this study consisted of a group of 22 women with 24 breast cancers, 
who underwent primary surgery as part of their treatment plan. Clinical characteristics of the 
patient population are given in Table 5.2. Due to insufficient diagnostic tumour material for 
histopathological analysis, H&E, CD31, CAIX and HIF-1α immunohistochemistry was 
performed on a total of 23 cancers. However, only 22 cancers had CAIX and CD31 data 
available and 21 cancers had HIF-1 alpha data. Stromal TIL and tumour cell percentages were 
derived from 23 cancers. PET-MRI information was obtained from the 23 breast cancers with 
IHC information available. However, DCE-MRI quantitative parameters were only extracted 
from 21 breast cancers (one patient presented inadequate acquisition of the DCE-MRI series 
and another DCE-MRI examination was excluded due to poor quality of images) and ADC 
calculations were done on 12 patients (and 12 breast lesions) with a successful DWI-MRI scan. 
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The majority of the lesions (14/23; 61%) were invasive ductal carcinomas (IDC) with nuclear 
grade 2 or 3 (20/23; 87%). All tumours were HR-positive, with 18/23 (78%) cancers being 
negative for HER2. Tumour characteristics are presented in Table 5.3. 
 
Table 5.2 Clinical characteristics for the patient population undergoing primary surgery (n=22 
patients). Data are presented as mean ± standard deviation (SD) or number (%).  
Characteristic Metric 
Age at diagnosis (years)
a  





Pre-menopausal 5 (23) 





Unilateral 20 (91) 










  27.5 ± 5.2 
aData presented as mean ± standard deviation (SD). 
bData presented as number (%) patients. 
 
With respect to the morphological features of the breast cancers evaluated (Table 5.4), the 
median tumour longest diameter on MRI was 24mm with a range of 10-117mm. Except for 
one cancer (1/23; 4%) which depicted an oval shape, all tumours showed an irregular shape 
(22/23). All malignant masses presented non-circumscribed margins, rim enhancement and fast 
initial phase enhancement. Almost half of the tumours (10/21) showed a plateau pattern1 in the 
delayed phase, 43% (9/21) washout and 10% (2/21) illustrated persistent enhancement (Table 







1 Kinetic curve assessment was not performed in 2/23 lesions due to inadequate DCE-MRI acquisition (1 lesion) 
and poor kinetic curve fitting (1 lesion). 
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Table 5.3 Characteristics of tumours for which immunohistochemistry (IHC) information was 
available (n=23 lesions). TNM information was available for n=23 lesions.  
Characteristic n (%) 
Lesion laterality  
Left 11 (48) 




  22 [10 – 63] 
  
Histological sub-type  
Ductal (IDC) 14 (61) 
Lobular (ILC) 5 (22) 
Mixed
b
 2 (9)  
Mucinous (IMC) 2 (9) 
  
Histological grade  
1 3 (13) 
2 11 (48) 
3 9 (39) 
  
Molecular subtype  
HR+/HER2- 18 (78) 
HR+/HER2+ 5 (22) 
  
Carcinoma in situ  
Absence 4 (17) 
Presence 19 (83) 
  
Tumour (T) status   
1 12 (52) 
2 8 (35) 
3 3 (13) 
  
Nodal (N) status   
0 13 (57) 
1 7 (30) 
2 3 (13) 
  
Metastatic (M) status   
0 23 (100) 
  
aPathological tumour size. Data are presented as median [range]. 
bInvasive carcinomas for which histology indicated the presence of both lobular and ductal components.  




Table 5.4 Morphologicala and enhancementb characteristics of tumours for which 
immunohistochemistry (IHC) information was available. Data are presented as median [range], 
mean ± standard deviation (SD) or number (%) as appropriate. 
Characteristic Metric 
Longest diameter (LD) on MRI (mm)
a,c 24 [10 - 117] 
  










2.38 [0.29 – 27.74] 
  









Oval 1 (4) 




   
Non-circumscribed   
Irregular 12 (48) 





Rim enhancement 21 (100) 
  
Signal intensity (S/I) curve description
b,e 
(n=21)  
Initial phase  
Fast 21 (100) 
Delayed phase   
Persistent (Type 1) 2 (10) 
Plateau (Type 2) 10 (48) 
Washout (Type 3) 9 (43) 
aEvaluation of morphological features was performed in the 23 cancers for which IHC data was available. 
bInternal enhancement, AFVs, ETV and signal intensity curve descriptors were evaluated in 21 of the 23 cancers 
for which IHC data was available. 
cData presented as median [range]. 
dData presented as mean ± SD. 








5.3.1 CD31, HIF-1α and CAIX immunohistochemistry 
A summary of expression values for the IHC markers used in this study is shown in Table 5.5. 
Representative examples of two cancers stained with HIF-1α, CAIX and CD31 are given in 
Figure 5.1. 
 
In the 22 lesions stained with CD31, the median number of blood vessels was 15643 [2364 – 
49074]. The mean micro vessel density (MVD) was 50.3 ± 21.9 vessels/mm2, while the median 
vessel diameter was 10.10 ± 0.75 μm. The correlation between MVD and total micro vessels 
number (ρ=0.45; p=0.03) or diameter of micro-vessels (r=0.66; p<0.001) was statistically 
significant, while no correlation was observed between the number and diameter of tumour 
micro vessels (ρ=0.18; p=0.41).  
 
Six out of 22 tumours (27%) stained positive for CAIX (intensity score ≥1), with all 6 lesions 
exhibiting heterogeneous immunostaining of either moderate (n=2 tumours) or marked (n=4 
tumours) intensity. The percentage staining in CAIX-positive tumours ranged from 1 to 20% 
and correlated significantly with CAIX intensity scores (τb=0.90; p=<0.001). Among cancers 
positive for CAIX, 3/6 tumours (50%) were IDC with the remaining being two mucinous 
carcinomas (IMC) and a lobular cancer. Negative HER2 expression was found in 4/6 (67%) 
CAIX-positive tumours.   
 
Positive staining for HIF-1α (intensity score ≥1) was found in 17/21 (80%) of the lesions2, 
being characterised as mild (13/21 cancers; 62%) or moderate (4/21 cancers; 19%).  
Homogeneous staining was observed in 6/17 (35%) tumours. Of the 11 cancers with a 
heterogenous staining distribution, 3 (27%) presented accentuated staining in the periphery, 
while 8 (73%) showed central staining. There was a strong correlation between HIF-1α 
intensity scores and staining percentages (τb=0.74; p=<0.001), which varied between 2 and 
20% in HIF-1α-positive tumours. Ductal cancers constituted approximately two-thirds of the 
lesions staining positively for HIF-1α (11/17; 65%), 3/17 (18%) were invasive lobular 
carcinomas (ILC), 2/17 (12%) were IMC and another one (5%) was a mixed cancer with 
lobular and ductal components. Negative HER2 expression was found in 12/17 (71%) tumours 
positive for HIF-1α. 
 
2 HIF-1α immunohistochemistry was performed in n=21 lesions. 
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Table 5.5 Summary of immunohistochemistry (IHC) results for HIF-1α, CAIX, CD31 and 
haematoxylin and eosin (H&E). Data are presented as number (%), median [range], mean ± 







0 4 (19) 
1 13 (62) 
2 4 (19) 
3 0 (0) 
% Staining
c 








0 16 (73) 
1 0 (0) 













15643 [2364 – 49074] 




50.3 ± 21.9 
Microvessel diameter (μm)
e 
10.10 ± 0.75  
  
Stromal tumour infiltrating lymphocytes (TILs; %)
c,f 




63.0 ± 22.9 
aHIF-1α immunohistochemistry was performed in n=21 lesions. 
b Data presented as number (%). 
cData presented as median [range]. 
dCAIX and CD31 immunohistochemistry was performed in n=22 lesions. 
eData presented as mean ± SD. 
fH&E immunohistochemistry was performed in n=23 lesions. 
 
 
There was a weak level of agreement between HIF-1α and CAIX staining intensity scores 
(Cohen’s κ = 0.1, % agreement = 23%, p=0.08) and staining percentages (ρ=0.22; p=0.33). 
Correlations between CD31 parameters and HIF-1α immunostaining percentages were positive 
and statistically significant for micro vessel density (ρ=0.47; p=0.03), but not for tumour micro 
vessel count (ρ=0.10; p=0.66) or micro vessel calibre (ρ=0.23; p=0.31). On the other hand, 
CAIX staining percentage correlated negatively with CD31 parameters, however none of these 
results were significant (micro vessel count: ρ=-0.08; p=0.74; MVD: ρ=-0.28; p=0.21; micro 
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vessel diameter: ρ=-0.31; p=0.16). Correlations between CD31 immunohistochemistry results 
and HIF-1α or CAIX staining intensity followed similar patterns, though also none of these 
were found to be significant (HIF-1α: micro vessel count: τb=0; p=1; MVD: τb=0.20; p=0.26; 
micro vessel diameter: τb=-0.01; p=0.94 | CAIX: micro vessel count: τb =-0.05; p=0.77; MVD: 
τb=-0.23; p=0.19; micro vessel diameter: τb=-0.27; p=0.13).  
 
The percentage of stromal TILs showed non-significant negative correlations with HIF-1α, 
CAIX and CD31 parameters, with the exception of total micro vessel count which showed a 
significant negative correlation with percentage of TILs (ρ=-0.491; p=0.02). Percentage of 
tumour cells showed positive correlations with CAIX and HIF-1α parameters, and also with 
CD31 micro vessel density (correlations with HIF-1α intensity and percentages were 
statistically significant; ρ=0.645; p=0.004 and ρ=0.681; p=0.002, respectively). Non-
significant negative correlations were seen between percentage of tumour cells and CD31-
derived total count of vessels and micro vessel calibre. 
 
Figure 5.1. Pathological microarrays of two grade 2, HR+/HER2- breast cancers. (Top row) Invasive mucinous 
carcinoma (IMC); (bottom row) invasive ductal carcinoma (IDC). In both cancers there is presence of ductal 
carcinoma in situ (DCIS). Immunostaining for HIF-1α, CAIX and CD31 can be seen in brown colour. In (a) and 
(b) there is moderate-marked immunostaining for both HIF-1α and CAIX. The staining pattern is diffuse for HIF-
1α and more focal for CAIX, whereas in (c) poor vascularity can be interpreted from the mild CD31 staining. The 
opposite occurs in the IDC lesion where there is mild HIF-1α (d) and CAIX (e) staining but marked CD31 staining 
(f). 
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Table 5.6 Associations between clinical variables and parameters from the expression of 
immunohistochemistry (IHC) markers. Correlations were computed using Kendall’s τb, 
Pearson (r) or Spearman (ρ) correlation co-efficient. Associations between markers intensity 
scores and lesion laterality were performed using chi-squared (χ2) tests. Asterisks denote 
statistically significant correlations/associations. 
Parameter Age Weight BMI Menopausal status Laterality 
Intensity score
 
τb, p τb, p τb, p χ2, p χ2, p 
HIF-1α -0.05, 0.80 0.25, 0.19 0.19, 0.34 2.2, 0.34 2.0, 0.36 
CAIX 0.09, 0.63 -0.01, 0.97 0.02, 0.93 2.9, 0.24 1.8, 0.40 
      
% Staining ρ, p ρ, p ρ, p p p 










      
CD31 ρ, p ρ, p ρ, p p p 




 r, p r, p ρ, p p p 








      
 ρ, p ρ, p ρ, p p p 
Stromal TILs (%)
 





      
 r, p r, p ρ, p p p 




aMann-Whitney U test 
bStudent’s t test. 
*p<0.05; **p<0.01  













5.3.2 Immunohistochemistry markers vs clinicopathological variables 
There was no statistically significant association between HIF-1α or CAIX expression 
parameters with clinical variables, such as patient age at diagnosis, weight, BMI, menopausal 
status or lesion laterality (Table 5.6). Similarly, no significant correlations were observed 
between these clinical parameters and the percentage of tumour cells or micro-vessel count, 
density, and diameter from CD31 immunostaining (Table 5.6). However, the percentage of 
stromal TILs presented a significant negative correlation with patient weight and BMI, 
indicating a potential interaction effect between these two variables in this sample of cancers 
(Table 5.6).   
 
Tables 5.7 – 5.10 present IHC results with respect to standard clinicopathological variables. 
HIF-1α and CAIX staining intensity showed no statistically significant associations with 
tumour pathological size, histology, grade, the presence of in situ carcinoma, HER2 and nodal 
status (Table 5.7). CAIX staining intensity and percentages showed statistically significant 
negative correlations with tumour T status (Table 5.7 and Table 5.8) which was measured on 
the pathological slide containing the tumour’s largest dimension. Similarly, tumour total vessel 
count obtained from CD31 immunostaining demonstrated statistically significant correlations 
with T status and tumour pathological size (Table 5.8). CAIX staining percentage and CD31-
derived tumour total vessel count were the only IHC parameters that were significantly 
associated with tumour histology (Tables 5.9) with a higher percentage of CAIX-positive cells 
observed in IMC in comparison to other histological categories. Invasive lobular cancers 
exhibited a higher vessel count than other histological types examined, despite of not being 
bigger in size than other cancers.  (Table 5.9). It should be noted that the majority of tumours 
in this sample were ductal carcinomas, which may have limited the evaluation of the effect of 
tumour histology on CAIX, HIF-1α and CD31 immuno expression. CD31 tumour vessel 
diameter showed a significant association with tumour HER-2 status. The diameter of tumour 
micro vessels was lower in HER2-positive cancers than in HER2-negative ones (Table 5.10). 
No significant associations were observed between IHC parameters and the presence of in situ 






Table 5.7 Associations between standard clinicopathological variables and staining intensity 
scores for HIF-1α and CAIX. Asterisks denote statistically significant 
correlations/associations. 
 Staining intensity score 
Parameter HIF-1α CAIX 
Pathological size (τb, p)a -0.03, 0.86 0.03, 0.85 
Histology (χ
2
, p) b 2.22, 0.90 7.71, 0.26 
Grade (τb, p) a -0.08, 0.70 -0.04, 0.84 
HER2 status (χ
2
, p) b 1.60, 0.45 2.43, 0.30 
Carcinoma in situ (χ2, p) b 3.54, 0.17 0.57, 0.75 
T stage (τb, p) a -0.16, 0.47 -0.49, 0.02* 
N stage (τb, p) a -0.26, 0.23 -0.19, 0.37 
aKendall’s τb. 
b Chi-squared (χ2) test. 
*p<0.05; **p<0.01 
HER2: Human epidermal growth factor receptor 2 
 
 
Table 5.8 Spearman (ρ) and Kendall (τb) correlation coefficients between continuous 
parameters from immunohistochemistry (IHC) with respect to tumour pathological size, 











% Staining – HIF-1α  
 
-0.02, 0.93 -0.10, 0.66 -0.12, 0.60 -0.12, 0.61 
% Staining – CAIX   0.10, 0.65 -0.07, 0.76 -0.52, 0.02* -0.19, 0.40 
CD31 – Vessel count 
 
0.58, 0.005** 0.16, 0.48 0.61, 0.004** 0.06, 0.78 
CD31 – MVD  0.11, 0.62 0.13, 0.58 0.17, 0.47 0.03, 0.90 
CD31 – Vessel diameter  -0.13, 0.59 0.02, 0.92 0.05, 0.83 0.06, 0.81 
Stromal TILs (%) -0.27, 0.21 -0.08, 0.71 -0.42, 0.05 0.17, 0.46 
Tumour cells (%) 0.02, 0.93 -0.07, 0.77 -0.29, 0.19 -0.29, 0.19 
*p<0.05; **p<0.01 
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5.3.3 Associations between immunohistochemistry markers and radiological descriptors 
Table 5.11 presents associations of IHC parameters with morphological or enhancement 
descriptors from DCE-MRI. The number of tumour micro vessels and HIF-1α staining intensity 
were the only IHC parameters exhibiting significant correlations with morphology or 
enhancement descriptors (Table 5.11). Moderate-strong positive correlations were observed 
between CD31 micro vessel count and tumour longest diameter on MRI (LD), volume, number 
of AFV and ETV (Table 5.11). Additionally, cancers with spiculated margins tended to display 
significantly lower HIF-1α intensity scores than those with irregular boundaries (0.73 ± 0.45 
vs 1.33 ± 0.71, respectively). The intensity and percentage of HIF-1α immunostaining showed 
positive correlations with tumour kinetic-curve type, and these results almost reached statistical 
significance. CAIX intensity and percentage also showed positive corelations with the type of 
tumour curve. The highest median of CAIX staining intensity scores and percentages were 
observed in cancers with a type 3 kinetic curve (2 [0-3] and 1 [0-10], respectively). Similarly, 
the highest median HIF-1 alpha intensity and percentages (1 [0-2] and 2 [0-20], respectively) 
were observed in cancers with kinetic curve type 3. ER positive cancers with a kinetic curve 
type 3 also presented the highest mean (20245.7 ± 2634.7) of total tumour vessels and the 
highest median (56.379 [11.809-91.707]) of tumour micro-vessels density. On the other hand, 
the cancers with a kinetic curve type 2 presented the highest mean (3.092 ± 2.561) of micro-
vessels calibre. Negative correlations, which were close to statistical significance, were 
obtained between the percentage of expression of stromal TILs and tumour volume or ETV 
(Table 5.11).  
 
Given the significant association between the number of AFV and the tumour longest diameter 
or volume reported in Chapter 4 (see Section 4.3.4), relationships between IHC parameters and 
AFV were also explored using regression analysis adjusted for an interaction effect between 
tumour size and the number of feeding vessels. In the pre-surgical sample of cancers considered 
in this chapter, there was a significant positive correlation between the number of AFV and the 
tumour longest diameter (ρ=0.50, p=0.01), whereas the correlation between AFV and tumour 
volume was close to statistical significance (ρ=0.39, p=0.07). Linear or ordinal regression 
analysis between continuous or ordinal IHC variables, respectively, with AFV adjusted for an 
interaction between AFV and either tumour LD or volume, did not alter the significance of the 
associations presented in Table 5.11, except for % HIF-1α staining, which exhibited a negative 
association with AFV when an interaction effect of the tumour longest diameter was included 
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Table 5.12 Kendall’s τb and p values for the correlation between HIF-1α and CAIX intensity 
scores and 18F-FMISO-PET/MRI parameters. Asterisks denote statistically significant 
correlations. 
 Staining intensity scores 
 HIF-1α CAIX 
Parameter τb, p τb, p 
DCE-MRI   
Ktrans 0.13, 0.51 0.17, 0.37 
hs-Ktrans -0.09, 0.62 -0.02, 0.93 
kep 0.01, 0.97 -0.11, 0.57 
ve -0.08, 0.68  -0.09, 0.63 
vp 0.09, 0.62 0.12, 0.52 
   
DWI   
ADC  0.00, 1.00 0.30. 0.25 
dp-ADC -0.14, 0.58 0.31, 0.26 
   
PET   
Ki  -0.15, 0.41 0.36, 0.046* 
%HF -0.03, 0.88 0.24, 0.25 
SUVmax -0.02, 0.93 -0.03, 0.87 
SUVmean -0.02, 0.94 -0.03, 0.88 
Tmax/M 0.06, 0.77 -0.09, 0.63 
Tmax/P 0.19, 0.32 0.11, 0.57 
*p<0.05; **p<0.01 
Ktrans: contrast influx rate (mL/g/min); kep: contrast efflux rate (min-1); ve: fractional volume of extravascular-
extracellular space; vp: plasma fractional volume; ADC: apparent diffusion coefficient (mm2/s); dp-ADC: ADC 
(mm2/s) in the darkest part of the tumour; Ki: 18F-FMISO influx rate (mL/cm3/min); %HF: percentage hypoxic 




5.3.4 Correlations between immunohistochemistry biomarkers and PET/MRI 
parameters 
Table 5.12 presents correlations between HIF-1α and CAIX staining intensity vs MRI and PET 
parameters. 18F-FMISO-PET/MRI revealed hypoxic fractions higher than 0% in 8 out of 23 
cancers. Results from the linear regression of 18F-FMISO-PET/MRI metrics vs continuous IHC 
parameters are shown in Tables 5.13, 5.14 and 5.15. Scatter plots illustrating the relationships 
between Ktrans and 18F-FMISO Ki vs HIF-1α, CAIX or CD31 immunohistochemistry are 
illustrated in Figures 5.2 and 5.3. Plots indicating relationships between IHC and DCE-MRI 
pharmacokinetic parameters, DWI ADC vs HIF-1α and CAIX staining percentages or CD31 
immunohistochemistry are shown in Figures 5.4 and Figures 5.5 – 5.6 respectively.  
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No associations were observed between DCE-MRI pharmacokinetic parameters and HIF-1α or 
CAIX immunohistochemistry (Tables 5.12 and 5.13; Figures 5.2 and 5.4).  Similarly, 18F-
FMISO PET parameters were not significantly associated with HIF-1α or CAIX 
immunohistochemistry results (Tables 5.12 and 5.13), except for Ki which showed a significant 
positive association with both the intensity and percentage of CAIX immunostaining (Tables 
5.12 and 5.13, respectively; Figures 5.2). Additionally, a statistically significant positive 
association was found between ADC values in the darkest part of the tumour (dp-ADC) and 
CAIX percentages (Table 5.13; Figure 5.4). 
 
Table 5.13 Fixed effects estimates (β) together with confidence intervals (CI) and p values 
from linear regression of MRI and PET parameters vs HIF-1α or CAIX staining percentage. 
Associations between the percentage of hypoxic fraction (%HF) and HIF-1α or CAIX staining 
percentages were calculated using Kendall’s τb. Asterisks denote statistically significant p 
values. 
 % Staining 
 HIF-1α CAIX 
Parameter β, [CI], p β, [CI], p 
DCE-MRI   
Ktrans 0.245, [-4.178 – 4.666], 0.90 0.062, [-4.640 – 4.764], 0.98 
hs-Ktrans 3.289, [-3.792 – 10.369], 0.34 -4.192, [-11.649 – 3.265], 0.25 
kep 0.177, [-0.355 – 0.710], 0.49 -0.102, [-0.673 – 0.469], 0.71 
ve -0.707, [-2.554 – 1.140], 0.43 -0.751, [-2.725 – 1.224], 0.44 
vp 0.055, [-1.149 – 1.260], 0.92 0.010, [-1.273 – 1.293], 0.99 
   
DWI   
ADC (×10-3) 4.702, [-13.176 – 22.581] 0.57 6.432, [-1.278 – 14.142], 0.09 
dp-ADC (×10-3) 4.857, [-10.333 – 20.047] 0.49 6.867, [1.022 – 12.711], 0.03* 
   
PET   
Ki (×10-3) -0.003, [-0.009 – 0.002], 0.21 0.009, [0.002 – 0.014], <.001*** 
%HFa -0.06, 0.75 0.30, 0.14 
SUVmax -1.26, [-4.46 – 1.93], 0.42 -1.86, [-5.10 – 1.39], 0.25 
SUVmean -0.74, [-2.76 – 1.25], 0.44 -0.80, [-2.87 – 1.27], 0.43 
Tmax/M -0.38, [-2.65 – 1.90], 0.73 0.67, [-3.08 – 1.73], 0.56 
Tmax/P 0.92, [-0.86 – 2.70], 0.29 0.26, [-1.66 – 2.18], 0.78 
aKendall’s τb. 
*p<0.05; **p<0.01; ***p<0.001 
Ktrans: contrast influx rate (mL/g/min); kep: contrast efflux rate (min-1); ve: fractional volume of extravascular-
extracellular space; vp: plasma fractional volume; ADC: apparent diffusion coefficient (mm2/s); dp-ADC: ADC 
(mm2/s) in the darkest part of the tumour; Ki: 18F-FMISO influx rate (mL/cm3/min); %HF: percentage hypoxic 






Figure 5.2: Scatter plots and regression lines of the contrast influx rate Ktrans (mL/g/min) from DCE-MRI and 
the 18F-FMISO influx rate Ki (mL/cm3/min) vs HIF-1α or CAIX staining intensity (left column) and percentage 
(right column).  
 
 
Figure 5.3: Scatter plots and regression lines of the contrast influx rate Ktrans (mL/g/min) from DCE-MRI and 
the 18F-FMISO influx rate Ki (mL/cm3/min) vs the CD31 parameters of tumour micro vessel count, micro vessel 
density (MVD; number of micro vessels/mm2) in the top row, and vessel diameter (μm).    
 
165 
 Table 5.14 F
ixed effects estim
ates (β) together w
ith confidence intervals (C
I) and p values from












 staining percentage. A
ssociations betw








 percent staining w
ere 
calculated using K
endall’s τb . A

















β, [CI], p 
β, [CI], p 










-5, [-1.10 – 3.34] ×10
-5, 0.30 
0.006, [-0.04 – 0.017], 0.21 




-5, [-1.44 – 5.79] ×10
-5, 0.22 
-8.354×10
-4, [-0.001 – 0.001], 0.74 




-7, [-2.01 – 3.44] ×10
-6, 0.62 
-0.102, [-0.673 – 0.469], 0.71 




-7, [-9.00– 1.06] ×10
-5, 0.87 
0.002, [-0.003 – 0.006], 0.46 




-6, [-3.32– 8.87] ×10
-6, 0.35 
0.002, [-0.001– 0.005], 0.11 














4.702, [-13.176 – 22.581] 0.57 
-0.004, [-0.018 – 0.011], 0.60 




4.857, [-10.333 – 20.047] 0.49 
-0.003, [-0.016 – 0.009], 0.60 










i   
-1.75×10






















-5, [-3.88 – 2.77] ×10
-5, 0.13 
-2.78×10
-4, [-0.008 – 0.008], 0.94 






-6, [-5.42 – 1.51] ×10
-5, 0.34 
-2.29×10
-4, [-0.005 – 0.005], 0.92 






-6, [-5.09 – 1.83] ×10
-5, 0.25 
-1.16×10
-4, [-0.006 – 0.006], 0.97 





-5, [-5.10 – 1.37] ×10
-5, 0.35 
0.001, [-0.003 – 0.006], 0.57 
0.62, [-0.065 – 0.189], 0.32 
aK










ep : contrast efflux rate (m
in
-1); v
e : fractional volum



























F: percentage hypoxic fraction; SU
V
: 














Table 5.15 Fixed effects estimates (β) together with confidence intervals (CI) and p values 
from linear regression of MRI and PET parameters vs the percent expression of stromal tumour 
infiltrating lymphocytes (%TILs) and tumour cells. Kendall’s τb. Asterisks denote statistically 
significant p values. 
 % TILs % Tumour Cells 
Parameter CC, p CC, p 
DCE-MRI   
Ktrans -0.610, [-1.918 – 0.699], 0.98 -0.166, [-1.167 – 0.834], 0.73 
hs-Ktrans -1.617, [-3.996 – 0.763], 0.17 -0.445, [-2.305 – 1.416], 0.62 
kep -0.064, [-0.218 – 0.090], 0.39 0.025, [-0.091 – 0.142], 0.45 
ve -0.319, [-0.931 – 0.292], 0.29 -0.334, [-0.777 – 0.110], 0.13 
vp -0.159, [-0.517 – 0.199], 0.36 -0.009, [-0.283 – 0.265], 0.94 
   
DWI   
ADC (×10-3) 1.486, [-3.243 – 3.380], 0.96 -1.101, [-2.674 – 0.472], 0.15 
dp-ADC (×10-3) -0.072, [-2.907 – 2.763], 0.96 -0.641, [-2.073 – 0.791], 0.34 
   
PET   
Ki (×10-3) 0.001, [-0.001 – 0.003], 0.38 3.1×10-4, [-0.001 – 0.002], 0.65 
%HFa 0.19, 0.28 0.20, 0.25 
SUVmax -0.92, [-1.76 – -0.08], 0.03* -0.16, [-0.88 – 0.56], 0.65 
SUVmean -0.47, [-1.03 – 0.08], 0.09 -0.21, [-0.66 – 0.23], 0.33 
Tmax/M -0.09, [-1.10 – 0.21], 0.17 0.02, [-0.51 – 0.54], 0.95 
Tmax/P -0.09, [-0.58 – 0.40], 0.71 0.22, [-0.14 – 0.58], 0.22 
aKendall’s τb. 
*p<0.05; **p<0.01; ***p<0.001 
Ktrans: contrast influx rate (mL/g/min); kep: contrast efflux rate (min-1); ve: fractional volume of extravascular-
extracellular space; vp: plasma fractional volume; ADC: apparent diffusion coefficient (mm2/s); dp-ADC: ADC 
(mm2/s) in the darkest part of the tumour; Ki: 18F-FMISO influx rate (mL/cm3/min); %HF: percentage hypoxic 
fraction; SUV: standardised uptake value (g/mL); Tmax/M: tumour-to-muscle ratio; Tmax/P: tumour-to-plasma 
ratio. 
 
The associations between DCE-MRI parameters and the percentage expression of stromal TILs 
or tumour cells were negative and not statistically significant (Table 5.15). 18F-FMISO Ki and 
%HF showed positive relationships with these IHC parameters, which were not statistically 
significant (Table 5.15). On the other hand, 18F-FMISO parameters were negatively associated 
with percentages of TIL expression, with SUVmax being the only parameter exhibiting a 
statistically significant p value (Table 5.15). Mean whole lesion ADC showed a positive 
relationship with TILs (%) and a negative relationship with the percentage of tumour cells 
which were not statistically significant (Table 5.15).  ADC from the darkest part of the tumour 
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The aim of our study was to determine if functional imaging parameters extracted from hybrid 
PET-MRI and DCE-MRI correlate with endogenous immunohistochemical markers of 
hypoxia and vascularity in ER+ breast cancers. Therefore, we correlated IHC biomarkers 
with 18F-FMISO-PET/MRI parameters from ER+ breast cancers. Immunohistochemistry 
analysis of CAIX, HIF-1α and CD31 was performed in tumour slides containing the highest 
proportion of tumour tissue. 
 
The median tumour size after surgical excision was 22mm, ranging between 10 and 63mm, 
whereas the median MRI tumour longest axis was 24mm with a range of 10-117mm. As it is 
widely known, ER+ breast masses are smaller in comparison to ER- breast cancers16. We found 
a statistically significant positive correlation between tumour pathological size and tumour 
longest axis from MRI (r=0.746, p=0.000). 
 
Even though the histological groups of cancers were unbalanced, CAIX expression was higher 
in IMC than in other cancers of different histological type. Ductal invasive carcinomas and 
mucinous carcinomas showed more HIF-1α expression (0-20%) than lobular and mixed 
cancers, those with ductal and lobular components (0-2%). HIF-1α staining intensity did not 
vary between histological groups. On the other hand, lobular carcinomas presented higher 
median of total tumour vessels, determined by immunohistochemical staining using anti-CD31 
monoclonal antibody in the paraffin blocks, than other histological types of cancers. Vessel 
density seemed to be lower in IMC whereas vessel calibre was lower in mixed carcinomas in 
comparison with other histological categories.  
 
Percentage of tumour cells was similar among the different histological types of cancers; 
however, mixed carcinomas and the IMC depicted higher percentage of TILs than ductal and 
lobular tumours. As previous authors have found38, we observed varying levels of TILs in 
ductal carcinomas (0-50%). 
 
Regarding tumour nuclear grade, CAIX expression and staining intensity remained modest in 
low- and high-grade cancers, similar to HIF-1α staining intensity. Surprisingly in this study, 
HIF-1α expression was higher in low grade cancers (grade 1) than in cancers of grade 2 and 3. 
Our results differ from those of Campbell et al39 who stated that HIF-1α activation was 
associated with higher tumour grade and pathological stage. The explanation given was that 
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grade 1 tumours had higher ascorbate levels than grade 2 and 3 tumours and higher ascorbate 
levels were associated with lower HIF-1α activity.  Grade 3 cancers presented higher mean of 
total tumour vessels and greater vessel density and calibre than grade 1 and 2 cancers. Like us, 
Sener et al40 did not observe a significant association between micro-vessel density and other 
prognostic factors such as histological type or nuclear grade in breast carcinomas. Percentage 
of tumour cells and stromal TILs were higher in low grade cancers than in high grade cancers. 
 
Some researchers have reported a positive correlation between carbonic anhydrase IX 
expression and ER negativity in breast cancer41. In line with this, only 6/22 (27%) of the breast 
cancers in our sample were positive for CAIX staining (all cancers were ER+). On the other 
hand, some authors are of the opinion that CAIX expression under hypoxic conditions might 
be cancer type dependant42. Perhaps, another explanation why few cancers in our sample 
stained positive for CAIX could be that 18F-FMISO PET-MRI only detected a hypoxic status 
in 8 out of 23 breast cancers and perhaps, there was relatively little hypoxia present in our 
sample of cancers. CAIX staining intensity and percentages were significantly correlated to 
cancer size (when divided into categories) and CAIX percentages were also significantly 
associated with breast cancer histology in keeping with findings of other authors41,43 but we 
did not observe any significant correlation of CAIX expression with tumour grade or presence 
of in situ carcinoma. 
 
It is widely recognised  that HIF-1α is activated under the presence of hypoxia in cancer44. 
However, in ER positive breast cancers the activation of HIF-1α may not be related to tumour 
hypoxia. Previous studies have found that HIF-1α can be regulated by oestrogen receptor (ER) 
alpha under normoxia and hypoxia45. Similarly, different studies have also stated that HIF-1 
alpha can be regulated by 17-beta oestradiol (E2) in the absence of hypoxia because HIF-1α  
possesses an oestrogen response element46,47. It has also been described that in all biological 
tissues including malignant tumours, HIF-1α can activate oestrogen receptors (ER) alpha and 
beta in the absence of ligand (hormone) and inversely, unoccupied ER beta can inhibit HIF-
1α48. In the present study, 81% (17/21) ER+ breast cancers stained positive for HIF-1α. Since 
only 8 out of 23 cancers showed hypoxia in 18F-FMISO PET/MRI, it was assumed that HIF-1 
alpha activation in these cancers was due to the influence of either oestrogen receptors or the 
hormone itself. It could be inferred that the reason why 19% of the cancers stained negative for 
HIF-1α was the presence of unoccupied ER beta inhibiting HIF-1α. Future studies comparing 
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HIF-1α expression in both ER positive and ER negative breast cancers may be needed to 
specify the relationship between HIF-1α and oestrogen receptors.  
 
HIF-1α staining intensity or percentages did not show significant correlations with tumour 
pathological size, histology, grade, presence of in situ carcinoma and tumour nodal or T status. 
HIF-1α (%) showed a significant positive correlation with tumour micro-vessels density 
calculated from quantitative analysis of CD31 immunostaining. Other authors have also found 
an association between increased levels of HIF-1α and breast cancer micro-vessel formation; 
furthermore, it has been proved that HIF-1α can upregulate VEGF which is a major 
lymphangiogenic and angiogenic factor49,50,51. 
 
The total number of tumour micro vessels calculated from CD31 staining was significantly 
associated with tumour pathological size and T status. Similarly, the number of tumour micro 
vessels significantly varied between histological types of breast cancer, being higher in ILC. 
Previous studies have confirmed that neo-angiogenesis enables tumour growth and leads to 
vascular hyperpermeability52,53. In concordance with this, the total count of tumour vessels had 
statistically significant positive correlations with tumour size metrics (MRI tumour longest 
diameter, ROI volume and ETV) and with tumour AFVs in our study, meaning that larger 
cancers seem to have more blood vessels. Likewise, the total number of tumour vessels was 
significantly correlated to the density and calibre of tumour vessels. Tumour micro-vessel 
density and calibre showed a poor positive correlation between each other. The diameter of 
tumour micro-vessels was significantly associated with tumour’s HER-2 status and in this 
study HER-2 negative cancers presented bigger diameters of tumour micro vessels than HER-
2 positive cancers.  
 
Tumour neo-angiogenesis influences on the tumour metastatic potential. High intra-tumoral 
micro-vascular density produced by an overexpression of VEGF via HIF-1α is related to 
greater incidence of lymph node metastasis51,54,55. However, we were unable to show 
significant correlations between lymph node status of the cancers (nodal status from the TNM 
classification) and CD31 parameters, total count of tumour blood vessels, tumour micro-
vessels density and calibre. This may be due to the low numbers of patients in our study with 
relatively low numbers of lymph node involvement. 
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In the present study, we could not demonstrate any significant association between the hypoxic 
endogenous markers, HIF-1α and CAIX in ER+ breast cancers. In head and neck cancers no 
association between HIF-1α and CAIX expression has been found either56. Equally, Arno 
Kuijper et al. did not find any association between HIF-1α and CAIX in phyllodes tumours of 
the breast57.   
 
We observed a non-significant positive correlation between the percentage of stromal TILs and 
the percentage of tumour cells. Perhaps, increased cell tumour proliferation in ER+ breast 
cancers is related to an increase of immune cells in the tumour stroma as the immune system 
tries to attack the cancer. Our results may be in concordant with those of Kurozumi et al25 who 
stated that high expression of TILs in ER positive breast tumours was a poor prognosis marker.    
 
This study shows a significant positive association between HIF-1α expression and the 
percentage of tumour cells. Previous authors have reported an increase of tumour growth 
factors under hypoxic conditions related to HIF-1α activation, which leads to tumour cell 
proliferation28. Likewise, it has been described that the activation of HIF-1α stimulates tumour 
growth by VEGF expression58. We also found a negative correlation between HIF-1α 
expression and TILs (%), although this was not statistically significant. Our results are similar 
to those of  Doedens et al., who reported a suppression of tumour-infiltrating T cells by HIF-
1α expression in macrophages of a murine model of breast cancer59. Similarly, Duechler et al60 
observed that the level of HIFs correlated with hormone receptor status and the expression of 
several immunosuppressive molecules in breast cancer. 
 
We reported a non-significant positive correlation between CAIX expression and percentage 
of tumour cells, meaning that high CAIX levels in the tumour may be related to increased 
proliferation of tumour cells like it has been proved before61,62. These results are also in 
concordance with the results of Güttler et al63, who observed a reduction in the number of 
tumour cells after inhibiting CAIX with CA9 siRNA. Likewise, we found a non-significant 
positive correlation between CAIX (i) and percentage of TILs and a negative correlation 
between CAIX (%) and TILs. To our knowledge, there is no literature reporting the association 
of CAIX with tumour infiltrating lymphocytes in breast tumours. 
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Our results showed negative correlations between CD31 parameters (total number of tumour 
vessels and tumour-vessel calibre) and percentage of tumour cells. These results support the 
theory that breast cancers with increased cell proliferation rate outgrow their vascular supply 
and consequently, they possess few blood vessels. On the other hand, in colorectal carcinoma, 
a positive correlation has been found between tumour vascularity and tumour cell 
proliferation64.  
 
 With respect to percentage of TILs, there was a statistically significant negative correlation 
between the total number of tumour vessels (which is closely related to tumour angiogenesis) 
and percentage of TILs. We also observed negative correlations between other CD31 derived 
vascular parameters (tumour micro-vessel density and calibre) and TILs (%). Our results 
support previous statements about how the tumour vasculature constitutes a barrier for T-cells 
and how endothelial cells lining the vessels can suppress T cell activity65. 
 
The number of tumour adjacent feeding vessels demonstrated negative correlations with 
endogenous hypoxic biomarkers and positive correlations with CD31 derived vascular 
parameters. The only statistically significant positive correlation was observed with the total 
number of tumour micro vessels. It would be logical to find positive correlations between 
AFVs and CD31 derived total count of tumour vessels, micro-vessels density and calibre since 
all of them are indicators of the tumour vascularity, although AFVs are a macroscopic vascular 
metric and CD31 parameters are measured microscopically. 
 
Almost half of the tumours (10/21) showed a delayed plateau pattern, 43% washout and only 
10% developed persistent enhancement. It is known that ER positive cancers depict less 
malignant DCE-MRI kinetics than ER- breast cancers16. The highest median CAIX expression 
(immune-staining and percentage) was observed in cancers with a type 3 kinetic curve. 
Similarly, the highest median HIF-1α intensity scores and percentage were observed in cancers 
with kinetic curve type 3. ER positive cancers with a kinetic curve type 3 also presented the 
highest mean of total tumour vessels and the highest median of tumour micro-vessels density. 
On the other hand, the cancers with a kinetic curve type 2 presented the highest mean of micro-
vessels calibre. Breast cancers with kinetic curve type 3, which represents higher aggressive 
potential66, showed the highest percentages of stromal TILs and higher percentages of tumour 
cells than breast cancers with curves type 1 or 2. This is the first study assessing the relationship 
between IHC endogenous biomarkers and DCE-MRI tumour kinetics in breast cancer. 
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Our results showed a significant positive correlation between 18F-FMISO Ki mean (an 
imaging marker of hypoxia) and CAIX expression (staining and percentage) and a non- 
significant positive correlation between tumour hypoxic fractions and CAIX, meaning that 
CAIX could be an indicator of hypoxia in ER+ breast cancers. Some previous authors believe 
that CAIX is unreliable for assessing tumour hypoxia42, however, others believe that CAIX is 
a good indicator of hypoxia in breast cancer due to its significant association with necrosis43 
which we could not demonstrate because only 2 out of 23 cancers in this sample presented 
areas of necrosis. Further studies with bigger sample size and necrotic tumours are needed in 
order to show the exact potential and role of CAIX as an immunohistochemical hypoxic marker 
in ER+ breast cancers. There were non-significant positive correlations between CAIX 
expression and DCE-MRI Ktrans and vp. Negative non-significant correlations were found 
between CAIX expression and DCE-MRI Kep and ve. Newbold et al67 did not find correlations 
between DCE-MRI or perfusion CT parameters and CAIX staining in head and neck cancers. 
 
In our study, HIF-1α (intensity and percentage) showed negative correlations with 18F-FMISO 
derived Ki and with tumour hypoxic fractions, although they were not significant. A previous 
study reported as well a poor correlation between 18F-FMISO uptake and HIF-1α expression 
in ER+ breast cancers68. As previously explained, the presence of HIF-1α in our study does not 
appear to indicate hypoxia in our ER+ breast cancer cohort. 
 
We observed a non-statistically significant positive correlation between Ktrans and HIF-1α (%). 
In ovarian cancer, negative correlations have been found between Ktrans and HIF-1α69. 
However, in human head and neck squamous cell carcinomas positive correlations have been 
reported between Ktrans and HIF-1α expression70 whereas in prostate cancer no correlations 
were found between HIF-1α and DCE-MRI parameters71. In this study, we also observed a 
positive correlation between Kep and HIF-1α IHC results. By contrast, Lindgren et al69. found 
a negative correlation between Kep and HIF-1α while studying DCE-MRI perfusion parameters 
in ovarian cancer. Ve was negatively correlated to HIF-1α staining and percentage (p=>0.05). 
We observed positive correlations between vp and HIF-1 alpha intensity and percentage (p= 
>0.05). No previous results were found in relation to the association between ve and vp with 
hypoxic endogenous biomarkers. 
 
In summary, we can conclude that results of correlations between DCE-MRI quantitative 
parameters and IHC tumour hypoxic markers are controversial among different types of 
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cancers and therefore, at present time no relationship has been clearly identified between 
imaging vascular parameters and IHC hypoxic markers of malignant tumours, including breast 
cancer. In particular, we believe that the presence of HIF-1α in ER positive breast cancers may 
not indicate hypoxia and perhaps, for this reason HIF-1α was weakly correlated to DCE-MRI 
parameters. 
 
Most of CD31 derived vasculature parameters demonstrated positive associations with DCE-
MRI quantitative parameters, with the exception of hotspot Ktrans and kep which showed 
negative correlations with tumour micro vessel density and calibre. CD31 derived vascular 
features were inversely correlated to 18F-FMISO PET tumour Ki. The negative correlations 
between tumour Ki, tumour micro vessel density and calibre were statistically significant.  
Previous correlations performed in different types of cancer between hypoxia PET parameters 
and tumour endogenous vascular markers have been inconsistent: Studies on gliomas72 have 
reported weak correlations between 18F-FMISO-PET parameters and VEGF, another vascular 
endogenous biomarker. However, another study on non-small cell lung cancer showed a 
significant positive correlation between 18F-FETNIM uptake (18F-
Fluoroerythronitroimidazole, another hypoxia radiotracer ) and VEGF73. 
 
This study showed positive non-significant correlations between tumour cells (%) and 18F-
FMISO-PET/MRI derived Ki and hypoxic fractions (%). This results are in concordance with 
the fact that tumour hypoxia has been closely related to rapid cell growth and proliferation74. 
Evans et al75 observed that proliferating cells (Ki-67-positive cells) could be found in regions 
of high EF5 binding (EF5 is a hypoxic exogenous marker) in many human glioblastoma tissue 
sections. On the other hand, some immunohistochemical (IHC) studies have reported an 
inverse spatial relationship between hypoxic and proliferating cells76,77.  
 
Concerning the relationship between 18F-FMISO-PET imaging parameters and TILs (%); 
Siegers et al78 reported an increased infiltration of immune Gamma delta T cells in areas of 
hypoxia in a small cohort of breast cancers. In line with their results, we observed positive 
correlations between TILs (%) and 18F-FMISO-PET derived Ki and hypoxic fractions (p= 
>0.05).  
 
There was a statistically significant negative correlation between 18F-FMISO SUV max and 
TILs (%). Likewise, 8F-FMISO SUV mean and tumour ratios were inversely correlated to TILs 
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(%), although these correlations were not statistically significant. These results support 
previous findings that confirm the existence of immunosuppression in breast cancer59,60. An 
explanation for how breast tumour cells restrict lymphocytic infiltration leading to 
immunosuppression may be that pathways which promote cell proliferation and malignant 
transformation are tightly associated with increased rates of glycolysis and thus secretion of 
lactic acid within the breast tumour microenvironment and lactic acid inhibits T-cell 
activation79 
 
There were negative and non-significant correlations between TILs (%) and all DCE-MRI 
parameters. Contrast-enhanced MRI quantitative parameters are indicators of the tumour 
vascularity and their negative correlation with the percentage of TILs may be associated with 
the finding of Siegers et al78 about increased TILs in hypoxic areas, from which we may 
interpret that poorly vascularised areas (hypoxic regions) will have a high percentage of TILs 
and by opposite, highly vascularised areas might present low number of TILs. To our 
knowledge, this is the first study which shows correlations between DCE-MR quantitative 
imaging parameters and TILs in ER positive cancers.  
 
DCE-MRI parameters (excepting Kep) showed non-significant negative correlations with 
percentage of tumour cells. The proportion of tumour cells depends on the tumour growth rate. 
Results of previous studies about the relationship between DCE-MRI quantitative parameters 
and tumour proliferation markers such as Ki67 have been inconsistent. Some authors have 
found no association between DCE-MRI vascular parameters and Ki6780,81. Other authors have 
reported  an association between quantitative parameters of DCE-MRI and Ki67 expression in 
breast tumours17,82. Jong et al83 found that ktrans was associated with the Ki67 status of patients 
with ER+ breast cancers. 
 
Finally, correlations with ADC were obtained from 12 patients (12 breast cancers) who had 
successful DWI and for whom IHC data was available. There was a significant positive 
association between CAIX staining percentage and ADC obtained from the darkest part of the 
tumour. This is an interesting result, and we recommend repeating this work in a larger dataset 
of ER positive and negative tumours. 
 
The main limitation of our study was the small sample size. Other limitations were that our 
tumour sample contained only ER positive tumours and the fact that these cancers were 
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relatively small. Few large cancers now go straight to surgery making this type of investigation 




All ER+ cancers stained positive for CD31, whereas 17 were positive for HIF-1 alpha and 6 
for CAIX. A significant positive correlation was found between the imaging parameter of 
hypoxia, ki and CAIX expression measured by IHC. HIF-1α may be an unreliable marker of 
hypoxia in ER positive breast cancer. Likewise, significant negative correlations were shown 
between tumour ki and CD31-derived tumour micro vessel density and calibre. These results 
from correlations between imaging and IHC markers of tumour vascularity and hypoxia 
demonstrated that hypoxia measurements from 18F-FMISO-PET/MRI are reliable and support 
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Chapter 6. Correlations between breast cancer imaging vascular biomarkers 
and tumour response to neoadjuvant chemotherapy 
 
Hypoxia is a well-known factor contributing to chemotherapy resistance in breast cancer. In 
previous chapters, the relationship between hypoxia, vascular function and 
immunohistochemistry markers of hypoxia and vascularity were investigated in a cohort of 
patients with treatment-naïve breast cancer, with the results supporting the hypothesis of 
perfusion-driven hypoxia in breast tumours. Given that vascular parameters from DCE-MRI 
may serve as surrogate markers of hypoxia in breast tumours prior to therapy, this chapter aims 
to investigate changes in qualitative and quantitative parameters of tumour vascular function 
in patients undergoing neo-adjuvant chemotherapy. The relationship between DCE-MRI 
qualitative and quantitative parameters with pathological response will also be investigated. 
 
6.1  Background 
 
Early-stage breast cancer patients are typically treated surgically to extract the tumour and with 
post-operative therapies, such as chemotherapy and/or radiotherapy, to kill remaining 
malignant cells. Primary systemic treatment or neoadjuvant chemotherapy (NAC), has become 
the standard initial treatment for patients who present with late stage disease or locally 
advanced breast cancer (LABC)1,2. One main advantage of NAC is the reduction of the size of 
the primary tumour, which allows breast surgery to be undertaken in patients considered 
inoperable prior to treatment. It also increases the probability that breast-conserving surgery 
can be performed in a minority of patients3,4. Patients with no evidence of residual macroscopic 
disease (pathological complete response) after NAC have an increased disease-free survival 
(DFS) and overall survival (OS) rate5,6,7. For this reason, pathological complete response (pCR) 
has been adopted as the primary end point for neoadjuvant chemotherapy trials but 
unfortunately, it has been shown that tumour pathological complete response only occurs in a 
subgroup of patients (3-34%)8,9,10,11. 
 
The monitoring of response to NAC is usually undertaken by clinical examination and 
mammography however, both have been shown to be inaccurate12. Clinical examination can 
overestimate the degree of residual disease due to the presence of fibrosis induced by 
chemotherapy13,12,14, while the accuracy of mammography is affected by chemotherapy-
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induced fibrosis and breast tissue density12,14,15.  MRI is superior to physical examination and 
other imaging techniques like mammography and ultrasound in assessing tumour response 
after NAC because it can differentiate fibrosis from tumour12,14,15 and its accuracy is not 
affected by the presence of dense breast tissue16. MRI has demonstrated high accuracy in 
predicting pathological complete remission17,18. As changes in tumour size tend to occur after 
physiological changes in the tumour19,20, DCE-MRI can also enable the evaluation of 
physiological changes during treatment, which can help identify early treatment failures and 
allowing prompt implementation of second-line therapy2.  
 
Neoadjuvant chemotherapy agents typically act by targeting cells with a high proliferation rate, 
which is a hallmark of cancer cells21. Given that physiological alterations in tumour perfusion 
and vascular permeability during treatment will manifest earlier than gross changes in tumour 
size, DCE-MRI pharmacokinetic modelling has the potential to monitor  response to treatment 
by tracking the kinetics of contrast through the lesion of interest22. It is generally accepted that 
NAC will induce changes in enhancement patterns of the tumour from wash-out to a less 
aggressive pattern of plateau or persistent enhancement20. Previous studies have reported a 
statistically significant reduction of up to a third in both the contrast influx (Ktrans) and efflux 
(kep) rates in breast cancer patients receiving NAC, whereas an increase in ve of nearly a third 
has been shown in patients not responding to treatment23. Although a change in Ktrans greater 
than 40% has often been considered as a threshold for definitive response24, discrepancies have 
been observed in the results reported by different studies. Some reports have shown little or no 
decrease in Ktrans, kep or other pharmacokinetic parameters after NAC2,25,26, while others have 
indicated that an early change in tumour size is a better response predictor than 
pharmacokinetic parameters from DCE-MRI during the early course of NAC26,27. Analysis of 
Ktrans hotspots prior to or early during treatment has provided superior results than mean lesion 
Ktrans in differentiating between responders and non-responders28.  
 
Despite variable results in treatment response prediction, previous literature29,30 indicates the 
suitability of DCE-MRI in monitoring changes in vascular function and, in a surrogate manner, 
tumour oxygenation during treatment. Ktrans has been shown to be indicative of naturally 
occurring or treatment-induced hypoxia in several types of cancer when hypoxia was caused 
by low blood perfusion31,32,33. Given that cancer therapy will induce some vascular damage to 
the tumour and taking into account the potential coupling of hypoxia and hypoperfusion in 
breast cancer as illustrated in previous chapters of this thesis, it can be hypothesised that 
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parameters of tumour vascular functionality derived from DCE-MRI can provide valuable 
information on both the vascular and hypoxic status of tumours. Assessment of the tumour 
altered vascularity with DCE-MRI may also provide additional information about the 
chemosensitivity of cancers and better understanding of mechanisms of resistance, as several 
common chemotherapeutic regimens used in breast cancer, which include combinations of 5-
fluouracil34,35, carboplatin34,35 and taxanes30,34 have demonstrated limited efficacy in hypoxic 
conditions36.  
 
The aim of this chapter was to investigate changes in DCE-MRI quantitative and qualitative 
parameters of tumour vascular function and vascularity in patients with primary breast cancer 
undergoing NAC. Pharmacokinetic parameters from DCE-MRI and tumour morphological 
features, including tumour diameter and volume, were assessed before, during and after NAC, 
and changes in these parameters were calculated and correlated with pathological response. 
Furthermore, changes in morphological metrics of local vascularity were evaluated by 
assessing the number of adjacent feeding vessels (AFV) 37,38,39 during NAC in order to assess 
the ability of a qualitative marker of vascularity to predict pathological response. 
 
6.2 Materials and methods 
 
6.2.1 Patient population 
This research was approved by a National Research Ethics Committee (13/LO/0411) and 
informed consent was obtained from all study participants. Imaging data from 82 patients, 
recruited between October 2014 and October 2017, were collected for a prospective analysis. 
Women with pathologically confirmed breast cancer undergoing NAC prior to surgery, and a 
lesion ³10 mm in size on mammography and/or ultrasound were considered eligible for the 
study. Patients unable to provide informed consent, who were medically unstable or with 
known contraindications to MRI were excluded from this study. Additional exclusion criteria 
included: previous surgery or radiotherapy for cancer, including chemotherapy or hormonal 
therapy for breast cancer; previous surgery in the ipsilateral breast for benign disease prior to 
diagnosis; history of serious breast trauma or undergoing MRI for the assessment of the 




6.2.2 Neo-adjuvant chemotherapy (NAC) treatment protocol 
According to the NAC protocol followed in our institution, patients received chemotherapy 
once every 21 days (the duration of each cycle) for up to a total of 6 or 7 cycles. For patients 
with HER2-negative cancers on core biopsy, the chemotherapy regimen typically involved the 
administration of reverse sequences of a taxane (docetaxel; T) for 3 or 4 cycles and a 
combination of anthracyclines (fluorouracil and/or epirubicin) and cyclophosphamide (FEC) 
for 3 cycles. Patients with HER2-positive tumours received either anthracycline-taxane based 
treatment in combination with a HER2-targetted agent, such as trastuzumab (Herceptin, 
Genetech Inc., CA) with or without the addition of pertuzumab (Perjeta, Genetech Inc., CA) 
for 3 or 4 cycles, or a combination of docetaxel and trastuzumab (with or without pertuzumab) 
for the entire duration of treatment. To offset cardiotoxicity risks associated with the co-
administration of trastuzumab and anthracycline-based treatment, trastuzumab was not given 
during FEC. Patients were assessed clinically before and after each cycle of chemotherapy and 
continued to a total of 6 or 7 cycles provided there was no evidence of disease progression or 
complete response. Details regarding the NAC treatment sequences administered to patients in 
this study are provided in Table 6.1.  
 
Table 6.1 Neoadjuvant chemotherapy (NAC) regimens given to patients.  
aChemotherapy involving co-administration of a Taxane and cyclophosphamide or carboplatin. 
 
6.2.3 Imaging protocol 
 Patient imaging was undertaken at four time-points: (i) prior to the initiation 
of NAC (baseline); (ii) after the first cycle of chemotherapy (PC#1); (iii) midway through 
treatment (after 3 or 4 cycles of chemotherapy) and (iv) at the end of NAC, before surgery. All 
examinations were performed on a 3T MRI scanner (MR750, GE Healthcare), using an 8-
channel breast coil with the subjects lying in the prone position. The imaging protocol 
NAC regimen Number of Cycles Description 
Taxane (T) + Anthracyclines (A) 6 or 7 T (3 or 4 cycles) - A (3 cycles) 
Anthracyclines (A) + Taxane (T) + Herceptin (H) 
and/or Pertuzumab (P) 
6 or 7 
 
A (3 cycles) / T + H (3 cycles) 
or 
T + H (3 cycles) / A (3 cycles) 
or 
A (3 cycles) / T + H + P (3 or 4 cycles) 
or 
T + H + P (3 or 4 cycles) / A (3 cycles)  
Taxane (T) + Herceptin (H) 4 or 6 
T + H (2 cycles) / T (4 cycles) 
T + H (4 – 6 cycles) 
Taxane + Othera (O) 4 or 7 
T (3 cycles) / O (4 Cycles) 
T + O (4 cycles) 
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included T1 and T2-weighted images, T1 and B1 mapping sequences, and a DCE 
series involving five pre-contrast phases and 48 phases following the administration 
of Gadovist (Bayer Healthcare) as described in Chapter 3 (Section 3.4.2.2). MRI sequence 
parameters are given in Chapter 3, Table 3.1. 
 
 
6.2.4 Image analysis 
 
6.2.4.1 Qualitative analysis 
Two radiologists (with three and >20 years of experience in breast MRI, respectively) reviewed 
the images and identified lesions in consensus, using information from T1, T2-weighted and 
DCE-MR images. In patients with multi-focal or multicentric disease, the largest measurable 
lesion, i.e. the largest focus that could be accurately measured in at least one dimension with a 
minimum size of 10 mm40, was regarded as the index lesion. Synchronous unilateral or bilateral 
cancers were regarded as independent lesions37. Morphological and enhancement features of 
the cancers such as shape, margins and internal enhancement characteristics were reported for 
all imaging examinations according to the 5th edition of the ACR BI-RADS lexicon41. Both 
readers were blinded to the histopathological outcome of the lesions.  
 
6.2.4.2 Tumour vascularity assessment 
Tumour vascularity was assessed by counting the number of feeding vessels adjacent to the 
tumour. The number of adjacent feeding vessels (AFV), defined as blood vessels either 
contacting the edge of the lesion or penetrating it, were counted using methodology previously 
described in Chapter 4 (Section 4.2.3.1).  
 
6.2.4.3 Region-of-interest (ROI) delineation and size assessment 
Tumour regions of interest (ROIs) were manually delineated in OsiriX, version 8.0.2 (Pixmeo 
SARL, Switzerland) on the peak-enhancing DCE-MR image (post-contrast T1WI 19 of the 
DCE-MRI), and included all consecutive axial sections encompassing the enhancing tumour 
mass. Subtracted images were used to display a clear tumour margin so as not to exceed tumour 
boundaries. In cases of multifocality or multicentricity on the MRI, ROIs were drawn for the 
largest enhancing tumour focus, excluding possible in situ carcinoma observed as non-mass 
suspicious enhancement around the enhancing tumour mass. Areas of low enhancement within 
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the tumour, which could be indicative of necrosis, and tumour blood vessels adjacent to the 
mass were not included in the ROIs. To maximise consistency in region delineation, ROIs for 
sequential imaging examinations for a patient were drawn with the baseline MRI exam 
displayed on the screen.   
 
Tumour size was estimated according to the criteria outlined in RECIST 1.1 by evaluating 
changes in the longest diameter of the enhancing lesion regardless of orientation40. In cases of 
tumour fragmentation during treatment, the longest diameter of each fragment was aggregated 
to calculate the size of the index lesion. In addition, total tumour volume was calculated by 
summing the volume of tumour areas across all slices encompassing the cancer and multiplying 
by the slice thickness (i.e. 1.4 mm). 
 
6.2.4.4 Quantitative analysis 
Pharmacokinetic analysis of the DCE-MRI series was performed in MIStar, version 3.2.63 
(Apollo Medical Imaging, Melbourne, Australia) using the extended Tofts’ model to calculate 
the contrast influx rate constant, Ktrans; the contrast efflux rate constant, kep, and the volume of 
extravascular-extracellular space, ve. Prior to pharmacokinetic modelling, corrections for the 
effect of transmission-field inhomogeneity on DCE-MR images were performed as previously 
described (Chapter 3, Section 3.4.2.2). Ktrans in the most vascularised area of the tumour 
(hotspot Ktrans) were calculated by averaging pixel values within a 3×3-pixel region placed 
around the area exhibiting the highest Ktrans value on the Ktrans parametric maps28. 
 
6.2.5 Histology 
Histopathological information including histological subtype, grade, and the expression of 
oestrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor 
receptor 2 (HER2) were obtained from pathology reports. Tumours were graded according to 
the Elston-Ellis scoring system42. For the purposes of analysis, tumour histological types were 
classified as follows43: breast cancers of no special type (NST), including invasive ductal and 
medullary carcinomas; invasive lobular carcinomas (ILC); mixed carcinomas involving two or 
more histological components, and breast cancers of special type including mucinous, 
apocrine, micropapillary or tubular carcinomas. Cancers with positive ER or PR expression 
were classified as hormone-receptor (HR) positive. Lesion molecular subtypes were 
categorised as follows: HR-positive/HER2-negative, HR-positive/HER2-positive (triple-
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positive), HR-negative/HER2-positive (HER2-enriched) and HR-negative/HER2-negative 
(triple negative). 
 
6.2.6 Tumour pathological response 
The assessment of pathological tumour response to neoadjuvant chemotherapy was performed 
by pathologists with >15 years of experience in breast cancer according to the criteria proposed 
by Pinder et al 44:  
1. Pathological complete response (pCR) involving either no residual invasive cancer or 
only including residual in-situ carcinoma. 
2. Pathological partial response to therapy (pPR), involving either:  
i. minimal residual disease or near total response with < 10% of tumour remaining  
ii. evidence of response to therapy with 10 – 50% of tumour remaining, or  
iii. evidence of tumour cellularity of >50% when compared with the previous core 
biopsy sample, with presence of some features of response to therapy (e.g. fibrosis). 
3. No evidence of response to therapy when no changes were observed in tumour 
cellularity in comparison with pre-treatment core-biopsies.  
 
In this study, breast cancers only showed either partial or complete pathological response to 
NAC. Patients whose cancers showed pathological partial response to chemotherapy were 
classified as partial responders, whereas those with lesions that showed complete pathological 
response to chemotherapy were classified as complete responders. 
 
6.2.7 Statistical analysis 
Data is presented as n (%), mean ± SD or median [range] as appropriate. Statistical analysis 
was performed in IBM SPSS Statistics for MacOS, v25.0 (IBM Corp., Armonk, NY) or R 
v3.5.2 (The R Foundation for Statistical Computing 2018). Continuous data were checked for 
normality using the Anderson-Darling test. Correlations between continuous variables were 
assessed via Pearson (r) or Spearman correlation (ρ), whereas associations between categorical 
variables were assessed using χ2 or Fisher’s exact tests and Cramer’s V. Comparison between 
means of two independent groups were performed using t-tests, and ANOVA when more than 
two groups were compared. Where data was not normally distributed, or normality could not 
be assessed, Mann-Whitney U and Kruskal-Wallis H or Mood’s median tests were employed 
for comparisons between two or more groups, respectively p-values <0.05 were considered 
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statistically significant, except for cases in which p-values were adjusted using the Holm-
Bonferroni method. 
 
Linear mixed effects (LME) models with random intercepts and slopes for subjects were used 
to assess changes in DCE-MRI parameter during chemotherapy and p values from post-hoc 
analyses were adjusted for multiple comparisons using the Holm-Bonferroni method. Where 
the ensuing residuals for the mixed effects models were not normally distributed as indicated 
by normality tests and Q-Q plots, dependent variables (i.e. quantitative DCE-MRI parameters) 
were transformed using the natural logarithm to yield more normally distributed residuals. The 
percentage rate of change in DCE-MRI metrics during NAC was calculated using 100× (eβ -
1), where β refers to the regression coefficient for chemotherapy cycle as estimated by the 
mixed models. Factors affecting DCE-MRI parameter changes during NAC were identified 
through univariate analyses and included into the models if p-values were ≤ 0.1. 
 
Binomial logistic regression was used to evaluate the probability of complete pathological 
response based on quantitative DCE-MRI parameters at baseline, post-cycle 1 and changes 
between these time points. Prior to logistic regression, case-wise deletion was applied to 
observations with missing data. In combination models involving quantitative DCE-MRI 
metrics and tumour prognostic factors (i.e. histological subtype, molecular subtype, grade, 
presence of in situ carcinoma), variables were selected for inclusion into the logistic regression 
based on univariate analysis using a cut-off for significance of p=0.1 for main effects and 
p=0.25 for interactions. Receiver-operating characteristic (ROC) curve analysis and the area 
under the curve (AUC) was used to assess the ability of DCE-MRI metrics in predicting 
pathological response. The AUC, sensitivity and specificity for each parameter or parameter 
combination were estimated using the De Long method, while the optimal cut-off point (i.e. 
the point on the ROC curve, which is furthest from the line of no discrimination and minimises 
the overall rate of misclassification) was selected according to the Youden index. p values were 










6.3.1 Clinical characteristics of the patient population  
Eighty-two women with 86 breast cancers were analysed. The median age of the patients was 
53 [28 – 75] years, with the vast majority 95% (78/82) presenting only one tumour. Of the 
breast lesions examined, 83% (71/86) were invasive carcinomas of no special type (NST), 11% 
(10/86) were cancers of special type and lobular carcinomas (ILC), while 5% were mixed 
invasive carcinomas (2 invasive carcinomas with NST and ILC components; 1 NST and 
mucinous carcinoma; 2 NST cancers with apocrine or micropapillary features, respectively). 
Our sample consisted of intermediate and high-grade tumours (grade 2 or 3), with 59/86 (69%) 
lesions being grade 3 NST carcinomas (nuclear grade vs tumour histology: Cramer’s V=0.34, 
p=0.02). Two-thirds of the tumours examined (57/86) were positive for hormone receptors, 
with 31% (27/86) also being positive for HER2. Approximately a quarter of the lesions (21/86; 
24%) were characterised as triple-negative, while HER2-enriched tumours constituted 9% 
(8/86) of the sample examined. Furthermore, two-thirds of the grade 3 tumours examined were 
classified as either triple-positive or triple-negative (39/59; 66%), while 56% (15/27) of the 
grade 2 cancers were HR+/HER2- (nuclear grade vs molecular subtype: Cramer’s V=0.32, 
p=0.04). Clinical information about the patient population at the time of diagnosis is given in 















Table 6.2 Clinicopathological characteristics for the patient population. (n=82 patients and 
n=86 breast cancers).   
Characteristic n (%) 
Age at diagnosis (years)a 53 [28 – 75]a 
  
Disease presentation (n=82)  
Unilateral (single tumour) 78 (95) 
Unilateral (two tumours) 3 (4) 
Bilateral  1 (1) 
  
Tumour location (n=86)  
Right breast 43 (50) 
Left breast 43 (50) 
  
Neoadjuvant chemotherapy regimen (n=86)  
Taxane + anthracyclines 50 (58) 
Taxane + trastuzumab (with anthracyclines) 33 (38) 
Taxane + trastuzumab (without anthracyclines) 2 (2) 
Taxane + othersb 1 (1) 
aData presented as median [range]. 


















Table 6.3 Tumour histological characteristics (n=86 lesions).   
Characteristic n (%) 
Histological sub-type  
No specific type (NST) 71 (83) 
Lobular (ILC) 3 (3) 
Mixeda 5 (6) 
Special type 7 (8) 
  
Histological Grade  
1 0 (0) 
2 27 (31) 
3 59 (69) 
  
Molecular subtype   
HR+/HER2- 30 (35) 
HR+/HER2+ 27 (31) 
HR-/HER2+ 8 (9) 
HR-/HER2- 21 (24) 
  
Presence of in situ carcinoma after surgery  
Absent 36 (42) 
DCIS 29 (34) 
LCIS 1 (1) 
Mixedb 1 (1) 
No information 19 (22) 
  
Pathological size after surgery (mm) 16 [0 – 152]b 
aInvasive or in situ carcinoma for which histology indicated the presence of two or more histological components.  
bData presented as median [range]. 
HR: hormone receptor; HER2: Human epidermal growth factor receptor 2; DCIS: ductal carcinoma in situ; LCIS: 
lobular carcinoma in situ. 
 
6.3.2 Clinical characteristics and pathological response 
Overall, 58% (50/86) of the cancers were treated with an anthracycline and taxane-based NAC 
regimen, and 40% (35/86) with a HER2-targeted agent in combination with taxanes with or 
without anthracyclines (Table 6.2). The clinico-histological characteristics of the breast 
tumours examined according to their therapeutic response are presented in Table 6.4. The 
majority of cancers (59/86; 69%) had pathological partial response (pPR) to NAC, while 31% 
(27/86) of the lesions showed pathological complete response (pCR). There were no cancers 
with no evidence of response to chemotherapy or disease progression and no significant 
association was observed between histological subtype or grade and pathological response 
(Table 6.4). However, it should be noted that most lesions examined were grade 3 (59/86; 69%) 
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and NST carcinomas (71/86; 83%). A statistically significant association was observed 
between molecular subtype and response (Cramer’s V = 0.44, p<0.001; Table 6.4), with triple-
negative cancers more likely to have a pCR (12/21; 57%) and HR-positive tumours to have a 
pPR (46/57; 81%). No statistically significant association was observed between the presence 
of in situ carcinoma on post-surgical pathological specimens and pathological response (Table 
6.4).  
 
Table 6.4 Tumour histological characteristics according to therapeutic response (n=86 lesions). 
 Pathological response  
Characteristic pCR n 
pPR 
n p 
Lesions 27 59  
    
Histological sub-type    
NST  23 48 0.12b 
ILC  0  3  
Mixed  0  5  
Special type 4  3  
    
Grade    
2  5 22 0.13a 
3 22 37  
    
Molecular subtype    
HR+/HER2- 2  28  <0.001b 
HR+/HER2+  9  18  
HR-/HER2+  4  4  
HR-/HER2-  12  9   
    
In situ carcinoma (n=67 lesions)    
Absent  13 23 0.43a 
Present  8 23  
    
Neoadjuvant chemotherapy regimen    
Taxane + anthracyclines  14 36 0.82b 
Taxane + trastuzumab (w/-w/o 
Anthracyclines) 12 23 
 
Taxane + others  1 0  
    
Neoadjuvant chemotherapy schedule    
Taxane first 14 30 0.78 b 
Taxane second 9 23  
Taxane throughout 4 6  
aFisher’s exact test  
bχ2 test with continuity correction 
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pCR: pathological complete response; pPR: pathological partial response. 
 
As described previously, all patients received taxane-based therapy with or without 
anthracyclines (Table 6.2). The type of NAC and the sequence of taxane administration (i.e. 
taxane use during the first or second phase of NAC, or for the entire duration of treatment) was 
not associated with therapeutic response (Table 6.4).  
 
Following surgery, 6/82 (7%) patients in our cohort died from cancer-related causes within 3 
years from diagnosis. Of the remaining 76 women, 4 (5%) developed local cancer recurrence 
or distal metastases within 3 years from initial diagnosis (records accessed in December 2019).  
 
6.3.2 MRI scans 
Of the recruited patients, 45% (37/82) underwent MRI examinations at baseline, mid-treatment 
and end-of-treatment, while a third of the patients (27/82) completed the baseline and all 
follow-up MRI scans. Post-cycle 1 MRI data were available from 36/82 (44%) women. In total, 
257 MRI examinations were available for analysis. Morphological data, enhancement 
characteristics and local vascularity features were extracted from 256 MRI examinations, with 
1 scan excluded from visual assessment (no contrast in the heart and blood vessels was seen). 
Pharmacokinetic analysis of DCE-MRI series included data from 244 scans and consisted of 
77 baseline, 33 post-cycle 1, 72 mid-treatment and 62 end-of-treatment MRI scans. A total of 
13 examinations were excluded from pharmacokinetic analysis due to inadequate MRI 
acquisition or DCE-MRI post-processing (errors in fat saturation or the acquisition of B1 and 
T1 mapping sequences and faulty correction of magnetic field inhomogeneity) and poor 
visualisation of contrast in the heart and blood vessels following injection. Eight patients 
showed complete radiological response on their MRI follow-ups and, pharmacokinetic 
estimates or morphology measurements could not be derived from 8 scans owing to the absence 
of a malignant lesion in the images (Figure 6.1). The median time between baseline and mid-
treatment or mid-treatment and end-of-treatment MRI scans was 42 [34 – 49] days, and the 
median time from the first DCE-MRI scan to the first cycle of NAC was 5 [2 – 10] days.  
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Figure 6.1 Flow chart of DCE-MRI scans included in the analysis. 
 
6.3.3 Tumour morphological and enhancement characteristics at baseline and 
associations with pathological response 
Tumour morphology and enhancement characteristics at baseline and according to tumour 
pathological response are summarised in Tables 6.5 and 6.6 respectively. The median tumour 
longest diameter on MRI at baseline was 30 [11 – 70] mm (Table 6.5), with no significant 
difference between lesions with pCR and pPR (Table 6.6). Similarly, no significant difference 
in tumour volume or the number of AFV was found between tumours in the two response 
groups (Table 6.6). However, a statistically significant association was observed between 
pathological response and the longest tumour diameter at baseline when cancers were classified 
as being ≤20 mm or >20 mm in the longest diameter (Cramer’s V = 0.26, p=0.03; Table 6.6). 
Masses featuring an irregular shape and non-circumscribed margins were prevalent among the 
breast cancers evaluated (Table 6.5), while 76% (65/86) of the lesions showed rim 
enhancement. Shape and margin descriptors at baseline were not extracted for 3/86 (3%) 
cancers, as these presented with non-mass like enhancement on the pre-treatment MRI. No 
association was observed between pathological response and AFV, morphological or 




*Reasons for exclusion: No B1 and/or T1 mapping images in the study, no
contrast seen in the heart and blood vessels after contrast injection, defective
DCE-MRI post-processing.
aReasons for exclusion: No contrast seen in the heart and blood vessels after
contrast injection.
*MRI scans excluded for 
quantitative analysis
N=13
Patients whose MRI was analyzed
N= 82 









MRI scans excluded for 
qualitative analysis















































MRI scans excluded for 
quantitative analysis
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Table 6.5 Tumour morphological and enhancement characteristics at baseline (n=86 lesions).   
Characteristic n (%) 
Lesion longest diameter on MRI (mm)  30 [11 – 70]a 
≤ 20 mm 17 (20) 
> 20 mm 69 (80) 
  
ROI volume (cm3) 4.6 [0.5 – 106.6]a  
  
Shape   
Oval 10 (12) 
Round 2 (2) 
Irregular 71 (83) 
Not evaluatedb  3 (3) 
  
Margins  
Circumscribed 2 (2) 
Non-circumscribed 81 (94) 
Irregular 34 (40) 
Spiculated 47 (55) 
Not evaluatedb  3 (3) 
  
Internal enhancement   
Heterogeneous 21 (24) 
Rim enhancement 65 (76) 
  
Adjacent feeding vessels (AFV; number) 36 [9 -112]a 
aData presented as median [range]. 















Table 6.6 Tumour morphology and enhancement characteristics at baseline according to 
therapeutic response (n=86 lesions). 
 Pathological Response  





Lesions 27 59  
    
Longest diameter on MRI (mm) 28 [14 – 70] 32 [11 - 69]  
£ 20 mm (n=17) 6 11  0.26a,b 
> 20 mm (n=69) 21 48 0.03*c 
    
Volume (cm3) 3.7 [1.0 – 30.7] 5.0 [0.5 – 106.6] 0.21a,b 
    
Shape (n=83 lesionse)   0.30d 
Oval 5 5  
Round 0 2  
Irregular 22 49  
    
Margins (n=83 lesionse)   0.12d 
Circumscribed 2 0  
Irregular 11 23  
Spiculated 14 33  
    
Internal enhancement    0.19c 
Heterogeneous 4 17  
Rim enhancement 23 42  
    
Adjacent feeding vessels (AFV; number) 31 [9 – 82] 42 [12 – 112] 0.27a,b 
aData presented as median [range]. 
bMann-Whitney U test  
cFisher’s exact test 
dχ2 test with continuity correction 
eMorphological descriptors not evaluated for lesions appearing as non-mass like on the MRI. 
*p<0.05; **p<0.01; ***p<0.001 
pCR: pathological complete response; pPR: pathological partial response. 
 
 
6.3.4 Changes in DCE-MRI parameters during NAC  
There was no statistically significant difference in DCE-MRI metrics between patients who 
received their mid-treatment scan after 3 or 4 cycles of chemotherapy (Table 6.7). Similarly, 
no difference was observed in hs-Ktrans, AFV, the longest lesion diameter and volume in 
patients who underwent a total of either 6 or 7 cycles of NAC (Table 6.7). However, significant 
differences in Ktrans, kep and ve were observed between 6 or 7 cycles of NAC, indicating that 
end-of-treatment DCE-MRI metrics could not be pooled in a single time point for subsequent 
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statistical comparisons. Consequently, the NAC cycle at which each patient received an MRI 
examination was explicitly specified in mixed effects analyses evaluating changes in DCE-
MRI metrics during treatment.  
 
Associations between DCE-MRI pharmacokinetic parameters, patient age at diagnosis and the 
longest tumour diameter or volume were evaluated using LME models with covariates for age, 
chemotherapy cycle and tumour LD or volume. The mixed models included terms for the 
interaction between chemotherapy cycle and LD or volume, and random effects for subject 
intercepts and slopes. Normality tests and Q-Q plots indicated that model residuals were not 
normally distributed for all the DCE-MRI parameters examined, hence these parameters were 
transformed using the natural logarithm before being inserted into the model (see Section 
6.2.7).  
 
Table 6.7 Median and range of DCE-MRI parameters at the mid and end-of-treatment 
timepoints. Statistical comparisons were performed using the Mann-Whitney U test. 
 Mid-treatment  End-of-treatment 
Parameter 3 cycles 4 cycles p 6 cycles 7 cycles p 
Lesions (n) 62 8  45 8  
Ktrans 
0.18  
[0.01 – 2.10] 
0.20  
[0.04 – 0.64] 0.89 
0.11 
[0.00 – 3.71] 
0.26 
[0.11 – 1.16] 0.01* 
hs-Ktrans 1.61  
[0.03 – 4.99] 
1.69  
[0.08 – 5.00] 
0.63 0.57 
[0.01 – 4.86] 
1.7 
[0.25 – 4.98] 
0.11 
kep 0.34  [0 – 1.96] 
0.33  
[0.11 – 1.85] 0.84 
0.21 
[0 – 1.86] 
0.39 
[0.15 – 1.10] 0.02* 
ve 0.42  
[0.01 – 0.99] 
0.44  
[0.14 – 0.80] 
0.95 0.35 
[0.00 – 0.99] 
0.56 
[0.34 – 0.87] 
0.01* 
Lesions (n) 62 7  43 11  
AFV 
12 
[1 – 38] 
12 
[2 – 29] 0.99 
10 
[4 - 39] 
9 
[3 - 17] 0.80 
Lesions (n) 64 8  46 12  
LD 
24 
[9 – 62] 
34.5 
[20 – 54] 0.07 
19.5 
[1 – 32] 
21 
[12 – 48] 0.16 
Volume 1.35 
[0.05 – 27.4] 
1.60 
[0.03 – 6.5] 
0.75 0.72 
[0.01 – 4.38] 
0.71 
[0.01 – 3.67] 
0.73 
*p<0.05; **p<0.01; ***p<0.001 
Ktrans: contrast influx transfer rate (mL/g/min); kep: contrast efflux transfer rate (min-1); ve: fractional volume of 
extravascular-extracellular space; AFV: adjacent feeding vessels (number); LD: tumour longest diameter on MRI 




Tables 6.8 and 6.9 present fixed effects estimates from LME models exploring the associations 
between log-transformed parameters from DCE-MRI and the longest lesion diameter or 
volume, respectively. Analyses revealed no statistically significant association between patient 
age at diagnosis and DCE-MRI metrics, except for the number of AFVs which displayed a 
significant increase of ~1% per year of age.  Similarly, hs-Ktrans and AFV exhibited positive 
associations with tumour LD and volume during NAC (Tables 6.8 and 6.9 respectively), 
indicating a tendency for larger tumours to display a higher number of feeding vessels and 
higher hs-Ktrans values. More specifically, hs-Ktrans showed an increase of 1.6% per mm of 
tumour diameter and 1.5% per cm3 of tumour volume, while the number of AFV increased by 
2.8% per mm and 1.1% per cm3. Cancers with smaller volumes at baseline tended to exhibit a 
larger percentage reduction in hs-Ktrans during NAC than lesions with bigger volumes (Figure 
6.2b.), whereas the rate of decrease in AFV during chemotherapy was higher for lesions 
displaying a larger tumour diameter (Figure 6.2c.). No statistically significant associations 
were observed between the other DCE-MRI pharmacokinetic parameters and the longest lesion 














































































































































































































β, [CI], p 
β, [CI], p 
β, [CI], p 
β, [CI], p 
ln(K
trans) 
-0.127, [-0.252 – -0.002], 0.047* 
0.007, [-0.006 – 0.021], 0.28 
0.007, [-0.006 – 0.019], 0.29 
-0.001, [-0.006 – 0.003], 0.51 
ln(hs-K
trans) 
-0.219, [-0.361 – -0.077], 0.003** 
0.007, [-0.007 – 0.021], 0.35 
0.016, [0.002 – 0.029], 0.02* 
0.002, [-0.004 – 0.007], 0.57 
ln(k
ep ) 
-0.144, [-0.236 – -0.052], 0.002** 
0.009, [0.000 – 0.018], 0.05  
0.002, [-0.006 – 0.010], 0.63 
-0.001, [-0.005 – 0.002], 0.49 
ln(v
e ) 
-0.013, [-0.084 – 0.058], 0.71 
0.004, [-0.004 – 0.013], 0.30 
0.000, [ -0.007 – 0.007], 0.99 




-0.122, [0.194 – -0.051], 0.001*** 
0.010, [0.002 – 0.018], 0.02* 
0.028, [0.020 – 0.036], <.001*** 
-0.003, [-0.006 – 0.000], 0.03*  
LD
 
-0.009, [-0.105 – -0.07], <.001*** 






-0.355, [-0.396 – 0.314], <.001*** 
0.015, [-0.006 – 0.036], 0.17 
- 
- 
*p<0.05; **p<0.01; ***p<0.001 

























































































































































































β, [CI], p 
β, [CI], p 
β, [CI], p 
β, [CI], p 
ln(K
trans) 
-0.203, [-0.273 – -0.133], <.001*** 
0.008, [-0.005 – 0.022], 0.24 
0.003, [-0.010 – 0.015], 0.68 
-0.010, [-0.023 – 0.003], 0.13 
ln(hs-K
trans) 
-0.137, [-0.216 – -0.059], <.001*** 
0.005, [-0.009 – 0.019], 0.48 
0.015, [0.001 – 0.029], 0.04* 
0.020, [0.004 – 0.036], 0.02* 
ln(k
ep ) 
-0.202, [-0.253 – -0.151], <.001*** 
0.009, [0.000 – 0.019], 0.045*  
0.004, [-0.004 – 0.013], 0.32 
-0.010, [-0.021 – 0.000], 0.05 
ln(v
e ) 
-0.028, [-0.067 – 0.0.12], 0.17 
0.005, [-0.003 – 0.014], 0.20 
-0.005, [ -0.012 – 0.003], 0.23 




0.222, [-0.261 – -0.199], <.001*** 
0.011, [0.000 – 0.021], 0.04* 
0.011, [0.002 – 0.020], 0.02* 







Figure 6.2 (a, b) Scatter plots of log-transformed values of hotspot Ktrans (hs-Ktrans; mL/g/cm3) 
and (c, d) the number of adjacent feeding vessels (AFV) vs chemotherapy cycle (n=86 lesions). 
Regression lines indicate the relationship between hs-Ktrans or AFV and chemotherapy cycle at 
the minimum, median, and maximum values of the tumour longest diameter and volume. 
 
Changes in log-transformed DCE-MRI parameters as a function of chemotherapy cycle were 
assessed using LME models which included chemotherapy cycle as a fixed effect together with 
random intercepts and slopes for subjects. Estimates for the fixed-effects proportion of the 
model together with 95% confidence intervals (CI) and p-values are presented in Table 6.10.  
 
With the exception of ve, there was a statistically significant decrease in DCE-MRI parameters 
during the course of NAC (Table 6.10; Figure 6.3 and 6.4). The largest decrease per treatment 
cycle was observed for tumour volume (-30.5%) followed by AFV (-21.9%) and hs-Ktrans (-
19.9%) (Table 6.10). These relationships were upheld when considering NST carcinomas 












































































Table 6.10 Fixed effect estimates (β) with 95% confidence intervals (CI) and p-values for the 
associations between chemotherapy cycle and log-transformed parameters from DCE-MRI. 
Percentage (%) changes in DCE-MRI parameters were calculated according to 100×(eβ – 1), 
where β denotes the slope estimate for each parameter as derived from LME models. 
 Cycle  %Change per cycle 
Parameter β, [CI], p Parameter %, [CI] 
ln(Ktrans) -0.173, [-0.229 – -0.117], <.001* Ktrans -15.9, [-20.5 – -11.0] 
ln(hs-Ktrans) -0.222, [-0.282 – -0.163], <.001* hs-Ktrans -19.9, [-24.6 – -15.0] 
ln(kep) -0.174, [-0.192 – -0.126], <.001* kep -16.0, [-19.0 – -12.7] 
ln(ve) 0.016, [-0.035 – 0.027], <0.80 ve 1.6, [-3.4 – 2.7] 
ln(AFV) -0.244, [-0.272 – -0.216], <.001* AFV -21.6, [-23.8 – -19.4] 
ln(LD) -0.090, [-0.114 – -0.067], <.001* LD -8.6, [-10.7 – -6.5] 
ln(Volume) -0.363, [-0.414 – -0.312], <.001* Volume -30.5, [-33.9 – -26.8] 
*p<0.05; **p<0.01; ***p<0.001 
 
 
Table 6.11 Fixed effect estimates (β) with 95% confidence intervals (CI) and p-values for the 
associations between chemotherapy cycle and log-transformed parameters from DCE-MRI for 
carcinomas of no special type (NST). Percentage (%) changes in DCE-MRI parameters were 
calculated according to 100×(eβ – 1), where β denotes the slope estimate for each parameter as 
derived from LME models. 
 Cycle  %Change per cycle 
Parameter β, [CI], p Parameter %, [CI] 
ln(Ktrans) -0.179, [-0.241 – -0.117], <.001* Ktrans -16.4, [-21.4 – -11.0] 
ln(hs-Ktrans) -0.229, [-0.298 – -0.161], <.001* hs-Ktrans -20.5, [-25.8 – -14.9] 
ln(kep) -0.175, [-0.218 – -0.132], <.001* kep -16.1, [-19.6 – -12.4] 
ln(ve) -0.005, [-0.044 – 0.033], <0.78 ve -0.5, [-4.3 – 3.4] 
ln(AFV) -0.242, [-0.272 – -0.211], <.001* AFV -21.5, [-23.8 – -19.0] 
ln(LD) -0.080, [-0.101 – -0.059], <.001* LD -7.7, [-9.6 – -5.7] 
ln(Volume) -0.362, [-0.417 – -0.306], <.001* Volume -30.4, [-34.1 – -26.4] 








Figure 6.3 (Left to right) Scatter plots and regression line of median (column 1) and log-
transformed (column 2) DCE-MRI pharmacokinetic parameters vs chemotherapy cycle (n=86 
lesions). 
 















































































































Figure 6.4 (Left to right) Scatter plots and regression line of median (column 1) and log-
transformed (column 2) values of the number of adjacent feeding vessels (AFV), the tumour 
longest diameter (LD) and volume vs chemotherapy cycle (n=86 lesions). 
 
6.3.4.1 Effect of tumour prognostic factors on DCE-MRI parameters during NAC 
Table 6.12 presents p values for the association between log-transformed DCE-MRI 
parameters during NAC and tumour histology (A), molecular subtype (B), grade (C) and the 
presence of in situ carcinoma (D) on post-surgical tumour specimens. 
 


























































































Table 6.12 Statistical significance (p-values) of fixed effects for the association between log-
transformed DCE-MRI parameters and (A) tumour histological subtype, (B) nuclear grade, (C) 
molecular subtype and (D) presence of in situ carcinoma. 
 A. Histological subtype 
Parameter Cycle Histological subtype Histological subtype*Cycle 
ln(Ktrans) 0.02* 0.45 0.43 
ln(hs-Ktrans) 0.005** 0.51 0.81 
ln(kep) <.001*** 0.85 0.57 
ln(ve) 0.91 0.49 0.72 
ln(AFV) <.001*** 0.23 0.38 
ln(LD) <.001*** 0.005** 0.002** 
ln(Volume) <.001*** 0.04* 0.047* 
    
 B. Nuclear grade 
Parameter Cycle Grade Grade*Cycle 
ln(Ktrans) <.001*** 0.30 0.86 
ln(hs-Ktrans) <.001*** 0.46 0.93 
ln(kep) <.001*** 0.33 0.35 
ln(ve)                0.64 0.048* 0.54 
ln(AFV) <.001*** 0.57 0.01* 
ln(LD) <.001*** 0.46 0.94 
ln(Volume) <.001*** 0.55 0.17 
    
 C. Molecular subtype 
Parameter Cycle Molecular subtype Molecular subtype*Cycle 
ln(Ktrans) <.001*** 0.20 0.76 
ln(hs-Ktrans) <.001*** 0.89 0.72 
ln(kep) <.001*** 0.65 0.93 
ln(ve) 0.98 0.25 0.29 
ln(AFV) <.001***   0.01* 0.73 
ln(LD) <.001*** 0.22 0.95 
ln(Volume) <.001*** 0.14 0.63 
    
 D. Presence of in situ carcinoma 
Parameter Cycle In situ carcinoma In situ*Cycle 
ln(Ktrans) <.001*** 0.55 0.59 
ln(hs-Ktrans) <.001*** 0.02* 0.50 
ln(kep) <.001*** 0. 24 0.36 
ln(ve) 0.40 0.63 0.26 
ln(AFV) <.001*** 0.48 0.41 
ln(LD) <.001*** 0.03* 1.00 
ln(Volume) <.001*** 0.04* 0.73 
*p<0.05; **p<0.01; ***p<0.001
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The relationships between log-transformed DCE-MRI metrics and tumour histology as a 
function of chemotherapy cycle together with mean effects plots and percentage changes 
during treatment according to histological subtype are shown in Figures 6.5 and 6.6. The 
percentage rate of change in DCE-MRI parameter values during NAC according to histological 
subtype is provided in Table 6.13. There was no statistically significant association between 
tumour histology and log-transformed values of DCE-MRI pharmacokinetic parameters or the 
number of AFV during NAC. Furthermore, no significant differences in average parameter 
values between histological subtypes were observed (Figures 6.5 (c), (g), (k) and (o)). 
However, the effects for both histological subtype and the interaction between histological 
subtype and chemotherapy cycle were significant on the tumour longest diameter and volume 
(Table 6.12.A). On average, mixed and NST carcinomas tended to be larger in size (either in 
terms of the longest tumour diameter or volume) than special-type or lobular tumours (Figures 
6.6 (g) and (k)).  Furthermore, special-type cancers displayed the largest percentage decrease 
in tumour size metrics per chemotherapy cycle (Table 6.13; Figure 6.6), while all histological 
subtypes displayed statistically significant rates of reduction in the number of AFV during 
treatment (Table 6.13; Figure 6.6 (d)). Significant decreases in Ktrans and kep were also observed 
for NST and mixed cancers (Figure 6.5 (d) and (l)). It should be noted however that NST 
carcinomas were the majority in this sample (Table 6.3), which limited exploration of the effect 
of tumour histology on DCE-MRI metrics during the course NAC. 
 
The number of AFV was the only parameter displaying a significant association with nuclear 
grade (Table 6.12.B). Although grade 2 cancers displayed higher ve values than grade 3 tumours 
(ln(ve) [95% CI] – grade 2 vs grade 3: -0.87 [-10.4 – -0.70] vs -1.03 [-1.15 – -0.91], p=0.121; 
Figure 6.7), the effect of tumour grade on ve only trended towards statistical significance (Table 
6.12.B). On the other hand, grade 3 tumours showed a larger percentage decrease in the number 
of AFV (Table 6.14.A) and a lower average number of AFV than grade 2 cancers (ln(AFV) 
[95% CI] – grade 2 vs grade 3: 3.07 [2.86 – 3.28] vs 2.81 [2.67 – 2.94], p=0.042; Figure 6.8 
(c)). Analogous relationships between tumour grade and the DCE-MRI parameters were 
observed when considering the portion of NST cancers in this sample (Tables 6.14.A and 
6.15.A; Figures 6.9 and 6.10). However, the statistical significance of the association between 
 
1 Untransformed mean estimates of ve with 95% confidence intervals [CI] in grade 2 vs grade 3 tumours were 
0.419 [0.353 – 0.496] vs 0.357 [0.317 – 0.402], respectively. 
2 Untransformed mean estimates of AFV with 95% confidence intervals [CI] in grade 2 vs grade 3 tumours were 
22 [17 – 27] vs 17 [14 – 19] vessels, respectively. 
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ln(ve) and nuclear grade was not maintained for NST carcinomas, while associations between 




























































































































































































































































Figure 6.5 (Left to right) Scatter plots and regression lines of m
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Figure 6.6 (Left to right) Scatter plots and regression lines of m
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Table 6.13 Percentage (%
) change in D
CE-M
RI param
eter values per chem
otherapy cycle together w
ith 95%
 confidence intervals (CI) and p 
values for the tum
our histological subtypes considered in this study. Percentage changes w
ere calculated according to 100×(e
β – 1), w
here β 
denotes the slope estim
ate for each param































-16.3, [-21.3 – -10.9], <.001*** 
-4.2, [-29.1 – 29.4], 0.78 
-24.3, [-39.3 – -5.6], 0.01* 
-3.8, [-25.9 – 24.9], 0.77 
hs-K
trans 
-20.6, [-25.8 – -15.0], <.001*** 
-7.4, [-33.6 – 29.0], 0.65 
-16.8, [-34.6 – 5.8], 0.13 
-21.7, [-41.4 – 4.7], 0.10 
k
ep  
-14.5, [-17.6 - -11.4], <.001*** 
-13.0, [-27.7 – 4.8], 0.14 
-22.4, [-31.9 – -11.5], <.001*** 
-7.4, [-11.5 – 8.2], 0.33 
v
e  
-0.3, [-3.7 – 3.3], 0.86 
-1.4, [-16.6 – 16.6], 0.87 
-5.2, [-16.1 – 7.1], 0.39 




-21.4, [-23.8 – -18.9], <.001*** 
-16.2, [-26.7 – -4.2], 0.01* 
-25.0, [-33.2 – -15.9], <.001*** 
-28.3, [-37.9 – -17.3], <.001*** 
LD
 
-7.8, [-10.0 – -5.5], <.001*** 
-3.8, [-13.4 – 6.8], 0.46 
-7.8, [-15.4 – 0.5], 0.06 




-30.4, [ -34.2 – -26.4], <.001*** 
-16.1, [-34.2 – 6.9], 0.15 
-25.2, [-39.0 – -8.3], 0.006** 
-46.5, [-57.3 – 33.0], <.001*** 
*p<0.05; **p<0.01; ***p<0.001 
 Table 6.14 Percentage (%
) change in D
CE-M
RI param
eter values per chem
otherapy cycle together w
ith 95%
 confidence intervals (CI) and p 
values for tum
our nuclear grades. Percentage changes w
ere calculated according to 100×(e
β – 1), w
here β denotes the slope estim
ate for each 
param





































-17.6, [-23.4 – -11.1], <.001*** 
-13.4, [-18.1 – -8.5], <.001*** 
-18.9, [-27.9 – -8.9], <.001*** 
-15.3, [-21.6 – -8.6], <.001*** 
hs-K
trans 
-20.1, [-26.7 – -12.8],  
-18.1, [-23.1 – -12.6],  
-22.4, [-31.7 – -11.7], <.001*** 
-19.8, [-26.4 – -12.7], <.001*** 
k
ep  
-14.4, [-19.1 – -9.43],  
-15.0, [-18.4 – -11.3],  
-13.8, [-19.5 – -7.9], 0.001** 
-14.8, [-18.5 – -10.8], <.001*** 
v
e  
-2.1, [-6.0 – 2.0], 0.50 
1.4, [-1.7 – 4.5], 0.90 
-2.0, [-6.8 – -3.2], 0.54 




-17.7, [-21.3 – -13.9], <.001*** 
-23.3, [-25.7 – -20.9], <.001*** 
-17.6, [-22.2 – -12.8], <.001*** 
-23.0, [-25.7 – -20.2], <.001*** 
LD
 
-8.5, [-11.1 – -5.7], <.001*** 
-8.3, [-10.2 – -6.4], <.001*** 
-6.3, [-9.8 – -2.6], 0.002** 




-27.0, [-31.9 – -21.7], <.001*** 
-31.3, [-34.7 – -27.8], <.001*** 
-26.0, [-33.4 – -17.7], <.001*** 
-32.0, [-27.3 – -36.4], <.001*** 
































































































































































































































Figure 6.7 (Left to right) Scatter plots and regression lines of m
edian (colum










otherapy cycle for tum
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ns 3 and 4, respectively. Error bars 
denote 95%





















































































































































Figure 6.8 (Left toright) Scatter plots and regression lines of m
edian (colum
n 1) and log-transform
ed (colum
n 2) values of the num
ber 







otherapy cycle for tum
our nuclear grades (n=86 
lesions). M
ean-effects plots and percentage (%
) changes in param
eter values per chem
otherapy cycle according to nuclear grade are 
given in colum
ns 3 and 4, respectively. Error bars denote 95%
 confidence intervals.  
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With the exception of ln(AFV), associations between molecular subtype and log-transformed 
DCE-MRI parameters were not statistically significant for either the entire sample of tumours 
(Table 6.12.C) or when considering NST cancers alone (Table 6.15.B). In general, mean 
pharmacokinetic parameter estimates were higher for HER2-enriched than other molecular 
sub-types (Figures 6.11 and 6.13), while triple-positive cancers displayed larger volumes 
(Figures 6.12 (k) and 6.14 (k)) and consequently a higher number of feeding vessels than triple-
negative lesions (ln(AFV) [95% CI] – HR+/HER2+ vs HR-/HER2-: 3.10 [2.91 – 3.20] vs 2.57 
[2.35 – 2.79], p=0.0043; Figures 6.12 (c) and  6.14 (c)). Additionally, HR-positive and triple-
negative cancers showed significant reductions in all DCE-metrics aside from ve (Table 6.16), 
and similar relationships were observed for the group of NST cancers in this sample (Table 
6.17). 
 
Finally, the presence of in situ carcinoma in post-surgical tumour specimens was not 
significantly associated with Ktrans, kep, ve or the number of AFV during NAC, although there 
was a tendency for cancers with an in-situ component to display a larger percentage reduction 
per NAC cycle and higher values in these parameters than cancers without in situ carcinoma 
(Table 6.12.D; Figures 6.15 and 6.16). hs-Ktrans was the only parameter exhibiting statistically 
significant differences between cancers with and without an in-situ component either for entire 
sample of lesions (ln(hs-Ktrans) – absence vs presence: 0.09 [-0.17 – 0.34] vs 0.46 [0.19 – 0.73], 
p=0.044) or the sub-group of NST cancers (ln(hs-Ktrans) – absence vs presence: -0.04 [-0.30 – 
0.23] vs 0.44 [0.16 – 0.73], p=0.025; also see Tables 6.12.D and 6.15.C; Figures 6.15 and 6.17).  
 
As expected, the presence of in situ carcinoma had a statistically significant effect on tumour 
size metrics when the entire sample of lesions was taken into consideration (Table 6.12.D), as 
tumours without an in-situ component were smaller in both the longest axis and volume than 
these in which in situ carcinoma was present (Figures 6.16 and 6.18).
 
3 Untransformed mean estimates of AFV with 95% confidence intervals [CI] in HR+/HER+ vs HR-/HER- tumours 
were 22 [18 – 27] vs 13 [10 – 16] vessels, respectively. 
4 Untransformed mean estimates of hs-Ktrans with 95% confidence intervals [CI] in cancers with absence vs 
presence of carcinoma in situ were 1.091 [0.846 – 1.408] vs 1.586 [1.212 – 2.075] mL/g/min, respectively. 
5 Untransformed mean estimates of hs-Ktrans with 95% confidence intervals [CI] in NST cancers with absence vs 
presence of carcinoma in situ were 0.96 [0.742 – 1.254] vs 1.556 [1.172 – 2.065] mL/g/min, respectively. 
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Table 6.15 Statistical significance (p-values) of fixed effects for the association between log-
transformed DCE-MRI parameters and (A) nuclear grade, (C) molecular subtype and (D) 
presence of in situ carcinoma in carcinomas of no specific type (NST). 
 A. Nuclear grade 
Parameter Cycle Grade Grade*Cycle 
ln(Ktrans) <.001*** 0.34 0.53 
ln(hs-Ktrans) <.001*** 0.26 0.68 
ln(kep) <.001*** 0.12 0.29 
ln(ve) 0.62 0.20 0.59 
ln(AFV) <.001*** 0.37 0.05 
ln(LD) <.001*** 0.78 0.38 
ln(Volume) <.001*** 0.49 0.18 
    
 B. Molecular subtype 
Parameter Cycle Molecular subtype Molecular subtype*Cycle 
ln(Ktrans) <.001*** 0.40 0.63 
ln(hs-Ktrans) <.001*** 0.97 0.62 
ln(kep) <.001*** 0.65 0.97 
ln(ve) 0.83 0.58 0.40 
ln(AFV) <.001*** 0.04* 0.63 
ln(LD) <.001*** 0.48 0.81 
ln(Volume) <.001*** 0.32 0.27 
    
 C. Presence of in situ carcinoma 
Parameter Cycle In situ carcinoma In situ*Cycle 
ln(Ktrans) <.001*** 0.35 0.61 
ln(hs-Ktrans) <.001*** 0.008** 0.53 
ln(kep) <.001*** 0.17 0.34 
ln(ve) 0.33 0.46 0.21 
ln(AFV) <.001*** 0.79 0.30 
ln(LD) <.001*** 0.18 0.36 
ln(Volume) <.001*** 0.06 0.60 

































































































































































































































re 6.9 (Left to right) Scatter plots and regression lines of m
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re 6.10 (Left to right) Scatter plots and regression lines of m
edian (colum
n 1) and log-transform
ed (colum










otherapy cycle for nuclear grades in cancers of no specific type 
(N
ST
; n=71 lesions). M
ean-effects plots and percentage (%
) changes in param
eter values per chem
otherapy cycle according to nuclear grade are 
given in colum
ns 3 and 4, respectively. E
rror bars denote 95%























































































































































































































re 6.11 (Left to right) Scatter plots and regression lines of m
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Figure 6.12 (Left to right) Scatter plots and regression lines of m
edian (colum
n 1) and log-transform
ed (colum
n 2) values of the num
ber 







otherapy cycle for tum
our m
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are given in colum
ns 3 and 4, respectively. Error bars denote 95%


























































































































































































































re 6.13 (Left to right) Scatter plots and regression lines of m
edian (colum
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Figure 6.14 (Left to right) Scatter plots and regression lines of m
edian (colum
n 1) and log-transform
ed (colum
n 2) values of the 
num
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Table 6.16 Percentage (%





eter values per chem
otherapy cycle together w
ith 95%
 confidence intervals (C
I) and p 
values for the tum
our m
olecular subtypes considered in this study. Percentage changes w
ere calculated according to 100×(e
β – 1), w
here β denotes 
the slope estim
ate for each param
eter and m

























































-18.5, [-25.8 – -10.3], <.001*** 
-15.9, [-24.0– -6.9], 0.001** 
-11.6, [-21.5 – -0.4], 0.04* 
-14.4, [-30.4 – 5.1], 0.13 
hs-K
trans 
-18.5, [-26.4 – -9.7], <
.001*** 
-22.7, [-30.6 – -13.7], <
.001*** 
-20.9, [-30.5 – -10.0], <
.001*** 
-11.8, [-29.2 – 9.9], 0.26 
k
ep  
-16.6, [-21.9 – -11.0], <
.001*** 
-12.4, [-23.7 – 0.8], <
.001*** 
-16.2, [-22.8 – -9.2], <
.001*** 
-15.8, [-21.4 – 9.8], 0.06 
v
e  
-3.5, [-8.5 – 1.7], 0.18 
-1.1, [-11.8 – 10.7], 0.91 
4.9, [-1.8 – 12.1], 0.16 




-20.1, [-24.0 – -16.0], <.001*** 
-22.1, [-29.3 – -14.3], <
.001*** 
-22.7, [-27.5 – -17.6], <
.001*** 





-9.0, [-12.5 – -5.3], <
.001*** 
-10.2, [-17.1 – -2.5], <
.001*** 
-8.7, [-13.2 – -4.0], <
.001*** 




-29.4, [-35.3 – -22.9], <
.001*** 
-24.2, [-37.6 – -8.0], <
.001*** 
-30.2, [-37.3 – -22.3], <
.001*** 
-33.3, [-39.3 – -26.8], 0.006** 
*p<0.05; **p<0.01; ***p<0.001 
 Table 6.17 Percentage (%





eter values per chem
otherapy cycle together w
ith 95%
 confidence intervals (C
I) and p 
values for m
olecular subtypes in carcinom
as of no specific type (N
ST). Percentage changes w
ere calculated according to 100×(e
β – 1), w
here β 
denotes the slope estim
ate for each param
eter and m

























































-20.0, [-28.2 – -10.8], <
.001*** 
-16.6, [-25.8– -6.3], 0.003** 
-10.9, [-21.3 – 1.1], 0.07 
-17.3, [-35.1 – 5.3], 0.12 
hs-K
trans 
-17.8, [-27.0 – -7.3], <
.001*** 
-25.2, [-34.2 – -14.8], <
.001*** 
-20.9, [-31.2 – -9.0], <
.001*** 
-12.1, [-32.6 – 14.6], 0.33 
k
ep  
-17.2, [-23.4 – -10.6], <
.001*** 
-15.4, [-22.0 – -8.1], <
.001*** 
-15.4, [-23.3 – -8.4], <
.001*** 
-14.4, [-27.8 – 1.5], 0.07 
v
e  
-4.1, [-10.5 – 2.8], 0.23 
-1.1, [-8.0 – 6.4], 0.77 
4.9, [-3.0 – 13.4], 0.23 




-19.7, [-24.0 – -15.1], <
.001*** 
-23.1, [-27.4 – -18.7], <
.001*** 
-22.9, [-27.7 – -17.7], <
.001*** 





-7.5, [-10.8 – -4.0], <.001*** 
-6.9, [-13.4 – -3.3], <
.001*** 
-9.1, [-10.5 – -5.3], <
.001*** 




-30.0, [-35.5 – -21.7], <
.001*** 
-34.5, [-40.8 – -27.5], <
.001*** 
-30.2, [-37.2 – -22.2], <
.001*** 
-17.9, [-33.8 – 2.0], 0.07 
































































































































































































Figure 6.15 (Left to right) Scatter plots and regression lines of m
edian (colum











otherapy cycle for tum
ours in w
hich in situ carcinom
a w
as either present or absent (n=
67 lesions). M
ean-effects plots and 
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) changes in param
eter values per chem
otherapy cycle according to the presence of in situ carcinom
a are given in colum
ns 3 and 
4, respectively. E
rror bars denote 95%

































































































































Figure 6.16 (Left to right) Scatter plots and regression lines of m
edian (colum
n 1) and log-transform
ed (colum
n 2) values of the 
num









hich in situ 
carcinom
a w
as either present or absent (n=67 lesions). M
ean-effects plots and percentage (%
) changes in param
eter values per 
chem
otherapy cycle according to the presence of in situ carcinom
a are given in colum
ns 3 and 4, respectively. Error bars denote 95%
 










































































































































































































Figure 6.17 (Left to right) Scatter plots and regression lines of m
edian (colum











otherapy cycle for tum
ours of no specific type (N
ST
) in w
hich in situ carcinom
a w
as either present or absent (n=
57 lesions). M
ean-
effects plots and percentage (%
) changes in param
eter values per chem
otherapy cycle according to the presence of in situ carcinom
a are given in 
colum
ns 3 and 4, respectively. E
rror bars denote 95%





























































































































re 6.18 (Left to right) Scatter plots and regression lines of m
edian (colum
n 1) and log-transform
ed (colum










otherapy in cancers of no specific type (N
ST
) in w
hich in situ 
carcinom
a w
as either present or absent (n=57 lesions). M
ean-effects plots and percentage (%
) changes in param
eter values per chem
otherapy 
cycle according to the presence of in situ carcinom
a are given in colum
ns 3 and 4, respectively. E
rror bars denote 95%
 confidence intervals.  
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Table 6.18 Percentage (%





eter values per chem
otherapy cycle together w
ith 95%
 confidence intervals (C
I) and p 
values for the absence or presence of in situ carcinom
a in tum
ours. Percentage changes w
ere calculated according to 100×(e β – 1), w
here β denotes 
the slope estim
ate for each param




























































-16.7, [-23.0 – -9.9], <
.001*** 
-19.3, [-25.6 – -12.4], <
.001*** 
-17.5, [-24.4 – -10.0], <
.001*** 




-18.7, [-26.1 – -10.6], <
.001*** 
-22.4, [-29.5 – -14.4], <
.001*** 
-19.6, [-27.8 – -10.5], <
.001*** 




-18.0, [-22.7 – -13.2], <
.001*** 
-15.0, [-19.8 – -9.8], <
.001*** 
-18.5, [-23.5 – -13.1], 0.001** 




    0.5, [-4.4 – 5.7]          0.84 
  -3.6, [-8.5 – 1.6],          0.17 
   0.7, [-5.4 – 7.1],          0.83 




-22.5, [-26.2 – -18.7], <
.001*** 
-20.3, [-24.1 – -16.3], <
.001*** 
-23.1, [-27.0 – -19.0], <
.001*** 





-8.2, [-11.1 – -5.2], <
.001*** 
-8.2, [-11.2 – -5.1], <
.001*** 
-8.8, [-11.8 – -5.6], <
.001*** 





-30.4, [-35.7 – -24.6], <
.001*** 
-29.0, [-34.8 – -22.6], <
.001*** 
-31.3, [-37.1 – -24.8], <
.001*** 
-28.8, [-35.4 – -21.], <
.001*** 
*p<0.05; **p<0.01; ***p<0.001 
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Table 6.19 Statistical significance (p-values) of fixed effects for the association between log-
transformed DCE-MRI parameters and (A) neoadjuvant chemotherapy (NAC) regimens or (B) 
the sequence of taxane administration. 
 A. NAC regimen 
Parameter Cycle Regimen Regimen*Cycle 
ln(Ktrans) 0.06 0.06 0.70 
ln(hs-Ktrans) 0.06 0.43 0.40 
ln(kep) 0.002** 0.31 0.82 
ln(ve) 0.81 0.43 0.56 
ln(AFV) <.001*** 0.48 0.59 
ln(LD) 0.002** 0.55 0.65 
ln(Volume) <.001*** 0.43 0.97 
    
 B. Sequence of taxane administration 
Parameter Cycle Sequence Sequence*Cycle 
ln(Ktrans) 0.003** 0.03* 0.97 
ln(hs-Ktrans) 0.001** 0.07 0.71 
ln(kep) <.001*** 0.27 0.83 
ln(ve) 0.86 0.27 0.84 
ln(AFV) <.001*** 0.13 0.60 
ln(LD) <.001*** 0.14 0.47 
ln(Volume) <.001*** 0.08 0.51 
*p<0.05; **p<0.01; ***p<0.001 
 
6.3.4.2 Effect of treatment regimens DCE-MRI parameters during NAC 
There were no statistically significant differences in DCE-MRI parameters during NAC 
between patients on different types of chemotherapy (taxane and anthracycline-based treatment 
with/without a HER2-targeted agent, or combinations of taxanes with other drugs; Tables 
6.19.A; Figure 6.19). On average, women receiving a combination of taxanes and HER2-
targetted treatment tended to display higher values in DCE-MRI pharmacokinetic parameter 
estimates than women on other types of NAC, but these differences were not significant 
(Figures 6.19). Furthermore, patients receiving taxane and anthracycline-based therapy with or 
without the addition of HER2-targeted agent exhibited a tendency for a larger percentage 
reduction in imaging parameters than patients receiving a combination of a taxane and other 
drugs (Figures 6.19 and 6.20), apart from ve which showed no change during treatment for all 


























































































































































































Figure 6.19 (Left to right) Scatter plots and regression lines of m
edian (colum








otherapy cycle in patients receiving taxanes and anthracyclines (w
ith or w
ithout the addition of H
ER2-targetted agent) or 
taxanes in com
bination w
ith other drugs (n=86 lesions). M
ean-effects plots and percentage (%
) changes in param
eter values per chem
otherapy 
cycle according to chem
otherapy regim
en are given in colum
ns 3 and 4, respectively. Error bars denote 95%









































































































































Figure 6.20 (Left to right) Scatter plots and regression lines of m
edian (colum
n 1) and log-transform
ed (colum
n 2) values of the 
num







otherapy cycle in patients receiving taxanes 
and anthracyclines (w
ith or w
ithout the addition of H
ER2-targetted agent) or taxanes in com
bination w
ith other drugs (n=86 lesions). 
M
ean-effects plots and percentage (%
) changes in param
eter values per chem




ns 3 and 4, respectively. Error bars denote 95%
 confidence intervals.  
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Table 6.20 Percentage (%
) change per chem
otherapy cycle in D
CE-M
RI param
eter values together w
ith 95%






ens or (B) sequences of taxane adm
inistration. Percentage changes w
ere calculated 
according to 100×(e β – 1), w
here β denotes the slope estim
















Taxane + anthracyclines 
Taxane + anthracyclines + H
ER
2 agent 




, [CI], p 
%
, [CI], p 
%
, [CI], p 
ln(K
trans) 
-16.5, [-22.6 – -9.9], <.001*** 
-15.9, [-23.2 – -8.0], <.001*** 
-1.9, [-32.6 – 42.7], 0.92 
ln(hs-K
trans) 
-20.0, [-26.3 – -13.2], <.001*** 
-20.7, [-28.0 – -12.6], <.001*** 
5.3, [-30.1 – 58.7], 0.80 
ln(k
ep ) 
-16.0, [-20.3 – -11.6], <.001*** 
-16.4, [-21.3 – -11.0], <.001*** 
-8.9, [-30.0 – 18.5], 0.48 
ln(v
e ) 
-0.3, [-4.5 – 4.1], 0.88 
-1.2, [-6.0 – 4.0], 0.65 




-21.0 [-24.1 – -17.9], <.001*** 
-22.7, [-26.1 – -19.1], <.001*** 
-22.3, [-35.2 – -6.8], 0.007** 
ln(LD
) 
-9.3, [-12.2 – -6.4], <.001*** 
-8.0, [-11.3 – -4.5], <.001*** 




-30.9, [-35.5 – -25.8], <.001*** 
-29.9, [-35.5 – -23.8], <.001*** 















, [CI], p 
%
, [CI], p 
%
, [CI], p 
ln(K
trans) 
-15.2, [-21.5 – 8.5], <.001***  
-16.5, [-24.0 – 8.2], <.001*** 
-16.6, [-35.7 – 8.3], 0.17 
ln(hs-K
trans) 
-21.2, [-27.3 – -14.5], <.001*** 
-18.3, [-26.0 – 9.7], <.001*** 
-12.9, [-34.5 – 16.0], 0.34 
ln(k
ep ) 
-15.2, [-29.5 – 2.3], <.001*** 
-17.3, [-22.4 – 11.8], <.001*** 
-15.0, [-29.5 – 2.3], 0.09 
ln(v
e ) 
0.6, [-3.6 – 5.0], 0.78 
-2.4, [-7.5 – 2.9], 0.36 




-21.4, [-24.4 – 18.2], <.001*** 
-21.5, [-25.2 – 17.7], <.001*** 
-26.1, [-34.2 – -17.0], <.001*** 
ln(LD
) 
-9.8, [-12.6 – 7.0], <.001*** 
-7.2, [-10.7 – -3.5], <.001*** 




-32.2, [-36.7 – -27.3], <.001*** 
-27.6, [-33.6 – -21.1], <.001*** 
-30.6, [-45.2 – 12.4], 0.002** 





































































































































































































































Figure 6.21 (Left to right) Scatter plots and regression lines of m
edian (colum










otherapy cycle in patients receiving taxanes in reverse sequences or throughout treatm
ent (n=86 
lesions). M
ean-effects plots and percentage (%
) changes in param
eter values per chem
otherapy cycle according to taxane sequence are 
given in colum
ns 3 and 4, respectively. Error bars denote 95%









































































































































Figure 6.22 (Left to right) Scatter plots and regression lines of m
edian (colum
n 1) and log-transform
ed (colum









otherapy cycle in patients receiving taxanes in reverse sequences 
or throughout treatm
ent (n=86 lesions). M
ean-effects plots and percentage (%
) changes in param
eter values per chem
otherapy cycle according 
to taxane sequence are given in colum
ns 3 and 4, respectively. Error bars denote 95%
 confidence intervals.  
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In a similar manner, the sequence of taxane administration during chemotherapy, i.e. taxane 
given during the first or last 3 or 4 cycles of NAC, or throughout treatment (see Table 6.1), did 
not influence any of the imaging metrics (Table 6.19.B). Patients receiving reverse sequences 
of taxanes showed similar rates of decrease in DCE-MRI parameter estimates, both of which 
were higher on average than for women on taxanes for the entire duration of treatment (Table 
6.20.B; Figures 6.21 (d), (h), (l) and (p)). Furthermore, women starting on anthracyclines 
exhibited higher pharmacokinetic parameter values and numbers of AFV than women 
receiving taxanes during the first phase of NAC or throughout treatment (Figure 6.22 (c)). 
However, differences in parameter reduction rates or values between these chemotherapy 
sequences were not statistically significant. Among DCE-MRI pharmacokinetic estimates, 
only Ktrans allowed differentiation between regimens involving reverse taxanes administration 
sequences, but the statistical significance of this comparison was not upheld after Holm-
Bonferroni adjustment of p-values (Table 6.20.B; Figure 6.21 (c)). There was no statistically 
significant difference in the tumour longest diameter or volume between patients on different 
taxanes sequences (Figures 6.22 (g) and (k), respectively), with size metrics also displaying 
similar reduction rates during NAC (Table 6.20.B; Figures 6.22 (h) and (l) for the tumour 
longest diameter and volume respectively).  
 
6.3.5 DCE-MRI parameters during NAC and pathological response 
DCE-MRI images and pharmacokinetic maps during NAC of two representative lesions 
showing partial and complete pathological response are given in Figures 6.23 and 6.24, 
respectively. Associations between DCE-MRI metrics and pathological response were 
assessed using LME models with fixed effects for chemotherapy cycle and pathological 
response as well as terms for the interaction between pathological response and chemotherapy 
cycle and pathological response and molecular subtype (see Section 6.3.2). Random effects 
included intercepts and slopes for subjects. The fixed-effects estimates for the association 
between log-transformed DCE-MRI metrics and model regressors, together with confidence 
intervals and p-values are given in Tables 6.21 and 6.22 for the whole sample of cancers and 
NST carcinomas, respectively. Figures 6.25 – 6.28 plot the median untransformed and log-
transformed DCE-metrics vs chemotherapy cycle according to response category, together with 
























Figure 6.23 62-year-old female patient presenting with a HR-/HER2+, grade 3 breast 
carcinoma of no specific type (NST). Red arrows on Ktrans maps indicate the area of the tumour 
that depicted the highest Ktrans at baseline (in this area Ktrans decreased during the course of 
NAC).  The patient showed pathological partial response (pPR) after surgery and radiological 
stable disease after neoadjuvant chemotherapy (NAC). Patient treatment involved the 
administration of taxanes and Herceptin for 3 cycles, followed by anthracyclines for another 3 
cycles (6 cycles of treatment in total). The cancer is shown at four time points during NAC: 
baseline (BL), post cycle 1 (PC1), mid-treatment (MT) and at the end of treatment (ET). Left 
to right: DCE-MR image at peak enhancement (phase 19); maximum intensity projection 
(MIP) image depicting the tumour adjacent feeding vessels (AFV); Ktrans, kep and ve maps of 





























Figure 6.24 60-year-old female patient presenting with a triple-negative, grade 2 carcinoma of 
no specific type (NST). The patient showed pathological complete response (pCR) after 
surgery and radiological partial response after neoadjuvant chemotherapy (NAC). The patient 
received taxane and anthracycline-based treatment for 6 cycles in total. The cancer is shown at 
three time points during NAC: baseline (BL), mid-treatment (MT) and at the end of treatment 
(ET). The red arrow on the Kep map at the end of treatment points out a small lesion observed 
in purple.   Left to right: DCE-MR image at peak enhancement (phase 19); maximum intensity 
projection (MIP) image depicting the tumour adjacent feeding vessels (AFV); Ktrans, kep and ve 





ates (β) together w
ith 95%
 confidence intervals (C








and pathological response and the interaction effect betw




















-0.181, [-0.246 – -0.116], <.001*** 
0.118, [-0.233 – 0.469], 0.51 
0.028, [-0.103 – 0.158], 0.68 
ln(hs-K
trans) 
-0.258, [-0.327 – -0.189], 0.003** 
0.026, [-0.365 – 0.418], 0.89 
0.136, [-0.001 – 0.274], 0.06 
ln(k
ep ) 
-0.188, [-0.232 – -0.143], <.001*** 
0.111, [-0.349 – 0.127], 0.36  
0.052, [-0.037– 0.142], 0.25 
ln(v
e ) 
0.002, [-0.035 – 0.038], 0.09 
0.062, [-0.152 – 0.276], 0.57 




-0.259, [-0.291 – -0.227], <.001*** 
0.222, [-0.042 – 0.486], 0.10 




-0.100, [-0.125 – -0.074], <.001*** 
0.063, [-0.113 – 0.239], 0.46 




-0.379, [-0.437 – 0.321], <.001*** 
0.413, [-0.046 – 0.872], 0.08 
0.069, [-0.047 – 0.185], 0.25 
*p<0.05; **p<0.01; ***p<0.001 
 Table 6.22 F
ixed-effects estim
ates (β) together w
ith 95%
 confidence intervals (C








and pathological response and the interaction effect betw
een pathological response and chem
otherapy cycle in carcinom























-0.188, [-0.259 – -0.118], <.001*** 
0.144, [-0.245 – 0.532], 0.47 
0.035, [-0.106 – 0.176], 0.63 
ln(hs-K
trans) 
-0.264, [-0.341 – -0.187], <.001*** 
0.102, [-0.340 – 0.545], 0.65 
0.120, [-0.013 – 0.294], 0.08 
ln(k
ep ) 
-0.195, [-0.244 – -0.146], <.001*** 
-0.173, [-0.433 – 0.087], 0.20  
0.081, [-0.017– 0.180], 0.11 
ln(v
e ) 
0.000, [-0.043 – 0.044], 0.98 
0.066, [-0.175 – 0.308], 0.59 




-0.256, [-0.291 – -0.221], <.001*** 
0.266, [-0.022 – 0.554], 0.08 




-0. 088, [-0.110 – -0.065], <.001*** 
0.109, [-0.067 – 0.284], 0.23 




-0.372, [-0.433 – -0.311], <.001*** 
0.485, [0.027 – 0.943], 0.04* 
0.054, [-0.068 – 0.176], 0.39 






































































































































































































































Figure 6.25 (Left to right) Scatter plots and regression lines of m
edian (colum











otherapy cycle per pathological response category (n=86 lesions). M
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ns 3 and 4, 
respectively. E
rror bars denote 95%
 confidence intervals. pPR




































































































































































Figure 6.26 (Left to right) S
catter plots and regression lines of m
edian (colum
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Figure 6.27 (Left to right) Scatter plots and regression lines of m
edian (colum











otherapy cycle per pathological response category in carcinom
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Figure 6.28 (Left to right) S
catter plots and regression lines of m
edian (colum
n 1) and log-transform
ed (colum
n 2) values of the 
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-17.7, [-26.7 – -7.6], <.001*** 
-19.3, [-20.8 – -9.6], <.001*** 
-18.6, [-28.0 – -7.9], 0.001*** 
-15.7, [-21.8 – -9.2], <.001*** 
hs-K
trans 
-27.8, [-3621 – -18.4], <.001*** 
-17.3, [-22.8 – -11.4], <.001*** 
-28.4, [-37.5 – -18.0], <.001*** 
-17.6, [-24.0 – -10.8], <.001*** 
k
ep  
-19.3, [-25.5 – -12.5], <.001*** 
-14.9, [-18.6 – -11.0], <.001*** 
-21.0, [-27.6 – -1381], <.001*** 
-14.3, [-18.5 – -9.8], <.001*** 
v
e  
1.4, [-4.9 – 8.2], 0.66 
-1.1, [-4.7 – 2.6], 0.56 
0.7, [-5.4 – 7.1], 0.83 




-25.0, [-29.2 – -20.5], <.001*** 
-20.5, [-23.2 – -17.9], <.001*** 
-24.9, [-29.5 – -20.1], <.001*** 




-11.2, [-15.1 – -7.1], <.001*** 
-7.7, [-10.1 – -5.2], <.001*** 
-10.1, [-13.5 – -6.5], <.001*** 




-33.9, [-40.2 – -26.8], <.001*** 
-29.2, [-33.4 – -24.1], <.001*** 
-32.9, [-39.6 – -25.5], <.001*** 
-29.2, [-33.9 – -24.2.], <.001*** 
*p<0.05; **p<0.01; ***p<0.001 
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All DCE-MRI parameters examined showed a significant decrease during chemotherapy 
regardless of response category, with the exception of ve which showed no significant change 
throughout treatment for both response groups (Tables 6.23.A and 6.23.B for all lesions and 
the group of NST cancers, respectively). Breast tumours in the pCR group displayed a larger 
percentage decrease per chemotherapy cycle in all parameter values than these in the pPR 
group, with hs-Ktrans, tumour volume and AFV showing the largest reduction rates among the 
parameters examined in both the entire sample of tumours or NST cancers alone (Table 6.23.A 
and 6.23.B, respectively). Though no significant difference between response groups was 
observed for the pharmacokinetic estimates examined, there was an overall tendency for mean 
parameter values to be higher in tumours showing pPR than those displaying pCR (Figures 
6.25 and 6.27 for the whole lesion sample and NST cancers, respectively).  
 
On the other hand, statistically significant differences between pathological response groups 
were found in the tumour volume (ln(Volume) [95% CI] – pCR vs pPR: 0.160 [-0.271 – 0.591] 
vs 0.746 [0.464 – 1.032], p=0.036) and number of AFV (ln(AFV) [95% CI] – pCR vs pPR: 
2.632 [2.428 – 2.835] vs 2.997 [2.863 – 3.131], p=0.0047), which were upheld when 
considering NST cancers alone (pCR vs pPR - ln(Volume) [95% CI]: 0.153 [-0.267 – 0.572] 
vs 0.777 [0.490 – 1.064], p=0.028; ln(AFV) [95% CI]: 2.542 [2.314 – 2.769] vs 2.963 [2.809 – 
3.118], p=0.0039). In NST cancers, hs-Ktrans and the tumour longest diameter also showed 
significant differences between pathological response categories (pCR vs pPR - ln(hs-Ktrans) 
[95% CI]: -0.086 [-0.431 – 0.259] vs 0.379 [0.156 – 0.602], p=0.0310; ln(LD) [95% CI]: 3.091 





6 Untransformed mean estimates of tumour volume with 95% confidence intervals [CI] in cancers with pCR vs 
pPR were 1.2 [0.8 – 1.8] vs 2.1 [1.6 – 2.8] cm3, respectively. 
7 Untransformed mean estimates of AFV with 95% confidence intervals [CI] in cancers with pCR vs pPR were 
14 [11 – 17] vs 20 [18 – 23] vessels, respectively. 
8 Untransformed mean estimates of tumour volume with 95% confidence intervals [CI] in NST cancers with pCR 
vs pPR were 1.2 [0.8 – 1.8] vs 2.2 [1.6 – 2.9] cm3, respectively. 
9 Untransformed mean estimates of AFV with 95% confidence intervals [CI] in NST cancers with pCR vs pPR 
were 13 [10 – 16] vs 19 [17 – 23] vessels, respectively. 
10 Untransformed mean estimates of hs-Ktrans with 95% confidence intervals [CI] in NST cancers with pCR vs pPR 
were 0.918 [0.650 – 1.296] vs 1.418 [1.169 – 1.826] cm3, respectively. 
11 Untransformed mean estimates of the longest tumour diameter (LD) with 95% confidence intervals [CI] in NST 
cancers with pCR vs pPR were 22 [19 – 25] vs 27 [25 – 30] mm, respectively. 
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6.3.6 Evaluation of pre-treatment and early changes in DCE-MRI parameters for the 
prediction of pathological response 
Table 6.24 summarises DCE-MRI parameters at baseline and after one cycle of NAC according 
to response category. Absolute and percentage changes between baseline and after one cycle 
of chemotherapy are given in Table 6.25.  
 
There were no significant differences in DCE-MRI parameters between lesions exhibiting pCR 
and pPR at either baseline or after one cycle of treatment (Table 6.24). Similarly, no significant 
absolute or percentage differences were observed between responding cancers and those 
partially responding to treatment (Table 6.25). Interestingly, tumours having pPR showed 
larger percentage changes between these two time points than cancers with pCR (Table 
6.25.B), however it should be noted that from the 37 cancers included in the evaluation of 
differences between metrics at post-cycle 1 and baseline, 25 (68%) exhibited pPR.  
 
Single parameters from DCE-MRI at baseline and post cycle 1 (Table 6.26) showed low 
predictive ability for pCR based on ROC analysis for either the whole sample of tumours or 
the group of NST cancers (AUC: <0.70; p=0.05-0.83). Except for kep, the probability of 
pathological complete response declined with increasing values in parameter values (Figure 
6.29), indicating that cancers with lower values in DCE-MRI metrics at baseline or after one 
cycle of treatment were more likely to achieve pCR. However, and as also indicated by the 
results of the ROC analysis, no single DCE-MRI parameter achieved a probability of >50% in 
predicting response. Overall, the best predictive ability was observed for the tumour longest 
diameter and volume at post cycle 1, with a sensitivity of >70% and a specificity of >62% at 
optimal cut-off values (Table 6.26B). Similarly, absolute and percentage differences in DCE-
MRI parameter values between baseline and after one cycle of treatment showed little ability 
in predicting pathological response (Table 6.27), with mean tumour Ktrans performing 
marginally better than other metrics. 
 
Logistic regression models involving single DCE-MRI parameters and tumour prognostic 
factors selected from univariate analyses (i.e., histological subtype, molecular subtype and 
grade) improved associations with pathological response (Table 6.28). In general, inclusion of 
both clinicopathologic factors and DCE-MRI metrics into regression models resulted in 
moderate-to-good ability for predicting pathological response, with AUC >0.75 for all 
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quantitative parameters examined. Compared to models including only the factors of 
histological and molecular subtype as well as grade in the regression, the introduction of single 
DCE-MRI metrics at baseline and after one cycle of NAC resulted in an increase in specificity 
of up to 22% (Table 6.29), with similar increases observed when entering changes between 
baseline and post-cycle 1 in DCE parameters into the model (Table 6.30).   Overall, 
combination models including tumour volume, the longest diameter or AFV after 1 cycle of 




























Table 6.24 Tumour DCE-MRI parameters at (A) baseline and (B) after one cycle of 
chemotherapy according to therapeutic response category. Data are presented as median 
[range] or mean ± standard deviation as appropriate. 
A. Baseline 
Parameter pCR pPR p 
Lesions (n) 25 55  
Ktrans 0.333 [0.113 – 0.937] 
0.376 
[0.057 – 2.133] 0.38
a 
hs-Ktrans 2.940 [0.270 – 4.988] 
3.498 
[0.077 – 4.850] 0.31
a 
kep 0.803 ± 0.227 0.782 ± 0.324 0.38b 
ve 
0.321 




Lesions (n) 27 56  
AFV 31 [9 – 82] 
42 
[12 – 112] 0.27
a 
Lesions (n) 27 59  
LD 28 [11 – 70] 
32 
[11 – 66] 0.26
a 
Volume  4.64 [0.50 – 106.57] 
2.36 
[0.04 – 19.79] 0.21
a 
B. Post Cycle 1 
Parameter pCR pPR p 
Lesions (n) 10 23  
Ktrans 0.339 
[0.052 – 0.601] 
0.195 
[0.065 – 1.190] 
0.68a 
hs-Ktrans 2.426 ± 1.909 2.021 ± 1.265 0.57
b 
kep 0.472 
[0.141 – 0.889] 
0.537 
[0.208 – 1.092] 
0.75c 
ve 0.476 




Lesions (n) 11 25  
AFV 33 [9 – 101] 
34 
[14 – 110] 0.42
a 
Lesions (n) 12 25  
LD 23 
[11 – 54] 
27 
[13 – 66] 
0.24a 
Volume  5.99 [0.04 – 19.79] 
3.87 
[0.31 – 15.45] 0.07
a 
aMann-Whitney U test 
bWelch’s t test 
pCR: pathological complete response; pPR: pathological partial response; Ktrans: contrast influx transfer rate 
(mL/g/min); kep: contrast efflux transfer rate (min-1); ve: fractional volume of extravascular-extracellular space; 
AFV: adjacent feeding vessels (number); LD: tumour longest diameter on MRI (mm); volume: cm3 
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Table 6.25 Absolute (A) and percentage changes (B) in DCE-MRI parameters between post-
cycle 1 and baseline according to therapeutic response category. Data are presented as median 
[range] or mean ± standard deviation as appropriate. 
A. Absolute change 
Parameter pCR pPR p 
Lesions (n) 10 23  
Ktrans -0.016 [-0.527 – 0.188] 
-0.136 
[-0.671 – 0.607] 0.42
a 
hs-Ktrans -0.201 ± 1.489 -1.011 ± 1.422 0.20b 
kep -0.313 ± 0.409 -0.258 ± 0.246 0.66b 
ve 0.056 ± 0.100 0.014 ± 0.138 0.46b 
Lesions (n) 11 25  
AFV -4 ± 26 -5 ± 26 0.90b 
Lesions (n) 12 25  
LD -4 [-10 – 6] 
-2 
[-21 – 17] 0.37
a 
Volume  -1.38 [-20.4 – 6.5] 
-1.56 
[-20.2 – 0.8] 0.21
a 
B. Percentage (%) change 
Parameter pCR pPR p 
Lesions (n) 10 23  
Ktrans -10.3 
[-76.6 – 45.5] 
-24.3 
[-79.8 – 112.4] 
0.87a 
hs-Ktrans -24.2 
[-96.0 – 98.7] 
-28.2 
[-93.3 – 140.2] 
0.98a 
kep -33.2 ± 33.9 -28.0 ± 23.0 0.57
b 
ve 16.6 
[-21.5 – 88.7] 
7.5 
[-37.5 – 114.3] 
0.56a 
Lesions (n) 11 25  
AFV 5.7 [-84.2 – 131.6] 
1.1 
[-63.6 – 147.4] 0.87
a 
Lesions (n) 12 25  
LD -14.8 
[-34.5 – 16.7] 
-6.7 
[-56.8 – 70.8] 
0.17a 
Volume  -67.6 [-89.1 – 49.3] 
-49.4 
[-90.3 – 16.1] 0.18
a 
aMann-Whitney U test 
bStudent’s t test 
pCR: pathological complete response; pPR: pathological partial response; Ktrans: contrast influx transfer rate 
(mL/g/min); kep: contrast efflux transfer rate (min-1); ve: fractional volume of extravascular-extracellular space; 
AFV: adjacent feeding vessels (number); LD: tumour longest diameter on MRI (mm); volume: cm3.
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C, [CI], p 
K
trans 
0.40, [0.08 – 1.97], 0.26 
0.536 
36.4, [23.8 – 50.4] 
84.0, [63.9 – 95.5] 
0.582, [0.442 – 0.724], 0.25 
hs-K
trans 
0.87, [0.62 – 1.21], 0.41 
3.688 
49.1, [35.4 – 62.9] 
76.0, [54.9 – 90.6] 
0.557, [0.421 – 0.694], 0.41 
k
ep  
1.27, [0.26 – 6.32], 0.77 
1.288 
9.1, [3.0 – 20.0] 
100, [86.3 – 100.0] 
0.479, [0.338 – 0.610], 0.77 
v
e  
0.21, [0.01 – 3.55], 0.28 
0.299 
74.5, [61.0 – 85.3] 
44.0, [24.4 – 65.1] 




0.99, [0.97 – 1.01], 0.23 
34 
62.5, [48.5 – 75.1] 
63.0, [42.4 – 80.6] 
0.580, [0.450 – 0.711], 0.23 
LD
 
0.98, [0.95 – 1.02], 0.37 
21 
94.9, [85.9 – 98.9] 
22.2, [8.6 – 42.3] 




0.96, [0.90 – 1.03], 0.27 
3.03 
78.0, [65.3 – 87.7] 
44.4, [25.5 – 64.7] 

































C, [CI], p 
K
trans 
0.28, [0.01 – 6.99], 0.44 
0.384 
36.0, [18.0 – 57.5] 
88.9, [51.8 – 99.7] 
0.596, [0.359 – 0.832], 0.43 
hs-K
trans 
1.22, [0.71 – 2.09], 0.47 
0.165 
100.0, [86.3–100.0] 
22.2, [2.8 – 60.0] 
0.430, [0.238 – 0.622], 0.47 
k
ep  
0.51, [0.01 – 27.5], 0.74 
0.482 
68.0, [46.5 – 85.1] 
55.6, [21.2 – 86.3] 
0.533, [0.329 – 0.738], 0.75 
v
e  
0.31, [0.00 – 31.1], 0.62 
0.662 
24.0, [9.4 – 45.1] 
100.0, [66.4–100.0] 




0.99, [0.96 – 1.02], 0.46 
47 
40.7, [ 22.4 – 61.2] 
90.0, [55.5 – 99.7] 
0.578, [0.373 – 0.784], 0.45 
LD
 
0.97, [0.92 – 1.03], 0.32 
24 
70.4, [49.8 – 86.2] 
63.6, [30.8 – 89.1] 




0.98, [0.83 – 1.16], 0.82 
1.91 
70.4, [49.8 – 86.2] 
72.7, [39.0 – 94.0] 
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C, [CI], p 
K
trans 
1.72, [0.038 – 77.98], 0.78 
-0.100 
58.3, [36.6 – 77.9] 
71.4, [29.0 – 96.3] 
0.607, [0.332 – 0.881], 0.44 
hs-K
trans 
1.49, [0.80 – 2.76], 0.20 
-0.223 
50.0, [29.1 – 70.9] 
71.4, [29.0 – 96.3] 
0.523, [0.239 – 0.808], 0.87 
k
ep  
0.51, [0.03 – 9.28], 0.51 
-0.223 
50.0, [29.1 – 70.9] 
71.4, [29.0 – 96.3] 
0.523, [0.239 – 0.808], 0.87 
v
e  
1.41, [0.15 – 12.8], 0.44 
-0.053 
33.0, [15.6 – 55.3] 
100.0, [62.2 –100] 




0.99, [0.97 – 1.02], 0.80 
-10 
44.4, [ 25.5 – 64.7] 
70.0, [34.8 – 93.3] 
0.522, [0.299 – 0.745], 0.85 
LD
 
0.98, [0.89 – 1.08], 0.68 
-14 
11.5, [2.4 – 30.2] 
100.0, [71.5–100.0] 




1.00, [0.87 – 1.15], 0.98 
-1.56 
53.8, [33.4 – 73.4] 
60.0, [26.2 – 87.8] 




































C, [CI], p 
K
trans 
0.97, [0.18 – 8.02], 0.97 
-11.2 
75.0, [53.3 – 90.2] 
57.1, [18.4 – 90.1] 
0.524, [0.218– 0.830], 0.88 
hs-K
trans 
1.04, [0.26 – 4.27], 0.95 
-33.3 
45.8, [82.4–100.0] 
71.4, [3.7 – 71.0] 
0.489, [0.164 – 0.752], 0.95 
k
ep  
0.44, [0.15 – 12.62], 0.63 
-33.3 
45.8, [25.6 – 67.2] 
71.4, [29.0– 96.3] 
0.464, [0.176 – 0.752], 0.81 
v
e  
2.09, [0.20 – 21.94], 0.54 
-3.9 
41.7, [22.1 – 63.4] 
85.7, [42.1 – 99.6] 




1.16, [0.32 – 4.27], 0.82 
-41.1 
88.5, [69.8 – 97.6] 
30.0, [6.7 – 65.2] 
0.519, [0.281 – 0.757], 0.87 
LD
 
0.21, [0.01 – 7.24], 0.39 
-45.1 
11.5, [2.4 – 30.2] 
100.0, [71.5–100.0] 




0.44, [0.04 – 5.25], 0.51 
-16.1 
100, [86.8–100.0] 
10.0, [0.3 – 44.5] 
0.350, [0.120 – 0.580], 0.20 




Figure 6.29 Probability of complete pathological response (pCR) vs DCE-MRI 
pharmacokinetic parameters at baseline. 
 




























































































































































Table 6.28 Univariate analyses of tumour prognostic factors and chemotherapy regimens as 
predictors of pathological response. The statistical significance (p) and area under the curve 
(AUC) of each parameter in predicting pathological response were calculated using binomial 
logistic regression. Main and interaction effects with p≤0.01 and p≤0.25 were selected for 
inclusion into multiple logistic regression models involving quantitative DCE-MRI 
parameters. p-values were adjusted using the Holm-Bonferroni method. 
 Statistical significance AUC 
Parameter p AUC, [CI], p 
Histological subtype 0.1 0.606, [0.474 – 0.738], 0.009 
Molecular sub-type <0.001*** 0.758, [0.640 – 0.875], <.001 
Grade 0.1 0.594, [0.461 – 0.726], 0.04 
In situ carcinoma 0.63 0.560, [0.409 – 0.711], 0.17 
NAC regimen 0.81 
0.765, [0.650 – 0.882], 0.45 NAC regimen*Molecular subtype 0.79 
Taxane sequence 0.81 0.540, [0.397 – 0.662], 0.31 
 
Table 6.29 Area under the curve (AUC), sensitivity (%) and specificity (%) of the DCE-MRI 
parameters at baseline (A) and after one cycle of chemotherapy (B), derived from multiple 
logistic regression models including the histological subtype, molecular subtype and grade as 
factors.  
A. Baseline 
 Sensitivity Specificity AUC 
Parameter % % AUC, [CI], p 
Ktrans 88.0, [67.8 – 82.7] 65.5, [62.8 – 69.5] 0.835, [0.730 – 0.941], <.001 
hs-Ktrans 76.0, [69.9 – 82.5] 80.0, [77.7 – 82.5] 0.846, [0.744 – 0.949], <.001 
kep 76.0, [44.0 – 92.0] 76.4, [52.7 – 86.3] 0.829, [0.722 – 0.936], <.001 
ve 72.0, [40.0 – 88.0] 80.0, [58.2 – 92.7] 0.836, [0.731 – 0.942], <.001 
AFV 70.4, [ 40.7 – 85.2] 82.1, [58.8 – 92.9] 0.835, [0.733 – 0.937], <.001 
LD 77.8, [48.1 – 88.9] 79.7, [39.0 – 89.8] 0.845, [0.747 – 0.795], <.001 
Volume 88.9, [66.7 – 85.2] 69.5, [15.3 – 83.1] 0.846, [0.340 – 0.699], <.001 
pFactorsa 88.9, [69.2 – 100.0] 59.3, [40.0 – 73.2] 0.817, [0.712 – 0.923], <.001 
    
B. Post cycle 1 
 Sensitivity Specificity AUC 
 % % AUC, [CI], p 
Ktrans 88.9, [11.1 – 100.0] 76.0, [24.0 – 88.0] 0.778, [0.347– 0.887], 0.01 
hs-Ktrans 88.9, [44.4 – 100.0] 64.0, [16.0 – 80.0] 0.769, [0.571 – 0.967], 0.01 
kep 88.9, [ 33.3 – 100.0] 68.0, [24.0 – 80.1] 0.769, [0.571 – 0.967], 0.01 
ve 88.9, [33.3 – 100.0] 60.0, [20.0 – 80.0] 0.760, [0.559 – 0.961], 0.01 
AFV 80.0, [20.0 – 100.0] 92.6, [37.0 – 100.0] 0.874, [0.725 – 1.000], <.001 
LD 81.8, [45.5 – 100.0] 92.6, [14.8 – 100.0] 0.875, [0.733 – 1.000], <.001 
Volume 81.8, [36.4 – 100.0] 81.5, [11.1 – 96.3] 0.832, [0.671 – 0.992], <.001 
pFactorsa 81.2, [45.5 – 100.0] 70.4, [33.3 – 92.6] 0.818, [0.712 – 0.923], 0.001 




Table 6.30 Area under the curve (AUC), sensitivity (%) and specificity (%) of absolute (A) 
and percentage (B) changes in DCE-MRI parameters after one cycle of NAC derived from 
multiple logistic regression models including the histological subtype, molecular subtype and 
grade as factors. Absolute changes were calculated as: ParameterPC1 – ParameterBaseline. 
Percentage (%) changes were calculated as: 100×(ParameterPC1 – 
ParameterBaseline)/ParameterBaseline. 
A. Absolute Changes 
 Sensitivity Specificity AUC 
 % % AUC, [CI], p 
Ktrans 71.4, [14.3 – 100.0] 83.3, [41.6 – 95.8] 0.804, [0.593 – 1.000], 0.01 
hs-Ktrans 76.0, [69.9 – 82.5] 80.0, [77.7 – 82.5] 0.846, [0.744 – 0.949], <.001 
kep 85.7, [ 42.8 – 100.0] 62.5, [12.5 – 95.8] 0.768, [0.545 – 0.990], 0.02 
ve 71.4, [14.3 – 100.0] 83.3, [25.0 – 100.0] 0.791, [0.577 – 1.000], 0.01 
AFV 80.0, [ 30.0 – 100.0] 85.2, [37.4 – 96.3] 0.865, [0.712 – 1.000], <.001 
LD 90.9, [54.6 – 100.0] 59.3, [37.0 – 88.9] 0.828, [0.666 – 0.990], <.001 
Volume 70.0, [20.0 – 90.0] 85.1, [40.7 – 100.0] 0.822, [0.651 – 0.993], 0.001 
pFactorsa 88.9, [69.2 – 100.0] 59.3, [40.0 – 73.2] 0.817, [0.712 – 0.923], <.001 
    
B. Percentage Changes 
 Sensitivity Specificity AUC 
 % % AUC, [CI], p 
Ktrans 85.7, [42.8 – 100.0] 58.3, [4.17 – 91.7] 0.732, [0.500– 0.964], 0.03 
hs-Ktrans 88.9, [44.4 – 100.0] 64.0, [16.0 – 80.0] 0.786, [0.576 – 0.960], 0.02 
kep 85.7, [ 42.9 – 100.0] 62.5, [12.5 – 95.8] 0.768, [0.546 – 0.990], 0.02 
ve 85.7, [28.6 – 100.0] 70.8, [16.7 – 91.8] 0.760, [0.553 – 0.994], 0.01 
AFV 80.0, [20.5 – 100.0] 80.8, [37.6 – 100.0] 0.865, [0.730 – 1.000], <.001 
LD 81.8, [27.3 – 100.0] 92.6, [40.7 – 96.3] 0.831, [0.671 – 0.992], <.001 
Volume 70.0, [20.0 – 90.0] 88.9, [40.7 – 100.0] 0.837, [0.672 – 1.000], <.001 
pFactorsa 81.2, [45.5 – 100.0] 70.4, [33.3 – 92.6] 0.818, [0.712 – 0.923], 0.001 
















Pathological response to neoadjuvant chemotherapy can indicate long-term outcome in 
primary breast cancer6,45,46. An accurate assessment of tumour response early during treatment 
may enable adjustment of therapy to the patient with the aim of increasing tumour response 
and improving patient outcomes. The main aim of this study was to investigate changes in 
quantitative and qualitative DCE-MRI parameters of breast cancers during neoadjuvant 
chemotherapy treatment and explore their relationship with tumour pathological response.  
 
Previous studies have investigated and demonstrated the potential of the adjacent vessel sign 
in DCE-MRI for breast cancer diagnosis38,39,47. This chapter investigated the association 
between the number of tumour adjacent feeding vessels (AFV) – a qualitative feature of tumour 
vascularity – and pathological tumour response, also, the potential of this tumour feature to 
predict tumour response to therapy.  
 
All DCE-MRI parameters decreased significantly during the course of treatment (with the 
exception of ve) in all tumours. Lesions that showed pCR exhibited a larger percentage 
reduction per chemotherapy cycle than lesions with pPR. These results are in concordance with 
findings from previous studies20,23,24,28,48 in which a reduction in  tumour pharmacokinetic 
parameters from DCE-MRI was observed in patients who responded to NAC treatment. Some 
studies have reported a difference in Ktrans between responders and non-responders before the 
commencement of treatment20,49,50. Overall, lower Ktrans values were observed in cancers 
showing complete pathological response in comparison to tumours with partial response to 
NAC from baseline to end of treatment. This may reflect that cancers displaying pCR have 
reduced blood supply owing to the effect of cytotoxic therapy contributing to increased 
apoptosis and leading to a complete pathological response51. 
 
 There was no significant reduction of ve in cancers with pPR or pCR. O’Flynn et al23. reported 
an increase of ve in breast tumours showing no response to treatment, whereas Yankeelov et 
al48 observed a decrease of tumour ve after treatment, although the study did not differentiate 
between responders and non-responders. Likewise, in a study by Cho et al52, DCE-MRI 
parameters (Ktrans, kep and ve) did not lead to identification of pathological response to NAC 
after one cycle of chemotherapy. Results about correlations between DCE-MRI quantitative 
parameters and pathological response to NAC are controversial. Ah-See et al46 showed that 
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Ktrans and kep after two cycles of NAC were significantly related to pathologic response. 
Tudorica et al53 presented that Ktrans, kep, and ve obtained after one cycle of NAC could be 
considered early predictors of pathologic response. In our study there were no non-responders, 
and this perhaps reflects the improvement in neoadjuvant chemotherapy over the past 10-15 
years.   
 
With respect to tumour volumes (ROI volumes), pre-treatment MRI evaluation of the 82 
patients with advanced breast cancer showed tumour ROI volumes ranging from 0.5 to 106.6 
cm3. After 6 or 7 cycles of chemotherapy (end of treatment), tumour volumes in complete 
responder cancers ranged between 0.007 and 3.67 cm3 and between 0.01 and 12.28 cm3 in 
partial responders. Cancers that completely responded to NAC treatment presented smaller 
median volumes at baseline, in comparison to cancers that showed pathological partial 
response. Tumour ROI volumes decreased during the course of NAC in all cancers, as has been 
observed previously46. This morphological metric of tumour vascularity presented the biggest 
decline per treatment cycle, followed by AFVs and hs-Ktrans. These observations were upheld 
when considering NST carcinomas alone. The reduction of tumour size during NAC has been 
previously identified as a good predictor of tumour pathological response and some researchers 
even consider that a reduction in tumour size is a better response predictor than DCE-MRI 
pharmacokinetic parameters26,27. In our study, the median number of adjacent feeding vessels 
of pCR cancers was lower than the median number of adjacent feeding vessels of cancers with 
pPR at baseline. Tumour volumes and the number of AFVs during NAC were significantly 
associated with pathological response. Previous studies have not reported the association of the 
number of adjacent feeding vessels with pathological tumour response. In the subset of NST 
cancers, hotspot Ktrans and tumour longest diameters were significantly correlated to tumour 
pathological response. Overall, a baseline tumour size ≤20 mm was significantly associated 
with complete pathological response. Samuel et al54. also reported a significant correlation 
between tumour size and tumour pathological response. Other researchers differ, with tumour 
size failing to correlate to final pathological response in their study46.  
 
Absolute or percentage changes of DCE-MRI tumour parameters did not show significant 
correlations with pathological tumour response. Contrary to our findings, Pickles et al28. 
observed that tumour volume changes between pre-treatment and early treatment time points 
demonstrated differences between responders and non-responders with percentage changes 
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revealing the most significant result. Results from the I-Spy trial showed that kep could 
significantly differentiate between responders and non-responders after a single cycle of 
NAC55. We observed that NAC regimes did not affect the changes of DCE-MRI parameters, 
however, the sequence of taxanes’ administration (taxanes first, taxanes second or taxanes 
throughout) did influence changes of Ktrans. 
 
There were not significant differences in changes (absolute or percentage) of parameters 
between pCR and pPR cancers from pre-treatment to post cycle 1. Interestingly, tumours 
having pPR showed bigger percentage changes between these two time points than cancers 
with pCR, however it should be noted that from the 37 cancers included in this evaluation of 
metrics’ changes between baseline and post-cycle 1, 25 (68%) exhibited pPR. Furthermore, the 
fact that pPR cancers were bigger than pCR at baseline may have influenced on partial 
responder cancers presenting bigger percentage changes than pCR tumours after one cycle of 
NAC. 
 
The association between patients’ age and the number of AFV at baseline was statistically 
significant and independent of size/volume of the tumour, which means that there was an ~1% 
increase in the number of AFV per year of age and hence we would expect older women to 
have more AFVs than younger ones regardless of how big the tumour was. No other parameter 
showed a significant association with patients’ age. Hotspot Ktrans and AFVs were significantly 
associated with tumour size (LD and volume). Similarly, AFVs at baseline significantly 
correlated to hotspot Ktrans and ve at the same time-point. According to these results, the number 
of AFVs is a measure of tumour vascularity that can be related to PK estimates and given the 
correlations with volume, AFVs can be a surrogate marker of tumour volume and vice versa: 
i.e more AFVs, larger cancer and higher probability of developing pathological partial response 
(given the statistically significant differences in AFV observed between complete and partial 
responder cancers).  The mixed effect statistical model revealed that the interaction between 
the number of chemotherapy cycles and tumour volume had a significant effect on hs-Ktrans. 
Likewise, the interaction between the number of chemotherapy cycles and tumour longest 
diameters had a significant effect on AFVs. 
 
With respect to the effect of tumour prognostic factors (histological and molecular subtype, 
grade and presence of in-situ carcinoma) on changes of DCE-MRI parameters, there was no 
effect of tumour histology or molecular subtype on changes of PK metrics, whereas tumour 
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histology and the interaction between the number of NAC cycles and histology influenced on 
the tumour size (LD and volume). NST cancers presented greater percentage changes of DCE-
MRI PK parameters whereas NST and special type carcinomas presented greater percentage 
changes of DCE-MRI morphological parameters. Petruolo et al56 also reported better 
pathological response to NAC in invasive ductal carcinomas (or NST) in comparison to 
invasive lobular cancers, which are unlikely to downstage56. 
 
There was a significant relationship between tumour grade and the pharmacokinetic parameter 
ve, not seen with other DCE-MRI parameters. Similar to our study, previous research did not 
find a correlation between AFVs and tumour grade38. The interaction between the number of 
NAC cycles and nuclear grade had a significant effect on the number of AFVs. Changes in 
DCE-MRI parameters did not vary significantly between grade 2 and grade 3 cancers. 
 
Tumour molecular subtypes showed a significant association with the number of AFVs, 
especially in NST cancers, and among all tumour prognostic factors, only tumour molecular 
subtype significantly influenced pathological response. This significant relationship between 
pathological response and receptor-based subtypes has been previously reported57,58.  In our 
study, hormone receptor negative cancers had a more favourable pathological outcome than 
HR+ cancers, regardless of the NAC regime given. Similarly, DCE-MRI parameters in HR- 
cancers decreased at a faster rate than those in HR+ cancers during NAC. Our findings are in 
concordance with previous literature which states that a correlation between pCR and optimal 
clinical outcomes is stronger for patients with TNBC and HER2+ disease than for patients with 
HR+ cancers56,59. Other pathological features of the cancer such as tumour histology, grade 
and presence of in-situ carcinoma and NAC regime or schedule did not show a significant 
association with tumour pathological response. Conversely, previous studies60,61 have reported 
that NAC therapy with taxanes (Docetaxel) or anthracyclines can influence pathological 
response by inducing a high pathological response rate. 
 
Even though the presence or absence of in-situ carcinoma in all tumours did not show a 
significant relationship with pathological response, in NST cancers it could possibly allow 
differentiation between pCR and pPR cancers. Previous authors62 have demonstrated high 
periductal vascularity around ducts involved by DCIS, and since most NST cancers in our study 
which were partial responders had DCIS, we could infer that this high periductal vascularity 
may have influenced the tumour response to NAC. The presence of in-situ carcinoma was 
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significantly associated with changes in hotspot Ktrans, tumour LD and volume at mid-treatment 
(also in the NST subset) although in general, we did not observe significant differences in 
percentage changes of DCE-MRI parameters between tumours with in-situ carcinoma and 
tumours without in-situ carcinoma. As expected, tumours with no in-situ carcinoma responded 
better to NAC.  
 
After assessing the ability of pathological features of breast cancer to predict pathological 
response, it was found that tumour receptor-based status was the only characteristic of the 
tumour which significantly predicted pathological response. Using baseline DCE-MRI 
parameters tumour volumes revealed the highest sensitivity (88.9%) and AUC (0.846) whereas 
hs-Ktrans and ve showed the highest specificity (80.0%) to predict pathological response. After 
one cycle of NAC, all PK metrics (Ktrans, hs-Ktrans, Kep and ve) presented the highest sensitivity 
(88.9%) whereas the morphological parameters, AFVs and tumour longest diameter showed 
the highest specificity (92.6%) and AUC (0.874 and 0.875, respectively). Generally, cancers 
with lower values in DCE-MRI metrics at baseline or after one cycle of treatment were more 
likely to achieve pCR.  
 
Absolute and percentage changes of DCE-MRI parameters after one cycle of neoadjuvant 
chemotherapy were also evaluated in order to know if they could predict tumour pathological 
complete response. Absolute changes in the tumour longest diameter after one cycle of therapy 
showed the highest sensitivity (90.9%) and absolute changes in tumour volumes revealed the 
highest specificity (85.1%). Post-cycle 1 absolute changes of AFVs had the highest area under 
the receiver operating characteristic curve (0.865). With respect to percentage changes of DCE-
MRI parameters, changes in hs-Ktrans showed the highest sensitivity (88.9%), changes in 
tumour LDs the highest specificity (92.6%) and changes in AFVs presented the highest AUC 
(0.865). In summary, changes in DCE-MRI derived tumour size and changes in the 
morphological biomarker of tumour vasculature, AFVs, were the best predictors of 
pathological complete response. Outcomes about the ability of DCE-MRI parameters to predict 
tumour response to NAC are controversial.  Ah-See et al46 reported that early changes in MRI-
derived tumour size did not predict pathological response. They also found that an early change 
in Ktrans was the best predictor of pathological non-response. Sharma et al2, stated  that a change 
of Kep from the first to the second MRI during NAC could significantly differentiate between 
responder and non-responder cancers. By contrast, other studies 1,26,27,28 have reported that 
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tumour volume changes between the pre-treatment and early treatment time-points were the 
best predictors of tumour response to NAC. 
 
Our study had several limitations. First, the problems presented during the acquisition or the 
post-processing of DCE-MR images for which some MRI evaluations needed to be excluded.  
Secondly, despite of having a variety of breast cancer types in our sample, the number of 
cancers within categories of histological and molecular subtypes was not the same, creating 
unbalance between groups. Likewise, our study participants were given different number of 
neoadjuvant chemotherapy cycles and drug regimens despite of sometimes having the same 
type of breast cancer, which it can be a plus point for oncologists in our health institution 
because as we know, cancer treatment should be individualised according to the patient’s 
needs.  There were no non-responders in the cohort making it difficult to compare our results 




In this study, DCE-MRI qualitative parameters of the tumour were better correlated to 
pathological tumour response than pharmacokinetic parameters. Post-cycle 1 changes of DCE-
MRI derived tumour size and the number of AFVs were the best predictors of pathological 
complete response We demonstrated the potential of the number of adjacent feeding vessels as 
a new parameter for assessing the tumour vascular function and, this parameter is immediately 
measurable by radiologists reporting the MRI examination. DCE-MRI parameters (with the 
exception of ve) decreased during the course of NAC in cancers achieving pCR and pPR 
although the decline was more accelerated in pCR cancers. Hotspot Ktrans showed better 
potential than whole lesion Ktrans in differentiating complete pathological tumour response from 
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This thesis provides insight into breast cancer pathophysiology using simultaneous PET and 
multi-parametric MRI. The relationships between imaging biomarkers of tumour vascularity 
measured by dynamic contrast-enhanced (DCE) MRI, markers of cellularity using diffusion-
weighted imaging (DWI) and tumour hypoxic status using 18F-fluoromisonidazole (18F-
FMISO) PET were explored. Correlations between functional PET-MRI parameters and 
immunohistochemical (IHC) biomarkers of hypoxia and vascularity as well as a new MRI 
morphological marker of tumour vascularity were presented. 
 
 
7.2 Summary and future work 
 
7.2.1. Relationship between hypoxia and vascularity in breast cancer by using PET-MRI  
 
This work has been undertaken from a radiologist’s perspective, imaging the relationship 
between vascularity and oxygenation in breast cancer. It is recognized that both processes are 
subject to temporal changes and most of the published data about these cancer hallmarks in 
breast has been acquired by performing two separate scans of the patient1,2,3, a PET-CT and an 
MRI scan at different times. To remove the effect of temporal fluctuations in hypoxia and 
perfusion in breast cancer, this relationship was measured using combined PET-MR imaging 
with 18F-fluoromisonidazole (18F-FMISO). A significant negative relationship between 18F-
FMISO-PET Ki and DCE-MRI Ktrans, the imaging parameters of tumour hypoxia and 
vascularity, respectively was found. Additionally, the relationship between DCE-MRI, DWI-
MRI ADC and 18F-FMISO-PET parameters was assessed.  
 
In post-processed maps of tumour perfusion (Ktrans) and hypoxia (Ki) intra-tumoral 
heterogeneity consistent with the dynamic changes of tumour blood flow and the hypoxic 
tumour micromilieu was demonstrated. A larger sample of breast carcinomas is needed in order 
to identify typical hypoxia-perfusion patterns in each molecular breast cancer subtype. Other 
MR techniques such as oxygen enhanced (OE)-MRI simultaneously to the PET could shed 
further understanding of this complex relationship.  
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This work allowed radiologists and oncologists to endorse the hypothesis of perfusion-driven 
hypoxia in breast cancer. I recommend the combined assessment of the hypoxic and vascular 
status of breast tumours (which could be achieved using simultaneous multi-modality imaging 
as reported here) because this needs to be considered for determining prognosis, treatment 
efficacy and therapy selection in breast cancer patients.  
 
7.2.2. Relationship between tumour radiological features, whole-breast vascularity and 
PET/MR imaging parameters of hypoxia and vascular function  
Previous authors have reported the diagnostic role of the “adjacent vessel sign” on DCE-MRI 
and so the total count of adjacent feeding vessels (AFVs) was investigated as a “new” imaging 
marker of the tumour vascular function. This is the first study in which correlations between 
18F-FMISO-PET/MRI and DCE-MRI morphological and quantitative features of the cancer 
were correlated to MR categories of signal-intensity curve and total number of adjacent feeding 
vessels in breast malignancies. The number of tumour adjacent feeding vessels (AFVs) showed 
a non-significant positive correlation with whole-breast vascularity scores. No significant 
correlations were observed between the number of adjacent feeding vessels and tumour 
histology, grade or molecular subtype. 
 
 
Breast cancers with an MR type 3 curve showed higher hypoxic fractions on 18F-FMISO-
PET/MRI than breast cancers with kinetic curves type 1 and 2. This may be due to the shunting 
effect in immature neo-vasculature. DWI-MRI ADC from the darkest part of the cancer showed 
a significant association with the type of curve. Breast carcinomas of the lobular type and grade 
2 presented the highest medians of AFVs and surprisingly, breast cancers with a kinetic curve 
type 1 showed higher median AFVs than breast cancers with kinetic curves type 2 and 
3.   Significant negative correlations were observed between AFVs and 18F-FMISO 
derived parameters and significant positive correlations between DCE-MRI Ktrans, ve and 
AFVs.  I encourage other researchers to continue exploring the role of the total number of 
tumour adjacent feeding vessels as a new imaging metric of tumour vascularity. Likewise, 
radiologists could use the total number of tumour feeding vessels on DCE-MRI evaluations as 
a good indicator of the quantitative parameter Ktrans which is currently only calculated for 




 7.2.3. Correlations between 18F-FMISO-PET/MRI parameters and 
immunohistochemistry (IHC) biomarkers of tumour vascularity and hypoxia in breast 
cancer 
 
After having proved that there was a correlation between tumour imaging biomarkers of 
vascularity and hypoxia in breast cancer, the next step was to confirm with 
immunohistochemical analysis the hypoxia and perfusion from imaging and to determine 
whether or not imaging biomarkers were associated to immunohistochemical biomarkers used 
to assess hypoxia and tumour vasculature. Only 19 breast cancers which were not treated with 
NAC were included for this analysis. Sixty-eight percent of breast cancers in the sample were 
positive for HIF-1 alpha immune-staining and 21% stained positive for CAIX. All cancers were 
CD31 positive. However, overall, non-significant negative correlations were shown between 
CD31 vascular markers and IHC hypoxic biomarkers. Similarly, I could not observe any 
significant association between HIF-1 alpha and CAIX expression.  
 
Although there was a significant positive correlation between the 18F-FMISO-PET parameter 
Ki mean and the immunohistochemical hypoxic marker, carbonic anhydrase IX (CAIX); there 
were no significant associations between 18F-FMISO-PET hypoxic markers and HIF-1 alpha. 
HIF-1 alpha activation in these cancers may be influenced by either oestrogen receptors or 17 
beta oestradiol rather than by hypoxia. A significant positive correlation was observed between 
Ki and the IHC parameter tumour vessel density. DCE-MRI pharmacokinetic parameters also 
showed positive correlations, although not significant, with CD31 derived vascular features 
(total count of tumour blood vessels, micro-vessel density and calibre). 
 
In this same chapter, we also established correlations with other pathological features of the 
cancer such as tumour infiltrating lymphocytes (TILs, as evidence strengthens the clinical 
relevance of this immunological biomarker4) and the percentage of tumour cells. To the best 
of our knowledge, this work is the first one to reveal correlations between PET-MRI hypoxic 
and vascular biomarkers of breast cancer and immunological biomarkers. This work showed 
a significant negative correlation between 18F-FMISO-PET parameter SUV (mean and max) 
and percentage of TILs. Similarly, we revealed a statistically significant negative correlation 
between tumour total count of vessels (obtained from CD31 staining) and TILs (%). There was 
a significant positive association between HIF-1 alpha expression and percentage of tumour 
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cells. However, further work on larger patient population is required to confirm the association 
between TILs and imaging markers of hypoxia and vascularity in breast cancer.  
 
 
 7.2.4. Correlations of breast cancer imaging vascular biomarkers with tumour response 
to neoadjuvant chemotherapy  
The association between DCE-MRI tumour vascular features (pharmacokinetic and 
morphological), including total number of tumour AFVs, and pathological tumour response in 
different types of breast cancer was assessed in order to have a clearer understanding of breast 
cancer vascularity before and after neo-adjuvant chemotherapy. There was a significant 
decrease of almost all DCE-MRI parameters (with the exception of ve) during the course of 
neoadjuvant chemotherapy in cancers with both, a complete and partial response. Tumour 
volumes showed the biggest decline after each treatment cycle, followed by AFVs and hotspot-
Ktrans. The last two were significantly related to tumour size. 
 
Changes in tumour size and in the number of AFVs were the best predictors of pathological 
complete response.  Furthermore, we observed that DCE-MRI qualitative metrics of the 
tumour vascular function correlated better to pathological tumour response than 
pharmacokinetic parameters which are more frequently used in research. 
 
More research needs to be done in order to reliably demonstrate the potential of AFVs as a 
good predictor and indictor of breast cancer pathological response to neoadjuvant 
chemotherapy. We encourage other researchers to not underestimate qualitative DCE-MRI 
vascular features, since they may provide similar or better information than quantitative 
parameters. 
 
7.3 Personal reflections upon my PhD 
Reflecting upon my PhD, I have undertaken research across a variety of fields from breast 
PET-MRI to breast immunohistochemistry. When I arrived in Cambridge University, I had 
brought with me a general knowledge of radiology because I had studied the specialization in 
my native country. However, as soon as I arrived here, I had to confront my lack of knowledge 
on other scientific fields such as PET-MRI and breast MRI. I must admit that this created some 
fear on me at the beginning, however, in addition to my self-initiative for learning about new 
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subjects I received great support from both of my supervisors who had full expertise and 
experience on breast radiology and PET, respectively. At the end, I have now acquired a variety 
of new skills which are extremely useful for doing research and that clinical radiologists usually 
do not learn. I believe that I have shown the ability to move between fields acquiring relevant 
knowledge as I progressed, and this would not have been possible without the fantastic support 
from my supervisors Professor Fiona J. Gilbert and Dr Roido Manavaki. 
In retrospect and reflecting on my work, if I were to start my PhD again having the experience 
that I have now, I would make the following adjustments: 
• Knowing that a request of NHS research documents can take a while, I would start my 
request earlier in order to be able to recruit more patients into my studies. This would allow 
me to analyse a larger cohort of cancers of different histological and molecular types, such 
as more triple negative breast cancers. 
• Instead of focusing myself on finding and brainstorming “new research ideas” I would 
start immediately working on my original plan and would spend more time extracting 
further information from the PET-MRI data already available and expanding the IHC 
analysis which could lead to more complex associations between biomarkers of breast 
cancer hallmarks. 
I would also like to emphasize the value of supervisors’ feedback, views, and advise, as being 
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